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While polyketides display a diverse range of biological properties and are used 
extensively in human medicine, a lack of methods for the concise preparation of these 
complex structures still poses a significant challenge in the field of synthetic organic 
chemistry. To address this issue, metal catalyzed methods for transfer hydrogenative C-C 
bond formation have been developed. These methods construct products of carbonyl 
addition through direct C-H bond functionalization, which provides a more atom 
economic and efficient approach to carbonyl addition products and circumvents the need 
for stoichiometric use of chiral auxiliaries, premetallated C-nucleophiles, and discrete 
alcohol-to-carbonyl redox reactions. Efforts have been focused on the development of 
ruthenium-catalyzed coupling reactions of secondary alcohols to basic chemical 
feedstocks as well as the application of iridum-catalyzed couplings of primary alcohols 
with π-unsaturates in the context of the total syntheses of (−)-cyanolide A and (+)-
cryptocaryol A. These total syntheses represent the most concise route reported to date 
for each natural product and illustrate the synthetic utility of transfer hydrogenative C-C 
bond forming methodology. 
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Chapter 1: Application of Two-Directional Allylation and Crotylation to the 
Total Synthesis of Natural Products 
1.1 Brief Overview of Asymmetric Carbonyl Allylations 
1.1.1 Introduction 
Organic molecules are defined as compounds primarily composed of carbon and 
hydrogen. As such, dynamic methods for the construction of C-C bonds are of great importance 
in the field of synthetic organic chemistry. Carbonyl addition is one such method and 
encompasses a broad field of reactions that utilize the inherent electron deficient nature of the 
carbonyl carbon in conjunction with an electron rich C-nucleophile to forge a new C-C bond. 
Over the past century, a myriad of valuable methods for the construction of C-C bonds via 
carbonyl addition have been developed and applied in the context of total synthesis. While 
natural products are of considerable importance due to the extent to which they exhibit 
pharmacological or biological activity, synthesis of these structurally complex compounds is 
often quite challenging.  
Polyketide natural products are a class of secondary metabolites produced by certain 
living organisms and are often composed of repeated polyacetetate or polypropionate 
substructures. As such, carbonyl addition chemistry has played an important role in the synthesis 
of polyketide natural products. The evolution of methods available for the construction of C-C 
bonds via carbonyl addition has facilitated the synthesis of polyketide natural products. 
Enantioselective carbonyl allylation ranks among the foremost methods used for the construction 
of chiral polyketide natural products. These methods typically transform aldehydes or ketones 
into chiral, homoallylic alcohols, which serve as useful synthetic building blocks as they contain 
C-O bond functionality as well as a pendant olefin. These functional groups can serve as 
synthetic handles for further synthetic manipulations.  
Due to the significance of chirality in the context of biology, biochemistry, and 
pharmacology as well as the abundant representation of chirality in natural products, methods 
 2 
 
that facilitate introduction of chirality into otherwise achiral molecules are of great importance. 
Over the past half-century, the development and application of asymmetric methods for carbonyl 
allylation has been extensive. These advancements can be differentiated by the strategy for 
chirality induction and includes stoichiometric, Lewis acid- or base-catalyzed, and Bronsted 
acid-catalyzed chirality transfer. The following chapter should serve as a brief overview of 
methods for enantioselective carbonyl allylation and crotylation as well as the application of 
two-directional variants to the total synthesis of complex natural products. 
1.1.2 Enantioselective Allylation via Stoichiometric Chirality Transfer 
The majority of methods for carbonyl allylation rely on the use of a preformed allyl metal 
reagent. Early examples of such reactions employed allyl boron reagents and allyl silanes.1 While 
these methods were useful for the construction of homoallylic alcohols, conditions that would 
install the allyl moiety with high levels of stereoselectivity were more desirable. In 1978, 
Hoffmann and coworkers published the first method for the enantioselective allylation of simple 
aldehydes.2 Stereoselectivity was induced through use of chirally modified allyl boronic ester 1.1 
derived from camphor (Figure 1.1). Inspired by this initial success, increasingly effective 





Figure 1.1 Methods for stoichiometric chirality transfer in carbonyl allylation reactions. 
 
In 1983, Brown and coworkers found that allyldialkyborane 1.2 derived from (α)-pinene 
could be employed in carbonyl addition reactions to give products of allylation with remarkable 
levels of stereoselectivity.3 Similarly high levels of stereoinduction were observed by Reetz and 
coworkers using their camphor-derived chiral auxiliary 1.3 in the allylation of aldehydes.4 
Interestingly, Masamune and coworkers found that the much less sterically encumbered borolane 
1.4 engaged in enantioselective allylation reactions.5 Corey and coworkers designed allylborane 
1.5 that is modified with readily available chiral 1,2-diamino-1,2-diphenylethylene and observed 
enantioselective allylation upon exposure to aldehydes.6 Roush and coworkers design 
allylboronic ester 1.6 derived from tartaric acid to effect allylation with high levels of 
selectivity.7  
In a departure from using organoboron complexes, Duthaler and coworkers developed 
allyldialkoxytitanium 1.7 and found it to be a successful reagent for enantioselective allylation.8 













































strained allylsilacycle 1.8 in an effort to develop a stable reagent that could be stored and used 
directly under mild conditions.9  
A stereochemical model for the Brown allylation is presented in Figure 1.2. Coordination 
of the aldehyde to boron occurs in such a way as to keep the substituent attached to the aldehyde 
in a pseudo-equatorial position and the aldehydic hydrogen in the pseudo-axial position. This 
minimizes the steric 1,3-diaxial interactions between the pseudo-axial substituent and the bulky 
isopinocampheyl substituents on boron. The stereochemical models for selectivity in the other 
allylation reactions mentioned above that employ an allylboron reagent are presumably very 
similar.  
Figure 1.2 Proposed stereochemical model for the Brown allylation. 
 
 While all of the methods described above provide access to enantioenriched homoallylic 
alcohols, they also share a number of significant drawbacks that stem primarily from the 
stoichiometric use of allyl metal reagents. Generation of stoichiometric byproducts often detracts 
from the utility of most chirally modified allyl metal reagents due to the additional challenges 
and costs associated with separation and disposal of the byproducts. Additionally, multistep 
syntheses are required in order to obtain the reagents and, with the exception of Leighton’s 
























significant barrier to their use. For these reasons, methods for the introduction of chirality in a 
catalytic manner are valuable and much work has been done in developing catalytic methods for 
carbonyl allylation that exhibit high levels of reactivity and stereoselectivity. 
1.1.3 Lewis Acid-Catalyzed Methods for Chirality Transfer 
In 1991, Yamamoto and coworkers reported the first catalytic asymmetric carbonyl 
allylation reaction.10 The catalyst employed was chiral (acyloxy)borane 1.9 derived from tartaric 
acid. Exposure of benzaldehyde and allyltrimethylsilane to catalytic 1.9 (20 mol%) afforded the 
corresponding homoallylic alcohol in modest yield and enantioselectivity (Scheme 1.1). 
Interestingly, higher levels of stereoinduction were observed in the case of 2-substituted 
allyltrimethylsilanes.  
Scheme 1.1 The first catalytic enantioselective carbonyl allylation reaction. 
 
In 1993, Umani-Ronchi and Keck independently developed the first highly 
enantioselective catalytic method for carbonyl allylation.11 Their method employed 
allyltributylstannane as the allyl donor and titanium(IV) catalyst 1.10 modified with a chiral 
BINOL ligand (Figure 1.3). While the mechanism is not fully understood, one plausible 
mechanistic pathway involves activation of the aldehyde with the catalyst to give intermediate A, 
which undergoes nucleophilic addition by allyltributylstannane to produce cationic species B. 
The cation is presumably stabilized through hyperconjugation with the adjacent C-Sn bond. 
Chloride attack on the Sn atom forms titanium alkoxide C, which likely undergoes 
transmetallation to afford tin alkoxide D, which releases the titanium catalyst. Hydrolysis of tin 




















Figure 1.3 Proposed catalytic cycle for the titanium-catalyzed allylation of aldehydes with 
allylstannanes. 
 
Lewis basic compounds have also been found to catalyze carbonyl allylation reactions 
with high levels of enantioselectivity. In 1994, Denmark and coworkers published a report 
detailing the development of chiral Lewis basic catalyst 1.11 capable of facilitating 
enantioselective carbonyl allylation using allyltrichlorosilane as the allyl donor (top, Figure 
1.4).12 It was proposed that these reactions proceed via a closed six-centered silconate transition 
state, which enhances the enantioselectivity. The nature of the silicon atom in the transition state 
could be either a cationic trigonal bypyamidal structure is which only one Lewis basic 
phosphoramide is bound to the silicon center (bottom left, Figure 1.4), or a cationic octahedral 

































Figure 1.4 Lewis basic catalyst 1.11 and two proposed transition states for the allylation of 
aldehydes with allyltrichlorosilane. 
 
Further development of tethered bisphosphoramide catalyst 1.12 afforded markedly 
higher levels of enantioselectivity and yield in the allylation of benzaldehyde (Scheme 1.2).13 
The strong cooperativity of dimeric catalyst 1.12 compared to monomeric catalyst 1.11 in 
conjunction with enhanced selectivity supports the hypothesis of a two-phosphoramide pathway. 
Scheme 1.2 Comparison of catalysts 1.11 and 1.12 in the allylation of benzaldehyde with 
allyltrichlorosilane. 
 
While methods that employ Lewis acidic or Lewis basic catalysts in carbonyl allylation 
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barrier to use due to the quantities of, and hazards associated with, the byproducts generated in 
these reactions. The allyl stannanes implemented in the Umani-Ronchi-Keck allylation generate 
stoichiometric quantities of tin byproducts and the trichlorosilanes used in the Denmark 
allylation are moisture sensitive and upon hydrolysis generate stoichiometric quantities of 
hydrochloric acid. 
1.1.4 Brønsted Acid-Catalyzed Methods for Chirality Transfer 
Chiral phosphoric acids with binaphthyl ligands have proven to be versatile and efficient 
catalysts that promote a number of enantioselective transformations, including C-C bond forming 
reactions as well as reduction and oxidation reactions.14 In 2010, Antilla and coworkers reported 
the enantioselective allylation of aryl and heteroaryl aldehydes using chiral phosphoric acid 
catalyst 1.13 (Scheme 1.3). The allyl donor employed was allyl pinacol boronate, an inexpensive 
and commercially available reagent. Exceptionally high yields and enantioselectivities were 
observed in the coupling of allyl pinacol boronate with aryl and heteroaryl aldehydes; however, 
selectivity was diminished when primary or secondary aliphatic aldehydes were employed. 




























A stereochemical model was proposed that invoked activation of the boronic ester via 
hydrogen bonding to the phosphoric acid. Computational studies performed by Goodman and 
coworkers indicated that in addition to activation of the boronic ester, hydrogen bonding between 
the phosphoryl oxygen and the aldehydic hydrogen atom.15 This dual hydrogen bonding was 
proposed to both activate the boronic ester as well as enforce a more rigid transition structure, 
which would explain the remarkably high levels of stereoselectivity observed. The computational 
model for the observed stereoselectivity is shown in Figure 1.5. Transition structure A projects 
the bulky pinacol group towards an empty pocket of the catalyst; however, the aldehyde 
substituent projects into the bulky aromatic group of the catalyst. Transition structure B projects 
the bulky pinacol group into the bulky aromatic group of the catalyst, but the aldehyde 
substituent points to an empty pocket of the catalyst. Calculations show that transition structure 
A is favored over transition structure B by 6.7 kcal/mol when benzaldehyde is used as the model 
aldehyde. This indicates that the steric clash between the pinacol moiety and the aromatic group 
of the catalyst is significantly greater than that of the aldehyde substituent projecting into the 
aromatic group of the catalyst. 
Figure 1.5 Comparison of two possible transition state structures in the chiral phosphoric 
acid-catalyzed allylation reaction. 
 
 While this Brønsted acid-catalyzed carbonyl allylation is very effective, it does exhibit 
































aldehydes, the reaction still employs stoichiometric quantities of the allyl metal reagent and 
therefore generates stoichiometric quantities of allyl metal byproducts. Challenges associated 
with the separation and disposal of the reaction byproducts can be significant and may preclude 
the use of such technology to industrial scale applications. 
1.1.5 Redox-Triggered Transfer Hydrogenative Methods for Chirality Transfer 
 In 2008, Krische and coworkers reported an iridium-catalyzed method to construct 
products of carbonyl allylation employing allyl acetate as the allyl donor.16 In this protocol, allyl 
acetate serves as a precursor to a transient allyl metal nucleophile, which upon carbonyl addition 
generates homoallylic alcohols with high levels of stereoselectivity. This nucleophilic behavior is 
a departure from that typically observed in allyliridium species, which most often exhibit 
electrophilic character and undergo addition by nucleophiles.17  
The iridium catalyst is generated in situ upon mixture of [Ir(cod)Cl]2, a chiral bidentate 
phosphine ligand, 3-nitrobenzoic acid, Cs2CO3, and allyl acetate and heating the mixture to 100 
°C  in THF. Upon addition of aldehydes and a terminal reductant, such as isopropanol, the 
corresponding homoallylic alcohols were obtained in typically high yields and high levels of 
enantioselectivity (Scheme 1.4). Both an acidic and a basic additive were found to be necessary 
to facilitate formation of the cyclometallated iridum catalyst 1.14 (Figure 1.8). The structural 
nature of an iridium complex modified with (R)-BINAP isolated from the reaction mixture was 
determined through single X-ray diffraction analysis. 
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Most interestingly, it was found that primary alcohols would undergo allylation directly 
under the above conditions. The proposed mechanism begins with cyclometallated iridium 
catalyst 1.14, which upon protonolysis of the π-allyl species affords iridium(III) alkoxide A 
(Figure 1.6). β-Hydride elimination generates iridium(III) hydride B, and subsequent 
dissociation of the newly formed aldehyde furnishes species C. Deprotonation of species C 
provides anionic iridium(I), which ionizes allyl acetate to regenerate catalyst 1.14. The π-allyl 
haptomer of the iridium complex exists in equilibrium with the σ-allyl haptomer E, which 
possesses an open coordination site. Association of the aldehyde and coupling of the allyl 
fragment affords complex F and subsequent alcohol exchange releases the homoallylic alcohol 
product regenerating complex A and closing the catalytic cycle. The secondary alcohol products 
do not undergo further allylation since the pendant olefin occupies the coordination site that 
would be required for β-hydride elimination. 
Figure 1.6 Proposed mechanism for the iridium-catalyzed allylation of primary alcohols. 
 
 As this methodology allows for direct allylation of primary alcohols without the need for 






































would generate an unstable or intractable aldehyde. The scope of this methodology has recently 
expanded to include α-chiral alcohols, which show no loss of enantiopurity upon transfer 
hydrogenative allylation.18 The ability to bypass stoichiometric pre-formation of aldehyde 
electrophiles enables allylation processes that cannot be performed efficiently from certain 
unstable aldehydes. Of particular note, 1,n-glycols were found to undergo two-directional 
allylation with high levels of enantioselectivity (Scheme 1.5). Under classical conditions for 
carbonyl allylation, in order to obtain product 1.15, a 1,3-dialdehyde would need to be employed; 
however, these dialdehydes are often unstable and are susceptible to enolization, self-
condensation, and trimerization.19 
Scheme 1.5 Two-directional allylation of 1,n-glycols. 
 
 As such, synthetic routes for generating products like 1.15 are often significantly 
complicated and require many steps in order to bypass the 1,3-dialdehyde. One can envision two 
alternative routes to synthesize 1.15 via traditional methods for carbonyl allylation, the first of 


























selective monoprotection of one hydroxyl group followed by oxidation to afford the 
corresponding aldehyde, which upon allylation furnishes the product of monoallylation. 
Protection of the secondary alcohol and deprotection of the primary alcohol followed by 
oxidation afford another aldehyde, which upon allylation and deprotection affords 1.15. This 
sequence requires eight steps to construct 2 C-C bonds and set two stereocenters. 




In an alternative route, 1.15 is prepared from 2,4-pentanedione (Scheme 1.7).20 Copper-
mediated bis-chlorination affords a dichloroketone, which is subjected to enantioselective 
ruthenium-catalyzed hydrogenation to give a diol. Deprotonation of the hydroxyl groups 
followed by SN2 displacement of the adjacent chlorine atoms produces a chiral diepoxide. 
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aforementioned methods grant access to the desired 1,3-anti diol, both require multiple synthetic 
transformations. 
Scheme 1.7 Alternative route to 1.15 via chiral ketone reduction, epoxidation, and ring-
opening.  
 
1.2 Iridium-Catalyzed Two-Directional Allylation in Total Synthesis 
Methods for the construction of the 1,3-anti diol substructure are important due to the 
prevalence of such motifs in polyketide natural products. Iridium-catalyzed two-directional 
allylation affords chiral C2-symmetric 1,3-diols in a single transformation from inexpensive, 
highly tractable glycols. As such, this methodology has been applied to the total synthesis of a 
number of complex natural products. As a consequence of the simplicity with which the 1,3-anti 
diol substructure is assembled, each total synthesis that has implemented the iridium-catalyzed 
two-directional allylation represents the most concise route to that natural product to date. The 
following is a brief summary of the natural products constructed through application of this 
technology and will aim to demonstrate how the implementation of this methodology facilitated 
such concise syntheses. 
1.2.1 Roxaticin 
Roxaticin 1.16 is pentaene macrolide isolated from streptomycete X-14994, found in soil 
near Ecalante, Utah, USA (Figure 1.7).21 It was found to exhibit antimicrobial activity that is 
selective for fungi over bacteria as is often the case with polyene macrolides. It was noted that 
















Key: (a) AlCl3, ClCH2COCl, 60 °C, then Cu(OAc)2; (b) H3O+ then [((S)-BINAP)RuCl2]2, Et3N, H2, 1200 
psi, 102 °C, MeOH then recrystallize; (c) KOH, Et2O; (d) Ph2CuCNLi2, THF, -78 to 0 °C.
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stereogenic centers. Due to this symmetry and as a means to challenge the utility of the newly 
developed iridum-catalyzed two-directional allylation methodolgy, roxaticin became a target of 
synthetic interest.  
Figure 1.7 Molecular structure of the polyene macrolide roxaticin 1.16 and anticipated 
precursor 1.17.  
 
The synthesis began with the first of what would be three separate two-directional 
allylations (Scheme 1.8). Exposure of 1,3-propanediol to allyl acetate in the presence of 
[Ir(cod)Cl]2, (R)-Cl,MeO-BIPHEP, 4-chloro-3-nitrobenzoic acid, and Cs2CO3 in dioxane 
furnished chiral C2-symmetric diol 1.18. Protection of the 1,3-anti diol as the 2,2-dimethyl acetal 
was achieved with PPTS and (MeO)2CMe2 in CH2Cl2, and subsequent oxidative cleavage of the 
terminal olefins reduction with NaBH4 afforded 1.20. A second two-directional allylation was 
accomplished using catalyst 1.19 in the presence of allyl acetate. Protection of the resulting diol 
as the corresponding TBS ethers followed by oxidative cleavage of the terminal olefins and 
reduction with NaBH4 provided another primary diol. A third two-directional allylation, acetal 























Scheme 1.8 Synthesis of the C14-C28 domain of roxaticin 1.16 using an iterative iridium-
catalyzed two-directional allylation approach. 
 
 The total synthesis of roxaticin was completed in 20 steps (longest linear sequence, LLS) 
and 29 total steps and is the shortest total synthesis of the natural product to date.22 Rapid 
assembly of the C14-C28 domain was accomplished in just 9 steps from 1,3-propanediol. Three 
iterations of iridium-catalyzed two-directional allylation were employed to construct six C-C 
bonds and set six stereocenters. This approach circumvents additional manipulations associated 
with the use of non-native functional groups or substructures to mediate bond construction, such 
as chiral auxiliaries, and minimizes refunctionalizations, especially redox manipulations. 
1.2.2 Tetrafibricin C21-C40 
 Tetrafibricin 1.21 is a fibrogen receptor inhibitor that exhibtis a unique array of 
functionality, including alternating 1,3-diol and 1,5-ene-diol substructures, a tetraenoic acid 
moiety, and a primary amine (Figure 1.8).23 Although biosynthetically related to oxo-polyene 
macrolide antibiotics such lienomycin,24 tetrafibricin is not macrocylic and not exhibit activity 
against Bacillus subtilis and Esherichia coli. The structure of tetrafibricin also differs from all 
other naturally occurring fibrogen receptor antagonists. Tetrafibricin is of interest as a tool to 
O O O O O OHOHO
MeMe MeMe MeMe
1.17
OHHO a OHHO b,c OOHO OH
MeMe
d-i
Key: (a) allyl acetate, [Ir(cod)Cl]2, (R)-Cl,MeO-BIPHEP, Cs2CO3, 4-Cl-3-NO2BzOH, dioxane, 110 
°C; (b) PPTS, (MeO)2CMe2, CH2Cl2; (c) O3, CH2Cl2:MeOH, -78 °C to rt; (d) 1.19, allyl acetate; 
(e) TBSCl, imidazole, DMF; (f) O3 then NaBH4; (g) 1.19, allyl acetate; (h) PPTS, (MeO)2CMe2, 






















study fibrogen binding as well as platelet aggregation and as a potential therapeutic agent for the 
treatment of arterial thrombotic disease.25 The total synthesis of tetrafibricin 1.21 remains an 
unmet challenge; however, Krische and workers have developed a strategy that enables rapid 
assembly of the C21-C40 fragment of the natural product.26 
Figure 1.8 Molecular structure of tetrafibricin 1.21 and anticipated precursor 1.22.  
 
 The synthesis began with iridium-catalyzed two-direction allylation of 1,3-propanediol 
and 2,2-dimethyl acetal protection of the resultant 1,3-diol to afford 1.23 (Scheme 1.9). 
Oxidative cleavage of the terminal olefins and reduction with NaBH4 afforded another primary 
diol, which underwent a second iteration of two-directional allylation to give 1.24. Protection of 
the secondary alcohols as silyl ethers and oxidative cleavage of the terminal olefins with ozone 
followed by reduction with NaBH4 furnished diol 1.25. Differentiation of the C2-symmetric 
molecule was accomplished through monoprotection with pivaloyl chloride to generate alcohol 
1.26. Grieco’s procedure for two-step primary alcohol dehydration followed by removal of the 
silyl ether protecting groups provided 1.22. Thus, the synthesis of this fragment was completed 
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in 10 steps from 1,3-propanediol. Further elaboration of 1.22 to construct the C21-C40 domain 
(1.22) of tetrafibricin was accomplished. Unfortunately, fragment union and further 
manipulations were not successful; therefore, completion of a total synthesis of tetrafibricin 1.21 
is still an outstanding challenge. 
Scheme 1.9 Synthesis of 1.22, a potential precursor to tetrafibricin 1.21. 
 
1.2.3 Bryostatin 7 
The bryostatins are a family of 20 marine natural products originally isolated from the 
bryozoan Bugula neritina.27 Bryostatin 7 1.27, an illustrative representative of this family of 
natural products and a target of total synthesis performed by the Krische group, is presented in 
Figure 1.9. The bryostatins exhibit a wide array of biological effects, including antineoplastic 
activity, immunopotentiating activity, restoration of apoptotic function, and the ability to act 
synergistically with other chemotherapeutic agents.28 They have also exhibited neurological 
TBDPSO O O OTBDPS
MeMe
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OHHO a,b OO c,d OOHO OH
MeMe
e,f
Key: (a) allyl acetate, [Ir(cod)Cl]2, (S)-Cl,MeO-BIPHEP, Cs2CO3, 4-Cl-3-NO2BzOH, dioxane, 
110 °C; (b) PPTS, (MeO)2CMe2, CH2Cl2; (c) O3, CH2Cl2:MeOH, -78 °C to rt; (d) allyl acetate, 
[Ir(cod)Cl]2, (R)-Cl,MeO-BIPHEP, Cs2CO3, 4-Cl-3-NO2BzOH, dioxane, 110 °C; (e) 
tBuPh2SiCl, imidazole, CH2Cl2; (f) O3, CH2Cl2:MeOH then NaBH4, -78 °C to rt; (g) PivCl, 

























effects such as activity against Alzheimer’s disease,29 neural growth and repair, and the reversal 
of stroke damage, 30 as well as memory enhancement.31 Given the challenges associated with 
finding a concise route to the bryostatins, bryostatin 7 1.27 was deemed another ideal candidate 
to illustrate the utility of the C-C bond forming hydrogenations developed in the Krische 
laboratory.32 
Figure 1.9 Molecular structure of bryostatin 7 1.27 and anticipated precursor 1.28.  
 
 The synthesis of the pyran fragment 1.28 began with two-directional allylation of 1,3-
propanediol to provide chiral C2-symmetric diol 1.15 (Scheme 1.10). Oxidative cleavage of the 
terminal olefins followed by reductive workup with PPh3 and then treatment with TBSCl 
furnished pyran 1.29. Diastereoselective reverse prenylation of the aldehyde was performed via 
iridium-catalyzed transfer hydrogenative coupling with 1,1-dimethylallene using catalyst 1.30 to 
afford secondary neopentyl alcohol 1.31. Acylation of the secondary alcohol followed by 


















































aldehyde 1.32, which underwent allylation with catalyst 1.33 to generate 1.34. Oxidation of the 
secondary alcohol afforded ketone 1.35. Treatment with PPTS led to formation of pyran 1.36 and 
the terminal alkene was oxidatively cleaved to afford aldehyde fragment 1.28. 
Scheme 1.10 Synthesis of fragment 1.28, a precursor to bryostatin 7 1.27. 
 
 In using the iridium-catalyzed two-directional allylation methodology, aldehyde fragment 
1.28 was synthesized in 10 steps from 1,3-propanediol. This fragment was successful joined with 
the western half of the molecule (shown in Figure 1.9) and elaborated further to complete the 




























































Key: (a) [Ir(cod)Cl]2, (S)-Cl,MeO-BIPHEP, Cs2CO3, 4-Cl-3-NO2BzOH, dioxane, 90 °C; (b) O3, CH2Cl2, -78 °C, 
then PPh3, TBSCl, imidazole; (c) 1.30, i-PrOH, 1,1-dimethylallene, toluene, 60 °C; (d) Ac2O, Et3N, DMAP, THF; 
(e) O3, CH2Cl2, then PPh3; (f) 1.33, i-PrOH, allyl acetate, Cs2CO3, THF, 90 °C; (g) TBAF, AcOH, THF; (h) DMP, 















1.30 Ligand = (S)-SEGPHOS
1.33 Ligand = BIPHEP
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the concise total synthesis of the natural product in just 20 steps LLS. This represents the most 
concise route to any of the members of the bryostatin family and illustrates the power and 
versatility of this new class of catalytic C-C bond forming reactions. 
1.2.4 Neopeltolide 
Neopeltolide 1.37 was isolated from a deep-water sponge of the family Neopelidae by 
Wright and coworkers in 2007 (Figure 1.10).34 The natural product exhibited significantly potent 
in vitro cytotoxicity against a variety of different cancer cell lines, including A-549 human lung 
adenocarcinoma, NCI-ADR-RES human ovarian sarcoma, and P388 murine leukemia cell lines. 
Neopeltolide 1.37 demonstrated antifungal activity against the fungal pathogen Candida 
albicans, and also inhibited cell proliferation in the PANC-1 pancreatic cancer cell line, as well 
as the DLD-1 colorectal adenocarcinoma cell line. Structurally, neopeltolide 1.37 is composed of 
a 14-membered macrolactone with an embedded tetrahydropyran ring, and six stereogenic 
centers. As prior total syntheses had resulted in structural reassignment, She and coworkers 
designed a concise formal synthesis of the known intermediate 1.38, which would be synthesized 




Figure 1.10 Molecular structure of (+)-neopeltolide 1.37, known intermediate 1.38, and 
proposed precursors 1.39 and 1.40.  
 
The synthesis of 1.38 began with construction of the pyran moiety 1.39. Krische two-
directional allylation of 1,3-propanediol furnished known C2-symmetric, chiral diol 1.18 
(Scheme 1.11). Palladium-catalyzed intramolecular alkoxycarboxylation reaction followed by 
protection of the resultant secondary alcohol as the corresponding benzyl ether afforded pyran 
1.41. Isomerization of the terminal olefin with Grubbs’ 2nd generation catalyst in methanol 
followed by hydrolysis of the methyl ester provided carboxylic acid 1.39. Coupling of fragment 
1.39 with fragment 1.40, which was prepared in nine steps from L-valinol, gave ester 1.42. Ring-
closing metathesis was achieved using Hoveyda-Grubbs’ 2nd generation catalyst and provided 
macrolactone 1.43. Diastereo-selective hydrogenation of the trisubstituted olefin and 
simultaneous cleavage of the benzyl ether furnished 1.38, which completed the formal synthesis 































Scheme 1.11 Synthesis of 1.38, a known intermediate in the total synthesis of neopeltolide 
1.37. 
 
1.2.5 Mandelalide A 
Mandelalide A 1.44 was isolated from a new species of Lissoclinum located in Algoa 
Bay, South Africa (Figure 1.11).36 The compound exhibited significant cytotoxicity against 
mouse Neuro-2A neuroblastoma cells as well as human NCI-H460 lung cancer cells. 
Structurally, mandelalide A 1.44 is composed of a 20-membered macrolactone with an 
embedded tetrahydropyran ring, tetrahydofuran ring, and an E/Z diene. Its impressive biological 
















































Key: (a) allyl acetate, [Ir(cod)Cl]2, (R)-Cl,MeO-BIPHEP, Cs2CO3, 4-Cl-3-NO2BzOH, dioxane, 110 
°C, 3 d; (b) PdCl2, CuCl2, CO, CH3CN, MeOH; (c)BnO(NH=C)CCl3, CF3SO3H, CH2Cl2, 0 °C; (d) 
Grubbs' 2nd Generation, MeOH, 60 °C; (e) LiOH, THF, MeOH; (f) 1.40, MNBA, DMAP, CH2Cl2; 
(g) Hoveryda-Grubbs 2nd Generation, toluene, 80 °C; (h) Pd/C, H2, EtOH.
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activity but scarce supply coupled with its interesting molecular architecture inspired Fürstner 
and coworkers to embark on a total synthesis of the natural product in 2014.37 Further structural 
reassignment and total synthesis of the corrected structure was reported the following year.38 
Figure 1.11 Molecular structure of mandelalide A 1.44 and proposed precursor 1.45.  
 
The synthesis of pyran fragment 1.45 began with Krische two-directional allylation of 
propanediol to provide known C2-symmetric, chiral diol 1.15. Iodoetherification and subsequent 
protection of the secondary hydroxyl group as the TBS ether provided pyran 1.46. Reaction with 
the lithium enolate of chiral auxiliary 1.47 followed by reductive removal of the auxiliary gave 
primary alcohol 1.48. Cross-metathesis with methyl acrylate followed by oxidation of the 
primary alcohol afforded aldehyde 1.49. Aldehyde 1.49 was subjected to conditions for Takai 
olefination to furnish vinyl iodide 1.50. Modified Suzuki propargylation followed by hydrolysis 
of the methyl ester completed the synthesis of fragment 1.45. The synthesis of fragment 1.45 was 
achieved in just 10 steps from 1,3-propanediol and was further elaborated to complete the total 



























Scheme 1.12 Synthesis of 1.45, a precursor in the total synthesis of mandelalide A 1.44. 
 
1.2.6 C8-epi-Cryptolatifolione 
The dihydropyranone motif is structural element associated with many diverse families of 
natural products. Compounds containing a dihydropyranone ring display a broad range of 
biological properties, including antitumor,39 antimicrobial40 and antiparasite41 activity, inhibition 
of HIV protease42 and hepatitis C virus polymerase,43 induction of apoptosis,44 and molluscicidal 
























































Key: (a) allyl acetate, [Ir(cod)Cl]2, (S)-Cl,MeO-BIPHEP, 
Cs2CO3, 4-Cl-3-NO2BzOH, dioxane, 90 °C; (b) I2, 
NaHCO3, MeCN, -40 °C; (c) TBSOTf, 2,6-lutidine, 
CH2Cl2, 0 °C; (d) 1.47, LDA, LiCl, THF, 0 → 45 °C; (e) 
LDA, BH3·NH3, THF, 0  → 25 °C; (f) methyl acrylate, 
Hoveyda-Grubbs' 2nd Generation, CH2Cl2; (g) DMP, 
CH2Cl2, 0 → 25 °C; (h) CHI3, CrCl2·THF, THF, -8 °C; (i) 
propynyl sodium, B(OMe)3, [Pd(dppf)Cl2·(CH2Cl2), THF, 
70 °C; (j) Me3SiOK, Et2O.
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coworkers in 1996 from the bark of Cryptocaria latifolia (Figure 1.12).46 As the relative 
stereochemistry of the natural product was unknown, Pilli and coworkers completed the first 
total synthesis of cryptolatifolione as well as C8-epi-cryptolatifolione 1.51 in 2015.47  
Figure 1.12 Molecular structure of cryptolatifolione and C8-epi-cryptolatifolione 1.51.  
 
The synthesis of C8-epi-cryptolatifolione began with Krische two-directional allylation 
of 1,3-propanediol to furnish known C2-symmetric, chiral diol 1.18. Desymmetrization was 
achieved by selective O-allylation of just one of the two hydroxyl groups to provide allyl ether 
1.52. The acetate moiety was installed with acetic anhydride to give acetate 1.53. Ring-closing 
metathesis with Grubbs’ 2nd generation catalyst afforded dihydropyran 1.54. Selective allylic 
radical-based C-H oxidation at the C2 position was achieved with PCC to give dihydropyranone 
1.55. Cross-metathesis with 3-hexene in the presence of Grubbs’ 2nd generation catalyst 
furnished C8-epi-cryptolatifolione 1.51. The total synthesis of 1.51 was completed in just eight 

















Scheme 1.13 Synthesis of C8-epi-cryptolatifolione 1.51. 
 
1.2.7 Cryptomoscatone E3 
Pilli and coworkers also reported the stereochemical assignment and total synthesis of 
cryptomoscatone E3 1.56, another dihydropyranone-containing natural product (Figure 1.13).48 
The natural product was first isolated by Cavalheiro and Yoshida in 2000 from the bark of the 
Brazilian tree Cryptocarya mandiocanna.49 Preliminary studies on the pharmacological 
properties of the cryptomoscatone family of natural products indicated that some of these types 
of structures possess G2 checkpoint inhibitory properties. However, a more thorough study of 
the biological activity of this family of natural products is necessary. 
Figure 1.13 Molecular structure of cryptomoscatone E3 1.56.  
 
As before, the synthesis began with Krische two-directional allylation of 1,3-propanediol 




























Key: (a) allyl acetate, [Ir(cod)Cl]2, (R)-BINAP, Cs2CO3, 4-Cl-3-NO2BzOH, dioxane, 90 °C, 
3 d; (b) allyl bromide, NaH, DMF; (c) Ac2O, Et3N, DMAP, CH2Cl2, 0 °C; (d) Grubbs' 2nd 









O-allylation of a single hydroxyl group to afford 1.52. The remaining free hydroxyl group was 
protected as the corresponding PMB ether 1.57. Upon exposure to Grubbs’ 2nd generation 
catalyst, ring-closure occurred and furnished dihydropyran 1.58. Selective oxidation at the C2 
position proved quite difficult, presumably due to competitive deprotection of the PMB ether 
under the reaction conditions; however, sufficient quantities of dihydropyranone 1.59 were 
obtained. Wacker oxidation of the terminal olefin generated ketone 1.60, which upon treatment 
with Cy2BCl and exposure to cinnamaldehyde provided alcohol 1.61. Selective 1,3-syn reduction 
of the ketone was achieved with LiBH4 and Et2BOMe at low temperature to afford diol 1.62. 
Unfortunately, all attempts to remove the PMB ether under oxidative conditions were 





Scheme 1.14 Attempted synthesis of cryptomoscatone E3 1.56. 
 
1.3 Brief Overview of Carbonyl Crotylation 
1.3.1 Introduction 
Asymmetric carbonyl crotylation is a powerful method for the construction of vicinal 
stereogenic centers and facilitates the construction of substructures commonly found in nature 
(Figure 1.14). The development of methods for enantioselective carbonyl crotylation has been of 
considerable interest to the synthetic community for over half of a century. The majority of these 
methods are analogous to methods for asymmetric carbonyl allylation in that they frequently 





























Key: (a) allyl acetate, [Ir(cod)Cl]2, (R)-BINAP, Cs2CO3, 4-Cl-3-NO2BzOH, dioxane, 90 °C, 
3 d; (b) allyl bromide, NaH, DMF; (c) PMBCl, NaH, TBAI, DMF; (d) Grubbs' 2nd 
Generation, CH2Cl2, 40 °C; (e) PCC, CH2Cl2, 80 °C; (f) PdCl2, CuCl, air, DMF, H2O; (g) 





















A particular challenging aspect of asymmetric carbonyl crotylation is control of 
diastereoselectivity as both 1,2-syn and 1,2-anti products are possible. A number of reviews have 
been published on the myriad methods available for carbonyl crotylation.13, 50 The methodology 
that will be the focus of this section will be catalytic redox-triggered transfer hydrogenative 
methods for chirality transfer as a means to access products of carbonyl crotylation with high 
levels of stereoselectivity. 
Figure 1.14 The products of a generic carbonyl crotylation reaction and examples of two 
complex natural products that contain similar substructures.  
 
1.3.2 Redox-Triggered Transfer Hydrogenative Methods for Chirality Transfer 
In 2009, Krische and coworkers published the first transfer hydrogenative method for 
enantioselective carbonyl crotylation.51 Using conditions similar to those found to effective for 
carbonyl allylation via transfer hydrogenation, products of carbonyl crotylation were obtained 
when α-methyl allyl acetate was employed. Prior to the development of this technology, all 





















































Krische allylation was capable of constructing products of carbonyl addition from the primary 
alcohol or aldehyde oxidation level, the crotylation reaction was also capable of using alcohols 
directly. The reaction was also tolerant of alkyl, aryl, and heteroaryl substrates (Scheme 1.15). 
Scheme 1.15 Abbreviated scope of the asymmetric transfer hydrogenative crotylation 
reaction. 
 
Mechanistically, the crotylation pathway is quite similar to that of the allylation reaction. 
An important difference is at the stage of ionization of α-methyl allyl acetate, in which 
isomerization between the cis-π-crotyl the trans-π-crotyl complex would lead to the erosion of 
diastereoselectivity. Since the cis-π-crotyl complex engages the carbonyl partner by way of an 
(E)-crotyl iridium intermediate, the product of crotylation becomes the 1,2-anti homoallylic 
alcohol. Conversely, the trans-π-crotyl complex engages the carbonyl partner by way of a (Z)-
crotyl iridium intermediate and gives rise to 1,2-syn products (Figure 1.15). In all cases in which 
α-methyl allyl acetate is employed, a significant preference for products of 1,2-anti carbonyl 
crotylation are observed presumably due to the kinetic preference for formation of the cis-π-
crotyl complex.  In the stereochemical model proposed in the initial report, the preference of the 































































Figure 1.15 Stereochemical features associated with formation and isomerization of the 
purported crotyl iridium intermediates and stereochemical model indicating the 
pseudo-equitorial positioning of the methyl group. 
 
While the development of this technology was a step forward in the art of synthesizing 
molecules that possess the 1,2-anti structural motif, it was not suitable for construction of the 
1,2-syn structural motif that is also quite prevalent in nature. This challenge was overcome 
through modification of the crotyl donor. In 2011, Krische and coworkers reported a ruthenium-
catalyzed method for diastereo- and enantioselective hydrohydroxyalkylation of 2-silyl 
butadienes to give access to products of 1,2-syn crotylation from either the alcohol or aldehyde 
oxidation state. Unlike in the case of the 1,2-anti crotylation is which α-methyl allyl acetate 
acted as the allyl donor, 1,2-syn crotylation products were obtained from 2-silyl-butadienes 






































































the methyl group and silyl groups to adopt pseudo-axial conformation in the transition state. This 
pseudo-axial conformer, upon C-C bond formation affords the product of 1,2-syn crotylation. 
Figure 1.16 Abbreviated scope of the asymmetric ruthenium-catalyzed 
hydrohydroxylalkylation of 2-silyl-butadienes and a stereochemical model for 
addition. 
 
Having developed complementary methods for 1,2-anti and 1,2-syn crotylation reactions, 
Krische and coworkers turned their focus to further simplification of the crotyl donor. Butadiene 
represents the most ideal choice for a crotyl donor as all atoms are transferred to the product and 
there is no inherent waste or further manipulations necessary to reveal the product of carbonyl 




















































































been developed, stereocontrolled hydrohydroxyalkylation of butadiene had proven elusive when 
either iridium52 or ruthenium53 catalysts were employed. While enantioselectivity was a 
challenging aspect of this type of coupling reaction, it was observed that addition of bulky 
sulfonic acid additives afforded products of 1,2-anti crotylation with moderate levels of 
diastereoselectivity. 
Encouraged by this discovery, Krische and coworkers investigated the use of chiral 
phosphoric acid additives in the ruthenium-catalyzed crotylation of aldehydes and alcohols with 
butadiene.54 Interestingly, it was observed that the chiral phosphoric acid constructed from the 
3’-ethyl-H8 derivative of BINOL enhanced the diastereo- and enantioselectivity of the reaction 
significantly (Figure 1.17). However, one limitation was found to be the intolerance of the 




Figure 1.17 Abbreviated scope of the asymmetric ruthenium-catalyzed 
hydrohydroxylalkylation of butadiene. 
 
Mechanistically, it was proposed that hydrometallation of butadiene delivers two 
isomeric π-allyl complexes (Figure 1.18). The syn- and anti-π-allyl complexes exist in 
equilibrium with each other as well as with the corresponding (E)- and (Z)-σ-allyl haptomers. 
The considerable bulk of the chiral phosphoric acid ligand promotes partitioning of the (E)- and 
(Z)-isomers, which precedes stereospecific carbonyl addition by way of the σ-crotylruthenium 
haptomer through a closed transition state. Using this method, a number of electron-rich and 
electron-deficient aryl aldehydes and alcohols were successfully coupled with butadiene to give 



































































Figure 1.18 Counterion-dependent partitioning of (E)- and (Z)-σ-crotylruthenium isomers (X 
= chiral phosphoric acid). 
 
While this methodology was significant in that allowed for the direct coupling of 
feedstock chemicals butadiene and aryl alcohols and aldehydes with high 1,2-anti 
diastereoselectivity, further modification was necessary in order to access the more challenging 
1,2-syn products as well as a method that could tolerate aliphatic substrates. In 2012, Krische and 
coworkers reported that use of a chiral ligand, such as (S)-SEGPHOS in addition to TADDOL-
derived phosphoric acid additives led to selective formation of 1,2-syn products of carboyl 
crotylation from either the alcohol or aldehyde oxidation state (Figure 1.19).55 Additionally, 
under these conditions aliphatic substrates were tolerated and were shown to engage in coupling 
with butadiene with high levels of enantioselectivity and good levels of diastereoselectivity. In 
this reaction, it is proposed that the (Z)-σ-crotylruthenium species is kinetically favored due to 











































Figure 1.19 Postulated mechanistic rationale illustrating partitioning of (E)- and (Z)-σ-
crotylruthenium isomers as a consequence of the stericac demand of the 
TADDOL ligand. 
 
Having successfully developed methods for the construction asymmetric carbonyl 
crotylation products, it was once again envisioned that the newly discovered crotylation 
technology could be applied to 1,3-diol systems. In 2011, Krische and coworkers reported the 
first two-directional crotylation of 1,3-propanediol and related 2-substituted-1,3-propanediols 
(Figure 1.20).56 Most interestingly, this methodology proved to be quite selective particularly in 
the case of 2-methyl-1,3-propanediol, which under the reaction conditions furnished the 
compound in 6:1 d.r, which refers to the proportion of the product relative to the combination of 
all of the stereoisomers. As this reaction sets potentially four stereocenters, there are a possible 



















































































Figure 1.20 Calculated theoretical distribution of stereoisomers obtained in the double 
crotylation of 2-methyl-1,3-propanediol based on 98% ee for both syn- and anti-
crotylation events and a 15:1 anti:syn d.r., as well as the observed results. 
 
This double crotylation process has no counterpart in conventional crotylmetal chemistry 
and is unique in its ability to produce acyclic stereoquintets from achiral reactants with good 
levels of relative and absolute stereocontrol. In addition to the installation of four stereocenters, 
the reaction also constructs two C-C bonds and the product contains two terminal olefins that 

















































































1.4 Iridium-Catalyzed Two-Directional Crotylation in Total Synthesis 
Methods for the construction of stereoquintet substructures are important due to the 
prevalence of such motifs in polyketide natural products. Iridium-catalyzed two-directional 
crotylation affords chiral C2-symmetric 1,3-diols in a single transformation from inexpensive, 
highly tractable glycols. As such, this methodology has been applied to the total synthesis of a 
number of complex natural products. As a consequence of the simplicity with which these 
complex substructures can be assembled, each total synthesis that has implemented the iridium-
catalyzed two-directional allylation represents the most concise route to that natural product. The 
following is a brief summary of the natural products constructed through application of this 
technology and will aim to demonstrate how the implementation of this methodology facilitated 
such concise syntheses. 
1.4.1 6-Deoxyerythronolide B 
Erythromycin A was the first macrolide antibiotic, produced by Eli Lilly in 1952 (Figure 
1.21). Beyond its pharmaceutical impact, the challenges associated with the synthesis of 
erythromycin A and related polyketides has inspired advances in acyclic stereocontrol via 
carbonyl addition, such as the construction of C-C bonds using the aldol reaction57 as well as 
carbonyl crotylation.13, 50a, 50c-h However, despite these advances all reported total syntheses of 
erythromycin A and related natural products have required lengthy synthetic sequences 
employing over 20 linear steps. 6-Deoxyerythronolide B 1.63, a biogentic precursor to many 
members of the erythromycin family of natural products, was chosen as a testing ground to 
evaluate the power and versatility of the Krische asymmetric two-directional crotylation in the 




Figure 1.21 Erythromycin A, 6-deoxyerythronolide B 1.63, and fragment 1.64 constructed via 
two-directional asymmetric crotylation. 
 
6-Deoxyerthronlide B 1.63 was synthesized from fragment 1.64 (Scheme 1.16).58 The 
synthesis of this fragment began with two-directional asymmetric crotylation of 2-methyl-1,3-
propanediol in the presence of catalyst 1.65 to afford C2-symmetric, chiral diol 1.66. 
Iodoetherification of 1.66 differentiates the olefin termini and diol moieties and defines the 
nonstereogenic chirotopic center at C4, which upon benzylation delivers pyran 1.67. Oxidative 
cleavage of the terminal olefin with catalytic OsO4 and oxone followed by Bernet-Vasella 
cleavage59 of the iodoether affords β-hydroxy carboxylic acid 1.68. To convert 1.68 into 
fragment 1.64, epimerization of the C3 hydroxy group was necessary. This stereoinversion was 
accomplished via conversion of 1.68 to β-lactone 1.69 using choromethanesulfonyl chloride. 



























































Scheme 1.16 Synthesis of fragment 1.64 of 6-deoxyerythronolide B 1.63. 
 
The synthesis of fragment 1.64 was accomplished in just eight steps from 2-methyl-1,3-
propanediol. Successful fragment union and further elaboration led to the completion of the total 
synthesis of 6-deoxyerythronolide B in just 14 linear steps. This represents the most concise total 
synthesis of any member of the erythromycin family of natural products to date.  
1.4.2 Premisakinolide A and C(19)-C(32) of Swinholide A 
The efficacy of anticancer agents that disrupt microtubule dynamics (e.g. paclitaxel, 
docetaxel, ixabepilone, eribulin mesylate)60 suggests that agents that exhibit the ability to bind 
actin hold promise for cancer therapy.61 One such actin-binding compound is swinholide A 1.70, 

























































Key: (a) 1.65, 2-methyl-1,3-propanediol, Na2CO3, H2O, THF, 70 °C; (b) I2, NaHCO3, 
MeCN, -20 → 0 °C; (c) Cl3C(=NH)OPMB, CSA, Et2O, 30 °C; (d) OsO4, oxone, 
NaHCO3, DMF; (e) Zn, NH4Cl, EtOH, reflux; (f) s-BuLi, ClCH2SO2Cl, THF:HMPA, -78 





(Figure 1.22).62 Many marine natural products, such as premisakinolide A 1.71, have structural 
features in common with swinholide A. The Krische group is currently investigating the 
application of the two-directional asymmetric crotylation to the total synthesis of swinholide A 
1.70. Recently, Krische and coworkers have reported the synthesis of the C(19)-C(32) domain of 




Figure 1.22 Swinholide A 1.70, premisakinolide A 1.71, and fragment 1.72. 
 
The synthesis of 1.72 began with the construction of the pyran moiety (Scheme 1.17). 
Iridium-catalyzed asymmetric allylation of commercially available (S)-1,3-butanediol affords 
homoallylic alcohol 1.73. Cross-metathesis with cis-1,4-diacetoxy-2-butene delivers 1.74 (5:1 
E:Z). Tsuji-Trost cyclization using the chiral palladium catalyst modified with ligand 1.75 































































generates 1.77. Cross-metathesis between 1.77 with 1.67, prepared previously in the synthesis of 
6-deoxyerythronolide A (Scheme 1.16), furnished 1.78. Unfortunately, this cross-metathesis 
proved quite difficult due to the competing isomerization of the terminal olefin of 1.67. In order 
to overcome this challenge, five equivalents of 1.67 were used in the reaction. While these 
conditions were far from ideal, a significant portion of the excess 1.67 could be recovered and 
recycled. After extensive evaluation of methods for the reduction of the alkene present in 1.78, it 
was found that diimide-mediated hydrogenation occurred without partial reduction of the C-I 
bond or epimerization at C27, which after Bernet-Vasella cleavage of the iodoether delived 1.79. 
Protection of the secondary alcohol as the corresponding MOM ether and oxidative cleavage of 
the terminal olefin furnished 1.72 and completed the formal synthesis of premisakinolide A 1.71 
as well as the C19-C32 domain of swinholide A 1.70. The synthesis of fragment 1.72 was 





Scheme 1.17 Formal synthesis of premisakinolide A 1.71 and C(19)-C(32) of swinhoilde A 
1.70 via fragment 1.72. 
 
1.4.3 Zincophorin Methyl Ester 
Isolated from an asporogenus strain of Streptomyces griseus in 1984,65 zincophorin 1.80 
is a polyketide ionophore antibiotic that exhibits potent (<1 ppm) in vivo activity against Gram-
positive bacteria (Figure 1.23).66 While there have been many prior syntheses of zincophorin 
1.80 and its methyl ester 1.81, all have required at least 21 steps in the longest linear sequence.67 
Inspired by the previous impact of the two-directional asymmetric crotylation reaction in 
facilitating a more concise route to natural products, Krische and coworkers sought to 




















































Key: (a) allyl acetate, [Ir(cod)Cl]2, (S)-Cl,MeO-BIPHEP, 4-Cl-3-NO2BzOH, Cs2CO3, THF, 100 °C; (b) cis-1,4-
diacetoxy-2-butene, Grubbs' 2nd Generation, CH2Cl2, 50 °C; (c) Pd2(dba)3·CHCl3, 1.75, Et3N, CH2Cl2; (d) MeI, 
tBuOK, THF; (e) 1.67, Hoveyda-Grubbs' 2nd Generation, benzoquinone, DCE, 80 °C; (f) TsNHNH2, NaOAc, 








synthesis of zincophorin methyl ester 1.81. It was anticipated that the molecule could be 
constructed from pyran fragment 1.82. 
Figure 1.23 Structures of zincophorin 1.80, zincophorin methyl ester 1.81, and fragment 1.82. 
 
The synthesis of fragment 1.82 began with two-directional asymmetric crotylation of 2-
methyl-1,3-propanediol followed by iodoetherification to generate iodoether 1.83.68 Cross-
metathesis with cis-butene diol diacetate, Bernet-Vasella cleavage of the iodoether, followed by 
protection of the 1,3-diol as the acetonide delivered allylic alcohol 1.84. Diastereoselective 
epoxidation using the Sharpless protocol69 and subsequent treatment with Gilman’s reagent 
furnishes primary alcohol 1.85.70 Hydroformylation of the terminal alkene provides the linear 
aldehyde,71 which upon exposure to methanol in the presence of substoichiometric p-
toluenesulfonic acid delivers pyran 1.86 as a 3:1 mixture of diastereomers that is seperable. 
Protection of the three free hydroxyl groups as the corresponding TES ethers and subsequent 


















R = H, (+)-Zincophorin 1.80














Scheme 1.18 Synthesis of fragment 1.82 using Krische two-directional asymmetric 
crotylation reaction. 
 
Fragment union and further elaboration concluded with the completion of the total 
synthesis of (+)-zincophorin methyl ester 1.81 in 13 linear steps. This represents the most 
concise total synthesis of the natural product to date and is eight steps shorter than the next 
shortest total synthesis. It is anticipated that the concise nature of this synthetic route will allow 
for a more complete investigation into its biological properties, studies that are currently 
underway. 
1.5 Conclusions and Outlook 
Methods for enantioselective carbonyl allylation and crotylation are of great importance 






















































Key: (a) (S)-Ir-SEGPHOS, 3-butenyl-2-acetate, Na2CO3, H2O, THF, 70 °C; (b) I2, NaHCO3, MeCN, -20 
→ 0 °C; (c) cis-butene diol diacetate, Stewart-Grubbs, CH2Cl2, 40 °C; (d) Zn, NH4Cl, MeOH, 85 °C; (e) 
Me2C(OMe)2, p-TsOH, CH2Cl2; (f) (-)-DIPT, Ti(OiPr)4, t-BuOOH, CH2Cl2, -20 °C; (g) CuCN, MeLi, THF, 
-78 → 0 °C; (h) H2/CO, Rh(CO)(acac), Xantphos, THF, 100 °C, then p-TsOH, MeOH, 25 °C; (i) Et3SiCl, 
imidazole, DMF; (j) (COCl)2, DMSO, CH2Cl2, -78 °C, then Et3N.
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of stereoselectivity and in designing catalytic systems for the transfer of chirality, most methods 
for carbonyl allylation still rely on the use of preformed stoichiometric allyl metal species. 
Krische and coworkers developed a suite highly enantioselective methods for constructing 
products of carbonyl allylation from either the aldehyde or alcohol oxidation state. Most 
importantly, the ability to employ the corresponding primary alcohols has facilitated the 
construction of homoallylic alcohol products that would not be accessible via traditional methods 
for carbonyl allylation. 
Diols are inexpensive chemical building blocks useful in the construction of polyol 
products. The two-directional asymmetric allylation and crotylation reactions with 1,n-glycols 
represent powerful methods for the construction of polyketide natural products as they allow for 
the construction of two C-C bonds and set mulitple stereocenters in a single transformation. This 
technology has been implemented in the total synthesis of a number of complex natural products 
and has resulted in the shortest routes reported to date in all cases in which it has been applied. 
Further demonstration of the utility of this methodology is ongoing as more biologically active 




Chapter 2: Background Cyanolide A 
2.1 Introduction 
Natural products are an important source of complex chemical structures that often 
exhibit biological activity.72 The identification and development of compounds derived from 
natural products has yielded new small molecule medicines.73 Hence, access to the compounds in 
quantities sufficient for biological evaluation is of critical importance. Methods for the 
acquisition of such compounds are typically limited to isolation from the natural source directly 
or through novel chemical synthesis.  
Polyketides isolated from soil bacteria are an important class of natural products and 
represent roughly 20% of the top-selling small molecule drugs.74 It is estimated that polyketides 
are five times more likely to possess drug activity compared with other natural product classes.75 
However, culture of soil bacteria is a long-standing problem and less than 5% of soil bacteria 
that produce polyketides are amenable to culture.76 Therefore, synthetic methods that provide 
facile access to complex polyketides are highly desirable, and it is anticipated that polyketides 
will become even more important as these methods improve and diversify.  
Polyketides exhibit biological activity in areas outside of human medicine as well, such 
as pesticides. Pesticides are of great importance in agriculture, environmental protection, and in 
preventing the spread of a number of diseases.77 Schistosomiasis, also known as bilharzia, snail 
fever, and Katayama fever, is one of the most prevalent parasitic infections with an estimated 
207 million people currently infected and 779 million people at risk of infection.78 At least 
200,000 deaths per year are related to the disease,79 which is caused by parasitic flatworms of the 
Schistosoma genus. Symptoms of schistosomiasis include abdominal pain, diarrhea, popular 
rash, fatigue, and fever. In individuals who have been infected over a long period of time, liver 
damage, kidney failure, or bladder cancer may occur. The disease is triggered via a complex 
immune system response to the eggs laid by a parasitic worm in a human host. It is estimated 
that 50% are destroyed through inflammation, which can result in scarring and organ 
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dysfunction. 50% of the eggs laid in a human host ulcerate through the wall of the bowel into the 
stool. When the eggs reach freshwater, they hatch and release microscopic larvae called 
miracidium.79 These tiny larvae next locate and penetrate an aquatic snail, typically of the genus 
Biomphalaria.80 Inside the snail vector, the miracidium transforms into a sporocyst, which begins 
to multiply. The daughter sporocysts reproduce asexually and produce thousands of new 
parasitic larvae, known as cercariae, which leave the snail and enter the surrounding water where 
they seek a mammalian host to complete their life cycle. 
The complexity of the life cycle of these parasitic worms makes prevention of worm 
transmission problematic.81 Even if one can eradicate the disease in the host, there remains the 
possibility of reinfection from exposure to aquatic environments that are inhabited by the snail 
vector. For this reason, development and application of molluscidal compounds have been 
explored as a method of controlling the spread of the disease. The most widely available 
molluscicide is niclosamide 2.1 (Scheme 2.1). While effective, niclosamide is expensive, 
exhibits poor water solubility, and adversely affects native fish. Alternative methods that 




Figure 2.1. Structures of niclosamide 2.1, (−)-cyanolide 2.2, and clavosolides A-D 2.3a-d. 
 
2.2 Isolation and Bioactivity 
 In 2010, Gerwick and coworkers isolated and identified cyanolide A 2.2,81 a dimeric, 
glycosidic diolide that exhibits potent molluscicidal activity (LC50 = 1.2 µM) against 
Biomphalaria glabrata, a species of snail known to be a host for Schistosoma. The compound 
was found in samples of cyanobacteria, which were identified as Lyungbya bouillonii. The 
biological material was obtained in the form of a dark-reddish mat and was collected by scuba 
from a shallow reef outside Pigeon Island, Papa New Guinea. The material was extracted 



































































column chromatography. The highly bioactive and spectroscopically interesting fraction was 
further purified to afford 1.2 mg of cyanolide A. 
The bioactivity was evaluated according to a previously developed procedure using the test 
organism Biomphalaria glabrata.82 A stock solution of cyanolide A (20 mg/mL) in EtOH was 
prepared. 35 µL of the stock solution was diluted to 7 mL with distilled H2O. Snails were placed 
in wells of varying concentrations and observed after 24 h. Snails were assessed to be dead if no 
heartbeat could be detected upon examination under a dissecting microscope (20x 
magnification).  
2.3 Stuctural Elucidation 
 Gerwick and coworkers determined the relative structure of cyanolide A. Observation of 
a parent ion at m/z 855.4735 via HRESIMS was consistent with the molecular formula C42H72O16 
and 7 degrees of unsaturation. IR spectroscopy indicated the presence of ester and ether linkages 
and a lack of hydroxyl groups. The 1H NMR spectrum in CDCl3 displayed a methane doublet at δ 
4.24, which suggested the presence of a sugar-like moiety. 13C NMR analysis revealed only 21 
peaks, which indicated that the molecule contained a plane of symmetry. Comprehensive 
analysis of cyanolide A using 2D NMR including HSQC, HMBC, COSY, and NOESY were 
consistent with a dimeric and symmetric structure.  
 Absolute stereochemistry was proposed assuming that the sugar moieties were derived 
from D-xylose. Structurally, cyanolide A is most closely related to the clavosolide family of 
natural products, isolated from the Philipine marine sponge Myriastra clavosa.83 Cyanolide A 
and the clavosolide family of natural products (2.3a-2.3d, Figure 2.1) share a flat dimeric 
macrocyclic framework that contains xylose-derived moieties. Cyanolide A lacks the trans-2-
methylcyclopropyl substructure and contains geminal dimethyl substitution at C4, whereas the 




2.4 Prior Total and Formal Syntheses 
 The synthetic challenges involved with cyanolide A include the stereoselective synthesis 
of the pyran core of the natural product, installation of the trimethylated D-xylose moiety, and 
dimerization to afford the macrodiolide structure. There have been six previous syntheses 
published from the laboratories of Hong, Reddy, She, Pabbaraja, Rychnovsky, and Jennings. 
Each synthesis will be reviewed focusing primarily on how the above synthetic challenges were 
overcome.  
2.4.1 Hong’s Total Synthesis of (−)-Cyanolide A 
Hong and coworkers completed the first total synthesis of cyanolide A and confirmed its 
absolute stereochemistry.84 The successful synthetic strategy relied on a tandem oxidation/oxa-
Michael cyclization of allylic alcohol 2.8 to generate pyran 2.7 (Scheme 2.1). Formation of the 
macrodiolide structure was proposed via diastereoselective ethylation to give monomer 2.6, 
which was anticipated to undergo dimerization to provide 2.4. Glycosylation of the dimeric 
macrodiolide was predicted to furnish the natural product. A second approach to the natural 
product was achieved by ethylation and glycosylation of 2.7 to give monomer 2.5, which was 




Scheme 2.1 Hong’s retrosynthesis of (−)-cyanolide A.  
 
The forward synthesis of the natural product began with generation of the enamine 2.12, 
which upon exposure to chloride 2.14 provided aldehyde 2.15 after workup (Scheme 2.2). Wittig 
homologation followed by DIBAL reduction afforded allylic alcohol 2.9.85 Dithiane coupling of 
















































































Treatment of 2.8 with MnO2 and dimethyl triazolium iodide in the presence of DBU furnished 
pyran 2.7 in 6 steps from commercially available 1,3-dithiane 2.13. 
Scheme 2.2 Synthesis of common intermediate 2.7.  
 
With key intermediate 2.7 in hand, Hong and coworkers first attempted to complete the 
total synthesis via a strategy consisting of dimerization and then late-stage glycosylation 
(Scheme 2.3). Deprotection of the PMB group was achieved using DDQ to afford primary 
alcohol 2.16. Swern oxidation of 2.16 yielded aldehyde 2.17, which was subjected to ethylation 
using Et2Zn and (+)-MIB to give monomer 2.6. The monomer 2.6 then underwent 















Key: (a) N-chlorosuccinamide, benzene; (b) 2.12, THF:ether (1:1); 

























6 steps in LLS
Key: (a) 2.9, t-BuLi, HMPA/THF, -78 °C; (b) MnO2, CH2Cl2, dimethyl triazolium iodide, DBU, 
















Scheme 2.3 Synthesis of the macrodiolide framework.  
 
Thiophenyl glycoside 2.20 was prepared according to a procedure by Willis and 
coworkers (Scheme 2.4).87 The synthesis began with the peracetylation of D-xylose to give 2.18, 
which was treated with thiophenol in the presence of BF3⋅OEt2. Hydrolysis with sodium 
methoxide followed by an acidic workup provided triol 2.19. Finally, methylation was achieved 
using NaH with MeI to afford thiophenyl glycoside 2.20. 
Scheme 2.4 Synthesis of thiophenyl glycoside 2.20.  
 
Completion of the first-generation route to cyanolide A was accomplished by 
deprotection of the 1,3-dithiane protecting group to provide the corresponding ketone 2.21 
(Scheme 2.5). Reduction of the ketone functionalities with NaBH4 afforded cyanolide A aglycon 
2.22. The final glycosylation of the aglycon was achieved by treating 2.22 with thiophenyl 
Key: (a) DDQ, H2O:CH2Cl2 (1:10), 25 °C; (b) SO3·pyr, Et3N:DMSO:CH2Cl2 (1:1:10), 0 to 25 °C; (c) Et2Zn, (+)-























































Key: (a) thiophenol, BF3·OEt2, CH2Cl2, 0 °C; (b) NaOMe, MeOH, 25 °C, then Amberlite IR-120(H+) 











glycoside 2.20 in the presence of MeOTf; however, the diastereoselectivity was quite poor 
(21:33:13, 2.2: β,α-anomer: α,α-anomer). This first-generation synthesis was completed with a 
longest linear sequence (LLS) of 14 steps.  
Scheme 2.5 Completion of the first generation total synthesis of (−)-cyanolide A.  
 
 
Hong and coworkers also explored a second route in which glycosylation would precede 
dimerization (Scheme 2.6). Compound 2.7 was first deprotected to afford secondary neopentyl 
alcohol 2.23. Glycosylation at this stage with thiophenyl glycoside 2.20 in the presence of 
MeOTf provided 2.24 as a 3.7:1 mixture of anomers favoring the desired β-anomer. 
Deprotection of the PMB ether with DDQ, oxidation of the resulting primary alcohol to the 
aldehyde oxidation state, and diastereoselective ethylation provided methyl ester 2.5. Ester 





























14 steps in LLS
Me Me Me Me
2.21 2.22
Key: (a) I2, sat. aq. NaHCO3:CH3CN (1:1), 0 °C; (b) NaBH4, MeOH, -40 to -20 °C; (c) 2.20, MeOTf, ether, 




Scheme 2.6 Second-generation total synthesis of (−)-cyanolide A.  
 
 The completion of the second-generation synthesis of (−)-cyanolide A provided the key 
insight that the installation of the xylose-derived moiety prior to dimerization resulted in higher 
levels of diastereoselectivity. Comparison of the [α]25D with that of natural 2.2 enabled the 
confirmation of the absolute stereochemistry of the natural product.  
2.4.2 Reddy’s Formal Synthesis of (−)-Cyanolide A 
Reddy and coworkers accomplished the formal synthesis of (−)-cyanolide A aglycon 
starting from (−)-pantolactone (2.29, ~$25 / g, Scheme 2.7).88 Their strategy relied on an oxa-
Michael cyclization to construct pyran 2.25. The requisite alcohol for cyclization, 2.26, was 
constructed via Mukaiyama aldol addition to aldehyde 2.28, which had been prepared previously 











































Reagents: (a) I2, sat. aq. NaHCO3:CH3CN (1:1), 0 °C; (b) NaBH4, MeOH, -40 to -20 °C; (c) 2.20, 
MeOTf, ether, 4Å MS, 25 °C; (d) DDQ, H2O:CH2Cl2 (1:10), 25 °C; (e) TPAP, NMO, 4Å MS, 
CH2Cl2, 25 °C; (f) Et2Zn, (+)-MIB, toluene:hexanes (1:2), 0 °C; (g) LiOH, THF:MeOH:H2O (2:1:1),
25 °C; (h) MNBA, DMAP, toluene, 90 °C.
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Scheme 2.7 Reddy’s retrosynthesis of (−)-cyanolide A.  
 
The synthesis began with protection of the secondary neopentyl alcohol of 2.29 as a 
benzyl ether followed by DIBAL reduction to provide lactol 2.31 (Scheme 2.8). Wittig 
olefination of the lactol afforded primary alcohol 2.32, which was protected as TBS ether 2.33. 
Hydroboration-oxidation of the terminal alkene produced primary alcohol 2.34, which was 

































Scheme 2.8 Synthesis of known aldehyde 2.28.  
 
 Mukaiyama aldol of silyl enol ether 2.35 and aldehyde 2.28 afforded the desired β-
hydroxy ketone 2.27 with very good diastereoselectivity (>95%, Scheme 2.9). Reduction of the 
ketone was achieved using catecholborane and the resulting syn-1,3-diol was protected as 
acetonide 2.36. Next, deprotection of the primary silyl ether and Swern oxidation provide the 
aldehyde necessary for Wittig olefination, which furnished enone 2.37. Treatment with PTSA 
facilitated oxa-Michael cyclization delivering ester 2.25, which was hydrolyzed and subjected to 
conditions for Yamaguchi macrolactonization.90 Completion of the formal synthesis was 
achieved after hydrogenative deprotection of the benzyl ethers and provided (−)-cyanolide A 






































Key: (a) AgO, BnBr, DMF, 0 °C; (b) DIBAL-H, DCM, -78 °C; (c) methyl triphenylphosphonium bromide, THF, n-
BuLi in hexanes, 0 °C; (d) TBDMSCl, DMAP, pyridine, 0 °C; (e) BH3·THF, THF, -20 °C to rt, then NaOH, H2O2; 
(f) (COCl)2, DCM, DMSO, Et3N, -78 °C.
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Scheme 2.9 Completion of the formal synthesis of (−)-cyanolide A.  
 
2.4.3 She’s Formal Synthesis of (−)-Cyanolide A 
She and coworkers’ approach to (−)-cyanolide A required the synthesis of methyl ester 
2.5 (Scheme 2.10),91 which could undergo macrolactonization to access the natural product as 
previously described by the Hong group.84 Synthesis of pyran 2.38 was anticipated to come from 
a Pd-catalyzed intramolecular alkoxycarbonylation reaction of terminal alkene 2.39. Installation 


























Key: (a) LDA, TMSCl, THF, -78 to 0 °C.
MeMe
2.37
Key: (a) 2.35, BF3·Et2O, DCM, -78 °C; (b) catecholborane, THF, -10 °C; (c) 2,2-dimethoxypropane, PPTS, 
DCM, 25 °C; (d) TBAF, THF, 60 °C; (e) (COCl)2, DMSO, Et3N, DCM, -78 °C; (f) Ph3PCHCOOEt, toluene, 
reflux. (g) PTSA, CHCl3, reflux; (h) LiOH·H2O, H2O:MeOH:THF (1:1:2), 25 °C; (i) 2,4,6-trichlorobenzoyl 

























Cyanolide A aglycon, 2.22




Scheme 2.10 She’s retrosynthesis of (−)-cyanolide A.  
 
 
 The synthesis began with the coupling of chiral epoxide 2.41 with 2-allyl-1,3-dithiane 
followed by deprotection to give ketone 2.43 (Scheme 2.11). Evans-Tishchenko reduction in the 
presence of ethyl formate provided terminal alkene 2.40. Barbier-type coupling with prenyl 
bromide afforded alkene 2.39 as a 1:1 mixture of diastereomers (only one diastereomer is shown, 





































Scheme 2.11 Synthesis of pyran precursor 2.39.  
 
Acetonide protection of the 1,3-diol substructure followed by reductive deprotection of 
the ethyl ester yielded terminal alkene 2.44 (Scheme 2.12). The stereochemistry of the free 
hydroxyl group was inverted under Mitsunobu conditions with 4-methoxyphenol, and acidic 
hydrolysis of the acetonide gave PMB ether 2.45. Upon exposure to carbon monoxide in the 
presence of CuCl2 and catalytic PdCl2, compound 2.45 underwent intramolecular 
alkoxycarbonylation to afford pyran 2.38. Glycosylation of the secondary neopentyl alcohol with 
2.20 followed by oxidative removal of the PMP ether furnished known methyl ester 2.5 and thus 
























Key: (a) 2-allyl-1,3-dithiane, BuLi, THF, 0 °C; (b) I2, CaCO3, THF:H2O (4:1), 0 °C; (c) SmI2, 





Scheme 2.12 Completion of the formal synthesis of (−)-cyanolide A.  
 
2.4.4 Pabbaraja’s Formal Synthesis of (−)-Cyanolide A 
 The Pabbaraja group’s formal synthesis of (−)-cyanolide A92 was proposed beginning 
with 2.29 in a manner similar to that of Reddy (Scheme 2.13) with the goal of synthesizing 
cyanolide A algycon 2.22. Their strategy to access the aglycon hinged on oxidation and 
dimerization of alcohol 2.47. This alcohol was to be synthesized from lactone 2.48 via a tandem 


































Key: (a) 2,2-dimethoxypropane, TsOH (cat.), DCM, 0 °C; (b) LiAlH4, THF, 0 °C; (c) 4-methoxyphenol, DIAD, 
PPh3, THF, 25 °C; (d) 1 N HCl, MeOH, 0 °C; (e) PdCl2 (cat.), CuCl2, CH3CN, MeOH, CO, 30 °C; (f) 2.20, 







13 steps in LLS
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Scheme 2.13 Pabbaraja’s retrosynthesis of (−)-cyanolide A.  
 
 The synthesis began from known alcohol 2.32 that was synthesized in three steps from 
2.29 (Scheme 2.14). Oxidation of the primary alcohol followed by a Crimmin’s acetate aldol 
reaction produced alcohol 2.50 with good levels of stereoinduction, 9:1, favoring the desired 
diastereomer. Compound 2.50 was transformed into amide 2.51 upon exposure to Weinreb’s salt 
and imidazole. Treatment of the amide with lithium naphthalenide resulted in debenzylation as 
well as cleavage of the N-O bond to afford diol 2.52. Exposure of diol 2.52 to Ba(OH)2⋅8H2O led 























Scheme 2.14 Synthesis of lactone 2.48.  
 
 Elaboration of 2.48 began with reduction of the lactone to the lactal and subsequent 
tandem Wittig olefination and oxa-Michael cyclization, which provided 2.53 as an inseperable 
mixture of diastereomers (7:2 in favor of the stereochemistry shown, Scheme 2.15). The 
secondary neopentyl alcohol was protected as a TBS ether and the ketone was reduced using the 
(S)-CBS catalyst to afford alcohol 2.47 as a seperable mixture of diasteromers (4:1 in favor of 
the stereochemistry shown). The terminal olefin underwent hydroboration-oxidation to provide 
primary alcohol 2.55. Selective oxidation of the primary alcohol with TEMPO and BAIB yielded 
the requisite seco-acid for macrolactonization, which proceeded smoothly under Shiina’s 
conditions to furnish macrodiolide 2.56. Deprotection of the silyl protecting groups completed 












Key: (a) PCC, CH2Cl2, rt; (b) (R)-1-(4-benzyl-2-thioxothiazolidin-3-yl)ethanone, TiCl4, DIPEA, CH2Cl2, 0 °C 
to -78 °C; (c) CH3NHOCH3·HCl, imidazole, CH2Cl2, rt; (d) lithium naphthalenide, THF, -20 °C; (e) 





































Scheme 2.15 Completion of the formal synthesis of (−)-cyanolide A.  
 
 
2.4.5 Rychnovsky’s Formal Synthesis of (−)-Cyanolide A 
 The formal synthesis proposed by Rychnovsky and coworkers showcased a Sakurai 
dimerization of allylsilane 2.57, which was to be converted to known ketone 2.21 (Scheme 
























Key: (a) DIBAL-H, CH2Cl2, -78 °C; (b) 1-(triphenylphosphoranylidene)butan-2-one, benzene, reflux; (c) 
TBSCl, 2,6-lutidine, DMF, 0 °C to rt; (d) (S)-CBS, BH3·DMS, THF, -30 °C; (e) BH3·DMS, NaOH, H2O2, THF, 0 
































Scheme 2.16 Rychnovsky’s retrosynthesis of (−)-cyanolide A.  
 
 The synthesis of carboxylic fragment 2.58 began with Barbier-type coupling of α-bromo 
ester 2.59 and ethylorthoformate to generate acetal 2.60 (Scheme 2.17). Exposure of the acetal to 
LiCH2TMS followed by enol triflate formation using KHMDS and PhNTf2 produced vinyl 
triflate 2.62. Kumada coupling and deprotection of the acetal under mildly acidic conditions 
afforded aldehyde 2.64. Aldol reaction with Nagao’s auxiliary under Sammakia’s conditions 


































Scheme 2.17 Synthesis of carboxylic acid 2.58.  
 
 Acetal fragment 2.68 was synthesized in two steps from chiral epoxide 2.66 (Scheme 
2.18). Coupling of fragment 2.68 and 2.58 was achieved under Yamaguchi’s conditions for 
esterification to produce β-hydroxy ester 2.57. Sakurai dimerization was achieved through 
treatment of 2.57 with TMSOTf to give macrodiolide 2.69, which was subsequently oxidized to 















































Key: (a) Zn, ethylorthoformate, benzene; (b) LiCH2TMS, pentane, 0 °C; (c) KHMDS, 
PHNTf2, THF, -78 °C; (d) ClMgCH2TMS, Pd(PPh3)4, LiCl, Et2O, 0 °C; (e) pTSA·H2O, 
H2O:acetone (1:1); (f) (S)-1-(4-(tert-butyl)-2-thioxothiazolidin-3-yl)ethanone, (-)-sparteine, PhBCl2, 








Scheme 2.18 Completion of the formal synthesis of (−)-cyanolide A.  
 
2.4.6 Jennings’ Formal Synthesis of (−)-Cyanolide A 
 The formal synthesis of (−)-cyanolide A devised by Jennings and coworkers required 
seco-acid 2.70 for macrolactonization to provide access to aglycon 2.22.94 Jennings hypothesized 
that alkylation of lactone 2.71 followed by a stereoselective oxocarbenium ion reduction would 
produce the desired monomer. Lactone 2.71 was anticipated to be accessible from aldehyde 2.72, 






















Key: (a) 2.68, Cl3PhCOCl, DMAP, Et3N, benzene; (b) TMSOTf, CH2Cl2, -78 °C; (c) OsO4, NMO, 
H2O:acetone (1:3.15), then NaIO4.
2.58
2.21


















Scheme 2.19 Jenning’s retrosynthesis of (−)-cyanolide A.  
 
The forward synthesis began with homoallylic alcohol 2.73, which had been prepared in 
three steps from (−)-α-pinene (Scheme 2.20). Cross-metathesis with 2-ethylhexyl acrylate 
provided enone 2.74, which underwent tandem acetalization and oxa-Michael cyclization to 
afford acetal 2.75. Reduction of the ester with DIBAL followed by diastereoselective 
Mukaiyama aldol gave β-hydroxy ester 2.76 and the hydroxyl group was protected as MOM 
ether 2.77. Hydrogenation of 2.77 removed the acetal protecting group and subsequent treatment 






























Scheme 2.20 Synthesis of lactone 2.71.  
 
The key step in Jennings’ synthesis was alkylation of lactone 2.71 and stereoselective 
reduction of the oxocarbenium ion generated under acidic conditions (Scheme 2.21). Coupling of 
allylmagnesium bromide to lactone 2.71 at low temperature followed by addition of TFA led to 
formation of an oxocarbenium ion, which was selectively reduced with Et3SiH to afford pyran 
2.78. Ozonolysis of the terminal alkene followed by Pinnick oxidation provided seco-acid 2.70, 
which underwent macrolactonization under Yamaguchi’s conditions to furnish macrodiolide 
2.80. Deprotection of the MOM ether produced (−)-cyanolide A aglycon and completed the 











































Key: (a) 2-ethylhexyl acrylate, Grubbs' 2nd Generation, benzene, rt; (b) PhCHO, tBuOK, THF, 0 °C; (c) DIBAL, 
CH2Cl2, -78 °C; (d) ((1-ethoxy-2-methylprop-1-en-1-yl)oxy)trimethylsilane, BF3·Et2O, CH2Cl2, -78 °C; (e) MOMCl, 










Scheme 2.21 Completion of the formal synthesis of (−)-cyanolide A.  
 
2.5 Conclusions 
The potent molluscicidal activity and complex structure compelled researchers to 
synthesize cyanolide A. Each of these completed syntheses confirmed the proposed structure and 
illustrated the utility and limitations of methodologies used to construct polyketides. However, 
these routes typically required synthetic concessions such as multiple protecting group 
manipulations and repeated oxidation state adjustments. Our intention was to develop a more 
concise and versatile synthetic route that combines the information learned from these previous 
syntheses with our newly developed metal-catalyzed transformations. In doing so, this would 
lead to the development of a synthetic route to (−)-cyanolide A that requires roughly half of the 







Key: (a) allylmagnesium bromide, THF, -78 °C, then TFA, CH2Cl2; (b) O3, CH2Cl2, -78 °C; (c) NaClO2, NaH2PO4, 









































14 steps in LLS
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Chapter 3: Total Synthesis of (−)-Cyanolide A 
3.1 First-Generation Total Synthesis of (−)-Cyanolide A 
 Within the field of synthetic organic chemistry, total synthesis has often been the testing 
ground for new methodologies and strategies.95 As chemical technology advances, the question 
of synthetic feasibility has diminished while concern for practicality and efficiency has been 
augmented. This balance between feasibility and efficiency is specifically exemplified in the 
synthesis of polyketide natural products. Progress made in the field of carbonyl addition 
chemistry has led to the development of a plethora of methods for the construction of 
polyketides; however, these methods typically require the use of stoichiometric chiral auxiliaries 
and pre-metallated reagents. While these transformations address the feasibility of complex 
chemical synthesis, they represent an interim solution to the challenge of de novo polyketide 
construction. As organic molecules are compounds composed of carbon and hydrogen, the 
terminal solutions to this challenge will encompass stereoselective and atom-efficient methods 
for skeletal assembly involving the addition, removal, or redistribution of hydrogen in the 
absence of protecting groups, discrete oxidation level adjustment, or non-constructive functional 
group interconversions.96 Therefore, methods that allow for the direct transformation of 
feedstock chemicals into complex, value-added compounds are ideal. The concept of ideality in 
regards to chemical synthesis has garnered significant attention over the last half century.  
In 1975, Hendrickson first defined parameters that he believed could be used to evaluate 
a synthetic sequence in an effort to establish the ideal chemical synthesis.97 His definition of an 
ideal synthesis involves a synthetic sequence that begins with available small molecules and is 
comprised only of successive construction events that require no intermediary re-
functionalization. Furthermore, functional groups should be correctly placed when installed 
within the carbon framework. Recently, Baran and coworkers have constructed a metric to 
evaluate and quantify the ideality of a synthesis. They define the percent ideality as the sum of 
construction reactions and strategic redox reactions divided by total number of steps (multiplied 
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by 100%). Non-strategic reactions included reduction and oxidation reactions that do not install 
functionality in the oxidation state present in the final compound as well as protecting group 
manipulations. Reducing the number of synthetic steps required to produce complex molecules is 
important as it reduces time, effort, and expenses associated with the development and 
implementation of a chemical synthesis.  
In prior syntheses of (−)-cyanolide A 3.1, multiple synthetic concessions were made in 
order to access the desired final compound. Due to the highly oxygenated nature of 3.1, 
oxidation state adjustments and differential protection of hydroxyl functional groups represented 
a significant fraction of the total number of synthetic transformations. Most syntheses began with 
commercially available chiral starting materials and thus stereoinduction was performed 
stoichiometrically. Even with a chiral center installed, many of the prior syntheses required 
chiral auxiliaries to enforce high levels of stereoselectivity. While chiral auxiliaries can 
sometimes be inexpensive and recyclable, their use still requires additional synthetic 
manipulations beyond the construction event. Finally, C-C bonds formed through the use of 
premetallated C-nucleophiles are often employed with great success; however, they typically 
require multiple stages of pre-activation and generate stoichiometric waste products. These waste 
products are often of higher molecular weight than the nucleophile that was incorporated into the 
chemical structure of the product. These issues of atom,98 step,99 and redox-economy100 are all 
concessions and illustrate the need for synthetic methodologies and strategies that can be used to 
synthesize complex molecules in a more direct manner. These concerns helped guide and shape 
our synthetic strategy as it applied to the total synthesis of (−)-cyanolide A. 
3.1.1 Retrosynthetic Analysis  
Our synthetic strategy for the total synthesis of (−)-cyanolide A 3.1 was derived from the 
idea that the macrodiolide natural product could be constructed through elaboration and 
dimerization of pyran 3.2, in a manner similar to that of the prior syntheses (Scheme 3.1).101 
Construction of pyran 3.2 was envisaged to take place via a bidirectional cross-metathesis of 
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chiral C2-symmetric, chiral diol 3.3 with ethyl vinyl ketone and subsequent acid-promoted oxa-
Michael cyclization. Chiral diol 3.3 had been previously prepared as an example of asymmetric 
iridium-catalyzed two-directional allylation.102 The total synthesis would thus begin from 
neopentyl glycol 3.4, an inexpensive (~$30 / mol) chemical feedstock. 
Scheme 3.1 Retrosynthetic analysis of (−)-cyanolide A.  
 
3.1.2 Synthesis of Pyran 3.2 
Our synthesis began with the installation of the C3 and C5 stereocenters through 
asymmetric two-directional allylation (Scheme 3.2). It is worth emphasizing again that the 
construction of diol 3.3 via traditional methods for carbonyl addition would require 8 steps, more 
than half of which are non-strategic reactions. This lengthy preparation stems from the inherent 
instability of 1,3-dialdehydes, which can undergo enolization and self-condensation in cases 
when not fully substituted at the 2-position.19 1,3-dialdehydes that are fully substituted at the 2-





















































glycol 3.4 is exposed to allyl acetate in the presence of [Ir(cod)Cl]2, (S)-Cl-MeO-BIPHEP, 4-Cl-
3-NO2-benzoic acid, and Cs2CO3 in 1,4-dioxane, C2-symmetric, chiral diol 3.3 is obtained in 48% 
yield with very high levels of stereoselectivity (20:1 d.r., > 99% e.e.).102 
While this transformation does generate a great deal of complexity in a single 
transformation directly from simple primary alcohols, it is not without its shortcomings. 
Extensive optimization was conducted during the initial development of the two-directional 
allylation and while yields were good for many substrates, the transformation of neopentyl glycol 
3.4 into chiral diol 3.3 is less than 50% yield. This is most likely due to the steric hindrance of 
the methyl substitution at the 2-position of the 1,3-diol (C4 as depicted in the schemes). 
Alkylation of the transient aldehyde generated upon dehydrogenation of one of the alcohol 
functionalities could require significant energy to overcome the stereoelectronic effects of the 
gem-dimethyl moiety. The allylation reaction is performed in a sealed tube and heated to 100 °C, 
which can be a hazard if high enough pressures are generated within the vessel. 
The major limitation is the cost of the chiral ligand. The results of the optimization 
screening of ligand indicated that (S)-Cl-MeO-BIPHEP provided the highest yield and 
stereoselectivity. While on small scale, use of this ligand was acceptable it was advantageous to 
identify a less expensive ligand for reactions on preparative scale for the total synthesis. It was 
found that (S)-binap could be used in gram-scale allylation reactions and provided similarly high 
levels of stereoselectivity, but the yield was limited to 40%. The development of conditions for 
catalyst recovery in these reactions has not been successful. Nevertheless, diol 3.3 was 




Scheme 3.2 Synthesis of 3.3 via transfer hydrogenative C-C bond formation.  
 
With 3.3 in hand it was anticipated that cross-metathesis with ethyl vinyl ketone (EVK) 
would install the desired C8-C11 fragment and furnish bis-enone 3.5 (Scheme 3.3). A number of 
parameters were screened including choice of metathesis catalyst, solvent, concentration and 
temperature. Exposure of 3.3 to ethyl vinyl ketone in the presence of Hoveyda-Grubbs 2nd 
Generation catalyst (HG-II) at room temperature in toluene afforded bis-enone 3.5 in high yield. 
Due to symmetry, both alkenes underwent metathesis with ethyl vinyl ketone; however, it was 
anticipated that desymmetrization would allow for the selective removal of the unwanted ethyl 
ketone moiety. Oxa-Michael cyclization was effected through treatment of 3.5 with PPTS in 
DCM and pyran 3.2 was obtained in 93% yield and ~6:1 d.r. in favor of the desired all syn pyran. 
 In the course of screening conditions for the cross-metathesis step, it was discovered that 
Fuwa and coworkers had developed conditions for tandem cross-metathesis and oxa-Michael 
cyclization to generate pyrans in a single transformation.103 Application of the reported 
conditions furnished 3.2 in 76% yield and 10:1 d.r. directly from 3.3. The improved 
diastereoselectivity can be attributed to thermodynamic control in the oxa-Michael cyclization. 
Through this synthetic sequence, three stereocenters and the entire non-sugar carbon framework 









chiral ligand (10 mol%)
4-Cl-3-NO2-BzOH (20 mol%)
Cs2CO3 (40 mol%)











d.r. %ee % yield
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Scheme 3.3 Cross-metathesis and oxa-Michael cyclization.  
 
3.1.3 Completion of the First-Generation Total Synthesis 
 With the compound now desymmetrized pyran 3.2 in hand, we sought to remove the 
ethyl vinyl ketone fragment at C1 that is not present in the natural product (Scheme 3.4). It was 
found that exposure of 3.2 to HG-II under an atmosphere of ethylene gas resulted in the removal 
of the fragment and afforded alkene 3.6 in 70% yield. Attempts to perform the ethylene 
metathesis directly after cross-metathesis and oxa-Michael cyclization were unsuccessful 
presumably due to catalyst decomposition at the elevated reaction temperatures.104 The 
secondary, neopentyl hydroxyl group was next glycosylated with thiophenyl glycoside 3.7, 
which was prepared according to literature precedent in 3 steps from D-xylose,87 to afford ketone 









































Scheme 3.4 Completion of the first-generation synthesis of (−)-cyanolide A 3.1.  
 
 With the carbon framework successfully constructed, reduction of ketone 3.8 with L-
Selectride provided alcohol 3.9 as a seperable 4:1 mixture of diastereomers in favor of the 
desired 1,3-syn relationship between C9 and C7. Less bulky hydride reagents such as LAH and 
NaBH4 gave lower levels of diastereoselectivity even when applied in conjunction with chelating 
salts such as LiI and ZnCl2, but ultimately L-Selectride was suitable for the reaction. The 
observed 1,3-syn diastereoselectivity using L-Selectride is in accordance with Evans’ revision of 
Cram’s polar model for the reduction of β-alkoxy ketones.105 Modified conditions for Johnson-
Lemieux oxidative cleavage of the terminal olefin in compound 3.9 was achieved using catalytic 
OsO4 and superstoichiometric oxone as the terminal oxidant,106 which afforded seco-acid 3.10. 
a
70%
Key: (a) HG-II (10 mol%), ethylene, toluene (0.01 M), 60 °C; (b) 3.7 (150 mol%), MeOTf (200 
mol%), 4 Å MS (200 wt%), Et2O (0.07 M); (c) Li(sBu)3BH (100 mol%), THF (0.05 M), -78 °C; (d) 
OsO4 (1 mol%), oxone (400 mol%), DMF (0.1 M); (e) 2-methyl-6-nitrobenzoic anhydride (300 


































































With the monomer in hand, macrolactonization was attempted. Upon treatment of seco-acid 3.10 
with Shiina’s reagent for esterification in the presence of DMAP,86 (−)-cyanolide A 3.1 was 
synthesized in 18% yield (over 2 steps). The first-generation total synthesis of the natural 
product was completed in 7 steps (LLS) from neopentyl glycol 3.4.  
3.2 Second-Generation Total Synthesis of (−)-Cyanolide A 
In evaluating the first-generation route to the natural product, it became clear that while 
the overall synthesis was quite concise there was still more opportunity for optimization of the 
sequence. In particular, it was recognized that the ruthenium-catalyzed ethenolysis of pyran 3.2 
to afford terminal alkene 3.6 was a major concession, as it did not construct any missing 
functionality or structure to molecule, but rather was a means of correcting an undesired 
metathesis event. Additionally, ethenolysis of 3.2 was thought necessary as a means of 
eliminating the undesired ketone, which could complicate the reduction of the C9 carbonyl later 
in the synthetic sequence.   
An ideal solution would have been to continue the synthesis and later attempt to 
oxidatively cleave the alkene directly to the desired carboxylic acid 3.10 (Scheme 3.5). This 
would no longer be a concession as it would correct for the erroneous installation of the ethyl 
ketone fragment while simultaneously installing the necessary functionality at C1. However, the 
viability of this proposed sequence would require that diastereoselective reduction of the C9 
carbonyl be performed in the presence of the enone. As the product of this reduction directly 
from 3.2 was anticipated to be a triol, concerns arose with respect to the chemoselectivity of the 
glycosylation of the C5 hydroxyl group at a later stage. Therefore, to ensure chemoselectivity 3.2 




Scheme 3.5 Unsuccessful route to 3.10 without relying on ethenolysis.  
 
 Reduction of 3.11 was attempted using a variety of hydride sources and conditions 
including NaBH4, LAH, and L-Selectride. Due to the four possible sites for reduction, it was 
anticipated that four possible products could be produced. High diastereoselectivity at C9 was 
required but selectivity in the reduction of the carbonyl of the enone was inconsequential as that 
fragment was to later be cleaved. However, in the reduction the reaction mixture was further 
complicated due to competition between 1,2- and 1,4-reduction of the enone. To further 
complicate matters, if 1,4-reduction occurred, the resulting aliphatic ketone could be reduced in 
the presence of excess hydride to give an alcohol. The products of 1,4-reduction would no longer 
contain the alkene necassry for oxidative cleavage and thus this route to 3.10 would not be 
feasible. Various conditions were explored to enforce 1,2-reduction of the enone carbonyl 
including the conditions developed by Luche,107 as well as Zn(BH4)2 in 1,2-dimethoxyethane.108 
However, no set of conditions was identified to provide simplified reaction mixtures.  
 Faced with this challenge of chemoselectivity, a new strategy for overcoming this 






































followed by oxidative cleavage had proven to be problematic, investigation into first performing 
oxidative cleavage followed by diastereoselective reduction was examined (Scheme 3.6).  
Typically, ozonides generated from the ozonolysis of alkenes are reduced using dimethyl sulfide 
or triphenylphosphine to give aldehydes. Reduction of the ozonide to primary alcohols is 
performed far less frequently, but a report by Srikrishna and coworkers demonstrated that 
ozonolysis and subsequent reduction with sodium borohydride afforded the corresponding 
primary alcohol directly from the alkene.109 Motivated by this precedent, attempts were made to 
perform the tandem oxidative cleavage and diastereoselective reduction of ketone 3.11.  
Scheme 3.6 Completion of the second-generation synthesis of (−)-cyanolide A.  
 
Exposure of 3.11 to ozone under cryogenic conditions followed by addition of L-
Selectride afforded diol 3.12 as a seperable 5:1 mixture of diastereomers in favor of the desired 
diastereomer. At this stage, chemoselective oxidation of the primary alcohol to a carboxylic acid 

























Key: (a) ozone, THF (0.05 M), -78 °C then Li(sBu)3BH (1000 mol%), -78 to 25 °C; (b) 
TEMPO (30 mol%), NaClO (225 mol%), NaHCO3 (aq.), CH2Cl2 (0.05 M), 0 °C then 
isobutylene (1400 mol%), NaClO2 (225 mol%), Na2HPO4 (aq.), NaBr (aq.), tBuOH 





















the primary alcohol to the corresponding aldehyde and Pinnick oxidation of the aldehyde 
provided seco-acid 3.10 in 62% yield, which was obtained as a crystalline solid. Confirmation of 
the relative and absolute stereochemistry was obtained through X-ray diffraction analysis of 3.10 
(Figure 3.1). Macrolactonization using the recrystallized product under Yamaguchi’s conditions 
for macrolactonization furnished (−)-cyanolide A 3.1 in 47%. The second-generation route to the 
natural product was completed in just 6 steps (LLS) from neopentyl glycol 3.4. This represents 
the most concise total synthesis of (−)-cyanolide A to date and requires half the number of steps 
(LLS) as the next shortest synthesis. Both generations of the synthesis of (−)-cyanolide A were 
done without protecting groups, chiral auxiliaries, and premetallated C-nucleophies, which 
significantly reduced the overall step count. According to Baran’s metric for synthetic ideality, 
both routes described above are ~80% ideal. Notably, this is the only synthesis in which chirality 
was introduced in a catalytic manner as opposed to using a chiral starting material.  
Figure 3.1 View of molecule 3.10 of 1 showing the atom-labeling scheme. Displacement 
ellipsoids are scaled to the 50% probability level. The hydrogen atoms on the 






Diastereoselectivity and chemoselectivity proved to be significant challenges in 
successfully completing the total synthesis of (−)-cyanolide A 3.1. Identification of conditions 
that facilitated multiple transformations in a single step was of critical importance with regard to 
overall step count, while some synthetic challenges required reorganization of the proposed 
synthetic sequence. Of critical importance was the rapid construction of the pyran core of the 
natural product, which was made possible through two metal-catalyzed reactions; asymmetric 
iridium-catalyzed two-directional allylation and ruthenium-catalyzed tandem cross-metathesis 
and oxa-Michael cyclization.  
The asymmetric iridium-catalyzed transfer hydrogenative C-C bond forming 
methodology generated two stereocenters and installed a significant portion of the carbon 
framework of the natural product. It is important to note that concise methods to address the 
preparation of polyketides are of significant interest. Accordingly, the Krische laboratory has 
devised a suite of catalytic methods for construction of polyketide substructures in which 
hydrogen exchange is accompanied by C-C bond formation.110 As illustrated by the present total 
syntheses of (−)-cyanolide A,101 application of this methodology has availed the most concise 
route to any member of this polyketide natural product family. 
3.4 Experimental Details 
3.4.1 General Information 
All reactions were run under an atmosphere of argon under anhydrous conditions unless 
otherwise indicated. Dichloroethane (DCE) and dichloromethane (CH2Cl2) were distilled 
over CaH2. Diethyl ether (Et2O), tetrahydrofuran (THF), and toluene (PhMe) were distilled over 
sodium and benzophenone. Pressure tubes (25x150 mm, PYREXPLUS, and 350 mL flask, 
purchased from Chem Glass) were dried in an oven overnight and cooled under a stream of 
nitrogen prior to use. Commercially available allyl acetate (Aldrich) was purified by distillation 
prior to use. Neopentyl glycol was purified by sublimation prior to use. Ethyl vinyl ketone was 
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purified by distillation prior to use. All other commercial reagents were used directly without 
further purification unless specified. All analytical thin-layer chromatography (TLC) was carried 
out using 0.2 mm commercial silica gel plates (DC-Fertigplatten Kieselgel 60 F254). Plates were 
visualized by treatment with UV, acidic p-anisaldehyde stain, ceric ammonium molybdate stain, 
or KMnO4 stain with gentle heating. Infrared spectra were recorded on a Nicolet 380 FTIR.  
3.4.2 Spectrometry and Spectroscopy 
Infrared spectra were recorded on a Thermo Nicolet 380 spectrometer. Low- and high-
resolution mass spectra (LRMS or HRMS) were obtained on a Karatos MS9 and are reported as 
m/z (relative intensity). Accurate masses are reported for the molecular ion or a suitable 
fragment ion. Melting points were obtained on a Stuart SMP3 apparatus and are uncorrected. 1H 
NMR spectra were recorded on a Varian Gemini (400 MHz) spectrometer at ambient 
temperature. Chemical shifts are reported in delta (d) units, parts per million (ppm), relative to 
the center of the singlet at 7.26 ppm for deuteriochloroform, or other reference solvents as 
indicated. Data are reported as chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q 
= quartet, m = multiplet), integration and coupling constant(s) in Hz. 13C NMR spectra were 
recorded on a Varian Gemini (100 MHz) spectrometer and were routinely run with broadband 
decoupling. Chemical shifts are reported in ppm, with the center peak of the residual solvent 
resonance employed as an internal standard (CDCl3 at 77.0 ppm). 
3.4.3 Procedures and Spectra 
(4S,6S)-5,5-dimethylnona-1,8-diene-4,6-diol (3.3) 
To an oven-dried sealed tube under one atmosphere of argon gas charged with 
[Ir(cod)Cl]2 (0.672 g, 1.00 mmol, 5 mol%), (S)-BINAP (1.25 g, 2.00 mmol, 10 mol%), Cs2CO3 
(2.61 g, 8.00 mmol, 40 mol%) and 4-chloro-3-nitrobenzoic acid (0.806 g, 4.00 mmol, 20 mol%) 
was added THF (50 mL) followed by allyl acetate (20.0 g, 200 mmol, 1000 mol%). The reaction 
mixture was stirred at 90 ºC for 0.5 h before cooling to ambient temperature. Neopentyl glycol 
(2.08 g, 20.0 mmol, 100 mol%) in THF (50 mL) was added and the reaction mixture was stirred 
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at 100 ºC for 5 days. The reaction mixture was cooled to ambient temperature, filtered, and 
excess solvent was removed under reduced pressure. Purification of the product by column 
chromatography (SiO2: ethyl acetate:hexanes, 1:6 to 1:4 with 0.1% TEA) provided 3.3 (1.48 g, 
40% yield, dr > 20:1, ee > 99%) as a pale yellow oil.  
TLC (SiO2): Rf = 0.25 (ethyl acetate:hexanes, 1:4). 
1H NMR: (400 MHz, CDCl3): δ 5.94-5.83 (m, 2H), 5.18-5.13 (m, 4H), 3.58-3.55 (m, 2H), 2.97 
(s, 2H), 2.35-2.30 (m, 2H), 2.19-2.07 (m, 2H), 0.93 (s, 6H). 
13C NMR: (100 MHz, CDCl3): δ 136.2, 117.8, 77.4, 40.0, 36.5, 20.9. 
FTIR (neat): ν 3368, 3074, 2972, 2940, 2909, 2874, 1708, 1637, 1472, 1423, 1370, 1249, 1054 
cm-1. 
HRMS: (ESI) Calcd. for C11H20O2Na (M+Na)+: 207.1356, Found: 207.1355. 
[α]20D: -18.77 ° (c = 0.52, CHCl3). 










To a stirred solution of 3.3 (747 mg, 4.05 mmol, 100 mol%) in DCE (21 mL, 0.2 M) was 
added ethyl vinyl ketone (6.82 g, 81.1 mmol, 2000 mol%, 8.1 mL) followed by Hoveyda-Grubbs 
2nd Generation catalyst (254 mg, 0.405 mmol, 10 mol%). The resulting mixture was stirred at 80 
ºC for 24 h. The reaction mixture was cooled to ambient temperature. KO2CCH2NC (200 mg, 40 
mol%) in MeOH (2 mL) was added111 and the mixture was stirred for 0.5 h. The mixture was 
filtered through Celite and the excess solvent was removed under reduced pressure. The crude 
material was purified via column chromatography (SiO2: ethyl acetate:hexane 3:7 to 2:3) to 
afford 3.2 (918 mg, 77% yield, dr =10:1) as a light brown oil. 
TLC (SiO2): Rf = 0.12 (ethyl acetate:hexanes, 2:5) 
1H NMR: (400 MHz; CDCl3): δ 6.78 (dt, J = 16.0, 6.8 Hz, 1H), 6.08 (d, J = 16.0 Hz, 1H), 3.86-
3.80 (m, 1H), 3.45 (dd, J = 11.5, 4.7 Hz, 1H), 3.07 (dd, J = 10.1, 2.6 Hz, 1H), 2.69 (dd, J = 15.4, 
8.1 Hz, 1H), 2.56 (q, J = 7.3 Hz, 2H), 2.47-2.25 (m, 5H), 1.76 (ddd, J = 12.5, 4.7, 2.4 Hz, 1H), 
1.42 (q, J = 12.0 Hz, 1H), 1.25 (t, J = 7.1 Hz, 1H), 1.08 (t, J = 7.3 Hz, 3H), 0.99 (t, J = 7.3 Hz, 
3H), 0.94 (s, 3H), 0.84 (s, 3H). 
13C NMR: (100 MHz, CDCl3): δ 209.5, 201.3, 144.8, 131.6, 82.8, 75.4, 72.8, 48.4, 39.0, 37.3, 
36.8, 33.0, 32.3, 22.5, 12.6, 8.3, 7.6. 
FTIR (neat): ν 3467, 2974, 2939, 2878, 1711, 1669, 1629, 1459, 1412, 1375, 1258, 1200, 1109, 
1030 cm-1. 
HRMS: (ESI) Calcd. for C17H29O4 (M+H)+: 297.2066, Found: 297.2066. 








To a stirred solution of 3.2 (1.109 g, 3.740 mmol) in toluene (374 mL, 0.01M) at 60 ºC 
under an atmosphere of ethylene was added Hoveyda-Grubbs 2nd Generation catalyst (235 mg, 
0.374 mmol, 10 mol%) and the solution was sparged with ethylene for 10 minutes. The solution 
continued to stir at 60 ºC under one atmosphere of ethylene gas for 24 h. The reaction mixture 
was cooled to ambient temperature. KO2CCH2NC (184 mg, 40 mol%) in MeOH (2 mL) was 
added111 and the mixture was stirred for 0.5 h. The reaction mixture was filtered through Celite, 
and the solvent was removed under reduced pressure. The crude material was purified via 
column chromatography (SiO2: ethyl acetate:hexanes, 2:5) to afford 3.6 (756 mg, 84% yield) as a 
light brown oil. 
TLC (SiO2): Rf = 0.23 (ethyl acetate:hexanes, 2:5) 
1H NMR (400 MHz; CDCl3): δ 5.86-5.76 (m, 1H), 5.01 (t, J = 14.5 Hz, 2H), 3.85-3.78 (m, 1H), 
3.45 (d, J = 11.8 Hz, 1H), 2.99 (dt, J = 10.1, 2.4 Hz, 1H), 2.72 (dd, J = 15.0, 8.1 Hz, 1H), 2.59-
2.37 (m, 3H), 2.22 (dd, J = 14.7, 7.1 Hz, 1H), 2.11 (dt, J = 15.8, 7.8 Hz, 1H), 1.78 (ddt, J = 12.4, 
4.7, 2.4 Hz, 1H), 1.47-1.38 (m, 2H), 1.04 (t, J = 8.7 Hz, 3H), 0.96 (s, 3H), 0.86 (s, 3H). 
13C NMR (100 MHz, CDCl3): δ 210.1, 136.7, 115.9, 83.4, 75.6, 72.9, 48.6, 38.9, 37.3, 37.0, 
33.6, 22.5, 12.6, 7.6. 
FTIR (neat): υ 3459, 3074, 2970, 2940, 2874, 2361, 1737, 1710, 1641, 1412, 1366, 1228, 1217, 
1092, 1076, 1025 cm-1. 
LRMS (ESI) Calcd. for C14H25O3 (M+H)+: 241.2, Found: 241.2. 











To a stirred solution of 3.7 (189 mg, 0.786 mmol, 100 mol%) and 3.7 (336 mg, 1.18 
mmol, 150 mol%) in Et2O (11.3 mL, 0.07 M) was added 4 Å MS (380 mg, 200 wt. %) followed 
by MeOTf (0.017 mL, 1.572 mmol, 200 mol%). The resulting mixture was stirred at ambient 
temperature for 48 h. The reaction was quenched with NaHCO3 and the mixture was extracted 
with Et2O (3 x 10 mL). The ethereal extracts were washed with brine, dried over MgSO4, and 
concentrated under reduced pressure. The crude material was purified via column 
chromatography (SiO2: ethyl acetate:hexanes, 1:3.33) to afford 3.8 (223.7 mg, 69%, dr = 2:1, 
seperable) as a colorless oil.  
TLC (SiO2): Rf = 0.38 (ethyl acetate:hexanes, 2:5) 
1H NMR (β-anomer): (400 MHz; CDCl3): δ 5.85-5.74 (m, 1H), 5.01 (t, J = 13.8 Hz, 2H), 4.24 
(d, J = 7.6 Hz, 1H), 3.96 (dd, J = 11.7, 5.1 Hz, 1H), 3.82-3.75 (m, 1H), 3.63 (s, 3H), 3.62 (s, 3H), 
3.54-3.49 (m, 1H), 3.47 (s, 3H), 3.31-3.21 (m, 2H), 3.12-3.05 (m, 2H), 3.01-2.95 (m, 2H), 2.70 
(dd, J = 15.1, 8.3 Hz, 1H), 2.56-2.35 (m, 3H), 2.20 (dd, J = 14.0, 7.3 Hz, 1H), 2.14-2.06 (m, 1H), 
1.93 (ddd, J = 12.7, 4.8, 2.2 Hz, 1H), 1.03 (t, J = 7.2 Hz, 3H), 0.99 (s, 3H), 0.91 (s, 3H). 
13C NMR (β-anomer): (100 MHz, CDCl3): δ 210.0, 136.6, 115.9, 106.1, 85.7, 85.6, 84.2, 84.0, 
79.5, 73.0, 63.4, 61.1, 61.0, 58.9, 48.6, 39.0, 37.3, 36.6, 33.5, 22.3, 13.6, 7.6. 
FTIR (neat): υ 2969, 2935, 2904, 1715, 1460, 1408, 1368, 1343, 1248, 1162, 1092, 1037, 1014 
cm-1. 
LRMS: (ESI) Calcd. for C22H38O7Na (M+Na)+: 437.3, Found: 437.3. 









pyran-2-yl)oxy)tetrahydro-2H-pyran-2-yl)butan-2-ol (3.9)  
To a stirred solution of 3.8 (23.2 mg, 0.056 mmol, 100 mol%) in THF (1.12 mL, 0.05 M) 
was added a 1 M solution of L-selectride (0.056 mL, 0.056 mmol, 100 mol%) in THF. The 
resulting mixture was stirred for 1.5 h at ambient temperature. The reaction mixture was 
concentrated onto silica gel and purified via column chromatography (SiO2: ethyl 
acetate:hexanes, 1:5 to 2:5) to afford 3.9 (17.1 mg, 73% yield, dr = 4:1, seperable) as a colorless 
oil.  
TLC (SiO2): Rf = 0.34 (ethyl acetate:hexanes, 2:5)  
1H NMR: (400 MHz; ((CD3)2CO): δ 5.83 (m, 1H), 5.04 (ddd, J = 17.1, 3.6, 1.5 Hz, 1H), 4.98 
(ddt, J = 10.2, 2.2, 1.2 Hz, 1H), 4.29 (d, J = 7.6 Hz, 1H), 3.90 (dd, J = 11.0, 4.9 Hz, 1H), 3.67 – 
3.56 (m, 1H), 3.55 (s, 3H), 3.53 (s, 3H), 3.41 (s, 3H), 3.40 – 3.30 (m, 1H), 3.18 – 2.97 (m, 3H), 
2.82 (dt, J = 10.8, 5.4 Hz, 3H), 2.28 (ddd, J = 8.3, 6.6, 2.1 Hz, 1H), 1.91 (ddd, J = 12.9, 4.8, 2.3 
Hz, 1H), 1.62 – 1.24 (m, 6H), 1.00 (s, 3H), 0.89 (app. t, J = 7.0 Hz, 6H). 
13C NMR: (100 MHz, (CD3)2CO): δ 137.6, 116.5, 106.7, 86.5, 85.4, 85.1, 84.4, 80.5, 76.9, 72.2, 
72.1, 63.7, 60.9, 60.7, 58.7, 43.4, 39.7, 37.9, 34.3, 22.4, 13.8, 10.2. 
FTIR (neat): υ 3519, 2934, 1738, 1643, 1463, 1369, 1259, 1161, 1094, 1016  cm-1. 
LRMS: (ESI) Calcd. for C22H40O7Na (M+Na)+: 439.3, Found: 439.3. 








trimethoxytetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-2-yl)acetic acid (3.10) 
To a stirred solution of 3.12 (41.4 mg, 0.0984 mmol) in CH2Cl2 (2.2 mL, 0.045 M) and 
sat. aq. NaHCO3 (0.27 mL) was added a 0.5 M aqueous solution of NaBr (5.67 mg, 0.055 mmol, 
56 mol%, 0.11 mL) and a 0.5 M aqueous solution of tetrabutylammonium bromide (35.2 mg, 
0.109 mmol, 111 mol%, 0.22 mL). TEMPO was added as a 0.5 M solution in CH2Cl2 (4.61 mg, 
0.0295 mmol, 30 mol%, 0.059 mL) and the mixture was cooled to 0 ºC. A 5% w/w solution of 
NaOCl (16.5 mg, 0.222 mmol, 225 mol%, 0.33 mL) was added and the reaction was vigorously 
stirred for 1 h while warming to ambient temperature. The reaction mixture was acidified with 
2N HCl, and tBuOH (1.64 mL) and 2-methyl-2-butene (0.72 mL) were added. NaClO2 (107 mg, 
1.18 mmol, 1200 mol%) and NaHPO4 (87.4 mg, 0.728 mmol, 740 mol%) were dissolved in H2O 
(0.43 mL) and slowly added to the reaction mixture over a period of 15 minutes. The resulting 
mixture stirred at ambient temperature for 2 h and was then diluted with sat. NaH2PO4 (5 mL) 
and extracted with EtOAc (3 x 10 mL). The organic layers were combined, dried over MgSO4, 
and concentrated under reduced pressure. The crude seco-acid was purified via column 
chromatography (SiO2: ethyl acetate:hexanes 7:3) to afford seco-acid 3.10 (26.4 mg, 62% yield) 
as a white crystalline solid.  
TLC (SiO2): Rf = 0.21 (ethyl acetate:hexanes, 7:3) 
1H NMR: (400 MHz; CDCl3): δ 4.23 (d, J = 7.6 Hz, 1H), 3.94 (dd, J = 11.5, 5.2 Hz, 1H), 3.86 
(dd, J = 8.7, 5.1 Hz, 1H), 3.72 – 3.64 (m, 1H), 3.62 (s, 3H), 3.60 (s, 3H), 3.55 (dd, J = 9.5, 3.2 
Hz, 1H), 3.46 (s, 3H), 3.30 (dd, J = 11.5, 4.7 Hz, 1H), 3.23 (ddd, J = 10.1, 8.6, 5.2 Hz, 1H), 3.13 
– 3.04 (m, 2H), 2.96 (dd, J = 9.1, 7.6 Hz, 1H), 2.48 – 2.36 (m, 2H), 1.92 – 1.82 (m, 1H), 1.69 – 
1.37 (m, 6H), 0.99 (s, 3H), 0.90 (s, 3H), 0.87 (d, J = 7.5 Hz, 3H). 
13C NMR: (100 MHz, CD3OH): δ 175.9, 106.9, 86.6, 85.9, 85.1, 82.0, 80.7, 76.2, 72.3, 63.9, 
61.1, 60.9, 58.8, 43.4, 39.5, 37.8, 35.9, 30.5, 22.4, 13.8, 10.1. 
FTIR (neat): ν  3475, 2935, 1727, 1445, 1370, 1252, 1162, 1089, 1016 cm-1. 
 103 
HRMS: (ESI) Calcd. for C21H38O9Na (M+Na)+: 457.2408, Found: 457.2410. 
[α]25D: -50.34 ° (c = 0.99, CH2Cl2). 







To a stirred solution of 3.2 (189 mg, 0.786 mmol, 100 mol%) and 3.7 (336 mg, 1.18 
mmol, 150 mol%) in Et2O (11.3 mL, 0.07 M) was added 4 Å MS (380 mg, 200 wt. %) followed 
by MeOTf (0.017 mL, 1.572 mmol, 200 mol%). The resulting mixture was stirred for 48 h at 
ambient temperature. NaHCO3 was added and the mixture was extracted with Et2O (3 x 10 mL). 
The ethereal extracts were washed with brine, dried over MgSO4, and concentrated under 
reduced pressure. The crude material was purified via column chromatography (SiO2: ethyl 
acetate: hexanes, 3:10) to afford 3.11 (189 mg, 68% yield, dr = 2:1, seperable) as a pale yellow 
oil. 
TLC (SiO2): Rf = 0.44 (Et2O:DCM, 1:5) 
1H NMR (β-anomer): (400 MHz; CDCl3): δ 6.77 (dt, J = 16.0, 6.8 Hz, 1H), 6.08 (d, J = 16.0 
Hz, 1H), 4.23 (d, J = 7.6 Hz, 1H), 3.95 (dd, J = 11.5, 5.2 Hz, 1H), 3.87 – 3.76 (m, 1H), 3.61 (s, 
3H), 3.61 (s, 3H), 3.46 (s, 3H), 3.28 (dd, J = 11.5, 4.7 Hz, 1H), 3.25 – 3.19 (m, 1H), 3.11 – 3.03 
(m, 3H), 2.96 (dd, J = 9.1, 7.6 Hz, 1H), 2.68 (dd, J = 15.4, 8.4 Hz, 1H), 2.56 (q, J = 7.3 Hz, 2H), 
2.47 – 2.19 (m, 5H), 1.92 (ddd, J = 12.7, 4.7, 2.3 Hz, 1H), 1.54 (q, J =  11.7 Hz, 1H), 1.08 (t, J = 
7.3 Hz, 3H), 0.99 (t, J = 7.3 Hz, 3H), 0.98 (s, 3H), 0.90 (s, 3H). 
13C NMR (β-anomer): (100 MHz, CDCl3): δ 209.5, 201.3, 144.7, 131.7, 106.1, 85.7, 85.3, 84.1, 
83.0, 79.5, 72.9, 63.4, 61.1, 61.0, 59.0, 48.4, 39.0, 37.3, 36.4, 33.0, 32.2, 22.9, 13.6, 8.2, 7.6. 
FTIR (neat): ν 3343, 1637, 1265, 1096, 733, 704 cm-1. 
HRMS: (ESI) Calcd. for C25H42O8Na (M+Na)+: 493.2772, Found: 493.2775. 












A stirred solution of 3.11 (166 mg, 0.353 mmol, 100 mol%) in THF (7.06 mL, 0.05 M) 
was cooled to -78 ºC. Ozone was bubbled through the solution until a light blue color persisted 
(about 3 min.). The solution was then sparged with O2 for 3 minutes followed by argon for 5 
minutes. L-selectride (3.53 mL, 3.53 mmol, 1000 mol%, 1M in THF) was added dropwise and 
the solution was allowed to warm to ambient temperature over the course of 1 h. The reaction 
was concentrated onto silica gel and purified via column chromatography (SiO2: ethyl 
acetate:hexanes, 1:1) to afford 3.12 (105.4 mg, 71% yield, dr = 5:1, seperable) as a white solid.   
TLC (SiO2): Rf = 0.10 (ethyl acetate:hexanes, 2:5) 
1H NMR: (400 MHz; CDCl3): δ 4.23 (d, J = 7.6 Hz, 1H), 3.94 (dd, J = 11.5, 5.2 Hz, 1H), 3.79 – 
3.67 (m, 3H), 3.61 (s, 3H), 3.61 (s, 3H), 3.46 (s, 3H), 3.30 – 3.18 (m, 3H), 3.12 – 3.03 (m, 2H), 
2.96 (dd, J = 9.1, 7.6 Hz, 1H), 1.88 (ddd, J = 12.9, 4.8, 2.3 Hz, 1H), 1.77 – 1.51 (m, 6H), 1.51 – 
1.40 (m, 2H), 0.97 (s, 3H), 0.91 (t, J = 7.5 Hz, 3H), 0.91 (s, 3H). 
13C NMR: (100 MHz, CDCl3): δ 106.2, 105.2, 85.7, 85.4, 84.1, 83.2, 79.5, 76.6, 73.1, 63.4, 61.4, 
61.2, 61.0, 59.0, 42.2, 39.1, 37.1, 31.3, 30.7, 22.3, 13.6. 
FTIR (neat): ν 3427, 2933, 1464, 1370, 1162, 1091, 1017 cm-1. 
HRMS: (ESI) Calcd. for C21H40O8Na (M+Na)+: 444.2650, Found: 444.2650. 
[α]24D: -38.16 ° (c = 0.76, CH2Cl2). 




(−)-Cyanolide A (3.1) 
To a stirred solution of 3.10 (45.1 mg, 0.104 mmol, 100 mol%) in THF (1 mL) was added 
Et3N (0.02 mL, 0.145 mmol, 140 mol%) and 2,4,6-trichlorobenzoyl chloride (0.02 mL, 0.125 
mmol, 120 mol%). The solution was stirred at ambient temperature for 2.5 h. The reaction 
mixture was diluted with toluene (7 mL) and added dropwise over 5 h to a solution of DMAP 
(63.5 mg, 0.520 mmol, 500 mol%) in toluene (27 mL) at 120 ºC. The syringe was rinsed with 2 
mL of dry toluene and added dropwise to the refluxing solution over 0.5 h. The reaction mixture 
continued to stir at 120 ºC for an additional 15 h. The solution was then cooled to ambient 
temperature and the solvent removed under reduced pressure. The crude material was purified 
via column chromatography (ethyl acetate:hexanes, 3:7) to afford 3.1 (20.4 mg, 47%) as a pale 
yellow oil.  
TLC (SiO2): Rf = 0.5 (ethyl acetate:hexanes, 3:5)  
1H NMR: (400 MHz; CDCl3): δ 4.91 (q, J = 6.9 Hz, 2H), 4.25 (d, J = 6.4 Hz, 2H), 3.97 (dd, J = 
11.0, 4.5 Hz, 2H), 3.62 (s, 6H), 3.61 (s, 6H), 3.46 (s, 6H), 3.47-3.40 (m, 4H), 3.35-3.29 (m, 2H), 
3.29-3.21 (m, 2H), 3.09 (t, J = 9.6 Hz, 4H), 2.96 (q, J = 7.1 Hz, 2H), 2.38 (d, J = 16.2 Hz, 2H), 
2.27 (dd, J = 16.2, 9.2 Hz, 2H), 1.98 (d, J = 12.8 Hz, 2H), 1.82 (dt, J = 15.6, 8.1 Hz, 2H), 1.64 – 
1.42 (m, 8H), 0.96 (s, 6H), 0.88 (s, 6H), 0.85 (d, J = 7.7 Hz, 6H). 
13C NMR: (100 MHz, CDCl3): δ 172.0, 106.3, 85.9, 85.7, 84.3, 80.7, 79.7, 75.6, 74.2, 63.6, 61.3, 
61.2, 59.1, 40.9, 39.0, 37.3, 35.4, 28.6, 22.4, 13.9, 9.8.  
FTIR (neat): ν 2966, 2932, 2360, 2340, 1739, 1465, 1370, 1302, 1259, 1162, 1095, 1019 cm-1. 
HRMS: (ESI) Calcd. for C42H73O16 (M+H)+: 833.4893, Found: 833.4900. 






























3.4.4 Crystal Data and Structure Refinement for 3.10 
Empirical formula  C22 H38 O7 
Formula weight  414.52 
Temperature  153(2) K 
Wavelength  0.71075 Å 
Crystal system  Triclinic 
Space group  P1 
Unit cell dimensions a = 8.377(4) Å a= 81.422(11)°. 
 b = 11.083(6) Å b= 89.682(10)°. 
 c = 12.860(6) Å g = 88.711(11)°. 
Volume 1180.3(10) Å3 
Z 2 
Density (calculated) 1.166 Mg/m3 
Absorption coefficient 0.085 mm-1 
F(000) 452 
Crystal size 0.26 x 0.16 x 0.05 mm 
Theta range for data collection 3.03 to 27.48°. 
Index ranges -10<=h<=10, -14<=k<=14, -16<=l<=16 
Reflections collected 12596 
Independent reflections 5388 [R(int) = 0.0940] 
Completeness to theta = 27.48° 99.6 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.00 and 0.443 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5388 / 51 / 559 
Goodness-of-fit on F2 1.004 
Final R indices [I>2sigma(I)] R1 = 0.0719, wR2 = 0.1309 
R indices (all data) R1 = 0.1567, wR2 = 0.1673 
Largest diff. peak and hole 0.202 and -0.255 e.Å-3 
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Table 3.1 Atomic coordinates ( x 104) and equivalent isotropic displacement parameters 
(Å2x103) for 3.10. U(eq) is defined as one third of the trace of the orthogonalized 
Uij tensor. 
_____________________________________________________________________________  
 x y z U(eq) 
_____________________________________________________________________________  
O1 2368(4) 7582(4) 1590(3) 30(1) 
O2 -1183(5) 7598(4) 546(4) 44(1) 
O3 4172(5) 5233(3) 4145(3) 33(1) 
O4 2381(5) 3907(4) 4963(3) 43(1) 
O5 2908(7) 983(4) 6708(4) 65(2) 
O6 5784(6) 2288(4) 7020(3) 56(1) 
O7 6747(5) 3684(4) 5018(3) 41(1) 
C1 1187(7) 6847(6) 2185(5) 33(1) 
C2 3772(7) 6894(6) 1375(4) 31(1) 
C3 4639(7) 6414(5) 2431(4) 29(1) 
C4 3451(7) 5637(6) 3121(4) 33(2) 
C5 1854(7) 6291(6) 3266(5) 33(2) 
C6 3963(8) 4029(5) 4576(5) 35(2) 
C7 2084(9) 2654(7) 5397(6) 53(2) 
C8 3160(8) 2257(6) 6350(5) 44(2) 
C9 4873(8) 2437(6) 6075(5) 45(2) 
C10 5190(8) 3688(6) 5450(5) 37(2) 
C11 -246(7) 7692(6) 2270(5) 39(2) 
C12 -847(7) 8238(6) 1191(5) 35(2) 
C13 -977(10) 9592(6) 930(6) 54(2) 
C14 -1528(10) 10092(7) -168(6) 63(2) 
C15 4754(8) 7734(6) 593(5) 37(2) 
C16 3916(8) 8037(6) -451(5) 42(2) 
C17 4560(10) 7967(7) -1358(6) 61(2) 
C18 5201(7) 7479(5) 2977(5) 34(1) 
C19 6079(7) 5594(6) 2221(5) 36(2) 
C22 7675(9) 4689(7) 5192(6) 56(2) 
O8 7435(4) 3447(4) 10045(3) 32(1) 
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O9 3907(5) 3441(4) 11112(4) 44(1) 
O10 9113(5) 5802(4) 7485(3) 35(1) 
O11 7241(5) 7121(4) 6654(3) 45(1) 
O12 7587(8) 10022(4) 4903(4) 75(2) 
O13 10584(7) 8738(5) 4607(3) 57(1) 
O14 11590(6) 7368(4) 6608(4) 46(1) 
C23 6228(7) 4185(6) 9448(5) 34(1) 
C24 8801(7) 4141(5) 10233(4) 30(1) 
C25 9653(7) 4631(5) 9197(4) 28(1) 
C26 8405(7) 5404(5) 8508(4) 31(1) 
C27 6865(7) 4734(6) 8384(5) 32(1) 
C28 8834(8) 7007(6) 7056(5) 37(2) 
C29 6875(10) 8365(7) 6213(6) 57(2) 
C30 7920(10) 8760(6) 5261(5) 49(2) 
C31 9679(9) 8597(6) 5551(5) 47(2) 
C32 10033(8) 7342(6) 6176(5) 38(2) 
C33 4857(7) 3336(6) 9378(5) 39(2) 
C34 4230(7) 2790(6) 10468(5) 34(2) 
C35 4029(9) 1436(6) 10668(6) 53(2) 
C36 3430(9) 959(7) 11775(5) 58(2) 
C37 9801(8) 3280(6) 11039(5) 37(2) 
C38 9003(8) 2989(6) 12082(5) 40(2) 
C39 9619(10) 3081(7) 12986(6) 58(2) 
C40 11036(7) 5447(6) 9407(5) 34(2) 
C41 10293(7) 3576(5) 8642(5) 34(1) 
C42 6834(13) 10325(8) 3988(7) 88(3) 
C43 11749(14) 9589(9) 4492(8) 101(4) 
C44 12605(9) 6386(8) 6421(6) 59(2) 
C21 6750(20) 1258(14) 7251(15) 62(6) 
C21A 7304(12) 1763(14) 6982(11) 60(5) 
C20 2280(40) 682(16) 7708(14) 51(8) 
C20A 1755(17) 711(11) 7481(10) 61(5) 
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Table 3.2  Bond lengths [Å] and angles [°] for 3.10. 
____________________________________________________________________________  
O1-C2  1.435(7) 
O1-C1  1.439(7) 
O2-C12  1.207(7) 
O3-C6  1.381(7) 
O3-C4  1.457(6) 
O4-C6  1.415(7) 
O4-C7  1.444(8) 
O5-C20  1.385(10) 
O5-C20A  1.388(9) 
O5-C8  1.438(7) 
O6-C21  1.380(9) 
O6-C21A  1.391(9) 
O6-C9  1.425(7) 
O7-C10  1.415(8) 
O7-C22  1.418(8) 
C1-C11  1.519(8) 
C1-C5  1.536(8) 
C1-H1  1.00 
C2-C15  1.517(9) 
C2-C3  1.560(7) 
C2-H2  1.00 
C3-C4  1.524(8) 
C3-C19  1.541(8) 
C3-C18  1.544(8) 
C4-C5  1.531(8) 
C4-H4  1.00 
C5-H5A  0.99 
C5-H5B  0.99 
C6-C10  1.526(8) 
C6-H6  1.00 
C7-C8  1.530(9) 
C7-H7A  0.99 
C7-H7B  0.99 
C8-C9  1.487(10) 
C8-H8  1.00 
C9-C10  1.523(9) 
C9-H9  1.00 
C10-H10  1.00 
C11-C12  1.512(9) 
C11-H11A  0.99 
C11-H11B  0.99 
C12-C13  1.490(9) 
C13-C14  1.508(9) 
C13-H13A  0.99 
C13-H13B  0.99 
C14-H14A  0.98 
C14-H14B  0.98 
C14-H14C  0.98 
C15-C16  1.508(8) 
C15-H15A  0.99 
C15-H15B  0.99 
C16-C17  1.294(9) 
C16-H16  0.95 
C17-H17A  0.95 
C17-H17B  0.95 
C18-H18A  0.98 
C18-H18B  0.98 
C18-H18C  0.98 
C19-H19A  0.98 
C19-H19B  0.98 
C19-H19C  0.98 
C22-H22A  0.98 
C22-H22B  0.98 
C22-H22C  0.98 
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O8-C24  1.435(7) 
O8-C23  1.437(7) 
O9-C34  1.203(7) 
O10-C28  1.382(7) 
O10-C26  1.451(7) 
O11-C28  1.429(8) 
O11-C29  1.438(8) 
O12-C42  1.333(9) 
O12-C30  1.428(8) 
O13-C43  1.364(9) 
O13-C31  1.418(8) 
O14-C44  1.414(8) 
O14-C32  1.423(8) 
C23-C27  1.512(8) 
C23-C33  1.513(8) 
C23-H23  1.00 
C24-C37  1.538(8) 
C24-C25  1.540(8) 
C24-H24  1.00 
C25-C26  1.535(8) 
C25-C40  1.535(8) 
C25-C41  1.544(8) 
C26-C27  1.524(8) 
C26-H26  1.00 
C27-H27A  0.99 
C27-H27B  0.99 
C28-C32  1.519(8) 
C28-H28  1.00 
C29-C30  1.517(10) 
C29-H29A  0.99 
C29-H29B  0.99 
C30-C31  1.522(10) 
C30-H30  1.00 
C31-C32  1.523(9) 
C31-H31  1.00 
C32-H32  1.00 
C33-C34  1.537(9) 
C33-H33A  0.99 
C33-H33B  0.99 
C34-C35  1.497(9) 
C35-C36  1.529(9) 
C35-H35A  0.99 
C35-H35B  0.99 
C36-H36A  0.98 
C36-H36B  0.98 
C36-H36C  0.98 
C37-C38  1.490(9) 
C37-H37A  0.99 
C37-H37B  0.99 
C38-C39  1.293(9) 
C38-H38  0.95 
C39-H39A  0.95 
C39-H39B  0.95 
C40-H40A  0.98 
C40-H40B  0.98 
C40-H40C  0.98 
C41-H41A  0.98 
C41-H41B  0.98 
C41-H41C  0.98 
C42-H42A  0.98 
C42-H42B  0.98 
C42-H42C  0.98 
C43-H43A  0.98 
C43-H43B  0.98 
C43-H43C  0.98 
C44-H44A  0.98 
C44-H44B  0.98 
C44-H44C  0.98 
C21-H21A  0.98 
C21-H21B  0.98 
C21-H21C  0.98 
C21A-H21D  0.98 
 121 
C21A-H21E  0.98 
C21A-H21F  0.98 
C20-H20A  0.98 
C20-H20B  0.98 
C20-H20C  0.98 
C20A-H20D  0.98 
C20A-H20E  0.98 
















































































































































































































































































Table 3.3 Anisotropic displacement parameters  (Å2x 103) for 3.10. The anisotropic 
displacement factor exponent takes the form: -2p2[ h2 a*2U11 + ...  + 2 h k a* b* 
U12 ] 
_____________________________________________________________________________ 
 U11 U22  U33 U23 U13 U12 
_____________________________________________________________________________  
O1 24(2)  34(2) 31(2)  1(2) 5(2)  0(2) 
O2 43(3)  49(3) 41(3)  -10(2) -9(2)  7(2) 
O3 46(3)  31(3) 21(2)  2(2) -9(2)  2(2) 
O4 49(3)  38(3) 39(3)  8(2) -3(2)  -4(2) 
O5 110(5)  36(3) 46(3)  8(2) 16(3)  -11(3) 
O6 85(4)  54(3) 27(3)  0(2) -17(3)  17(3) 
O7 46(3)  42(3) 35(3)  -5(2) -4(2)  4(2) 
C1 27(3)  41(4) 29(3)  -3(3) 1(3)  2(3) 
C2 34(3)  37(4) 23(3)  -4(3) 1(3)  0(3) 
C3 33(3)  29(3) 24(3)  -2(3) -7(3)  0(3) 
C4 40(4)  35(4) 20(3)  4(3) -6(3)  1(3) 
C5 33(3)  39(4) 25(3)  3(3) -3(3)  1(3) 
C6 48(4)  26(4) 30(4)  3(3) -2(3)  3(3) 
C7 60(5)  45(5) 48(4)  11(4) -5(4)  -12(4) 
C8 67(5)  32(4) 32(4)  -1(3) 5(4)  -3(3) 
C9 72(5)  33(4) 26(4)  1(3) -9(3)  13(4) 
C10 47(4)  33(4) 29(3)  5(3) -1(3)  5(3) 
C11 35(4)  43(4) 35(4)  3(3) 1(3)  3(3) 
C12 23(3)  45(4) 36(4)  -7(3) 2(3)  -2(3) 
C13 72(5)  45(5) 44(4)  1(3) -9(4)  -6(4) 
C14 71(5)  53(5) 57(5)  17(4) -13(4)  -4(4) 
C15 35(4)  41(4) 33(4)  0(3) -5(3)  -4(3) 
C16 43(4)  45(4) 32(4)  13(3) -2(3)  -3(3) 
C17 64(5)  80(6) 35(4)  5(4) -3(4)  15(4) 
C18 35(3)  34(4) 32(3)  -2(3) -5(3)  -2(3) 
C19 37(4)  34(4) 36(4)  -3(3) -1(3)  4(3) 
C22 64(5)  54(5) 51(5)  -11(4) -8(4)  -5(4) 
O8 29(2)  37(2) 28(2)  2(2) -3(2)  -6(2) 
O9 40(3)  55(3) 39(3)  -12(2) 7(2)  -8(2) 
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O10 41(2)  34(3) 25(2)  3(2) 6(2)  -1(2) 
O11 42(3)  46(3) 41(3)  13(2) 2(2)  2(2) 
O12 141(6)  36(3) 42(3)  7(2) -24(3)  9(3) 
O13 89(4)  59(3) 25(3)  -4(2) 19(3)  -28(3) 
O14 52(3)  45(3) 40(3)  -5(2) 5(2)  -11(2) 
C23 30(3)  42(4) 27(3)  3(3) -4(3)  1(3) 
C24 33(3)  27(3) 27(3)  3(3) 0(3)  -3(3) 
C25 27(3)  26(3) 30(3)  -1(3) 4(3)  1(3) 
C26 37(4)  27(3) 26(3)  2(3) 0(3)  2(3) 
C27 34(3)  33(4) 28(3)  2(3) 0(3)  1(3) 
C28 49(4)  30(4) 29(4)  2(3) 5(3)  -2(3) 
C29 68(5)  48(5) 49(5)  12(4) -3(4)  10(4) 
C30 94(6)  27(4) 23(3)  8(3) 1(4)  -6(4) 
C31 83(6)  36(4) 23(3)  -4(3) 7(4)  -13(4) 
C32 54(4)  37(4) 22(3)  -1(3) 1(3)  -8(3) 
C33 34(3)  57(4) 24(3)  -1(3) -2(3)  -4(3) 
C34 22(3)  41(4) 38(4)  0(3) -2(3)  -2(3) 
C35 64(5)  43(4) 49(4)  5(4) 14(4)  4(4) 
C36 62(5)  60(5) 45(4)  9(4) 7(4)  4(4) 
C37 35(4)  40(4) 32(4)  5(3) -5(3)  4(3) 
C38 39(4)  50(4) 27(4)  10(3) 0(3)  -3(3) 
C39 65(5)  67(5) 40(4)  4(4) -9(4)  -3(4) 
C40 37(4)  39(4) 27(3)  -5(3) 7(3)  -3(3) 
C41 38(4)  32(3) 32(3)  -6(3) 3(3)  -2(3) 
C42 123(9)  67(6) 71(6)  -2(5) -44(6)  22(6) 
C43 139(10)  96(8) 78(7)  -40(6) 47(7)  -70(7) 
C44 57(5)  78(6) 45(5)  -17(4) 2(4)  3(5) 
C21 51(10)  55(12) 78(11)  -6(10) -25(9)  18(9) 
C21A 68(10)  44(9) 69(9)  -12(7) -30(8)  18(7) 
C20 64(15)  41(11) 44(11)  9(9) 7(12)  -9(10) 
C20A 57(9)  51(7) 70(9)  4(6) -2(7)  -11(6) 
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Table 3.4 Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2x 10 3) 
for 3.10. 
_____________________________________________________________________________  
 x  y  z  U(eq) 
_____________________________________________________________________________  
H1 876 6176 1792 39 
H2 3445 6180 1039 37 
H4 3235 4898 2787 39 
H5A 2009 6943 3702 40 
H5B 1088 5705 3632 40 
H6 4134 3496 4021 42 
H7A 2298 2122 4856 64 
H7B 950 2570 5611 64 
H8 2863 2739 6922 53 
H9 5228 1798 5646 53 
H10 5126 4310 5938 45 
H11A -1110 7229 2664 46 
H11B 57 8354 2663 46 
H13A 81 9932 1039 65 
H13B -1727 9894 1435 65 
H14A -783 9821 -680 94 
H14B -1564 10985 -255 94 
H14C -2596 9793 -281 94 
H15A 4953 8497 880 44 
H15B 5800 7335 489 44 
H16 2830 8301 -443 50 
H17A 5644 7708 -1399 74 
H17B 3949 8175 -1981 74 
H18A 4300 8042 3043 51 
H18B 6048 7915 2557 51 
H18C 5614 7157 3678 51 
H19A 6554 5224 2892 54 
H19B 6877 6086 1800 54 
H19C 5723 4949 1837 54 
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H22A 7175 5448 4838 84 
H22B 8752 4597 4910 84 
H22C 7738 4718 5949 84 
H23 5871 4855 9843 40 
H24 8427 4853 10572 36 
H26 8136 6144 8840 37 
H27A 6059 5310 8018 39 
H27B 7072 4079 7951 39 
H28 8960 7545 7607 44 
H29A 7050 8903 6749 68 
H29B 5737 8444 6004 68 
H30 7672 8269 4692 59 
H31 9981 9239 5979 57 
H32 10018 6717 5691 45 
H33A 5217 2666 8996 46 
H33B 3978 3790 8970 46 
H35A 5068 1032 10555 64 
H35B 3265 1208 10149 64 
H36A 4221 1121 12293 87 
H36B 3268 78 11839 87 
H36C 2417 1373 11903 87 
H37A 10027 2511 10756 44 
H37B 10836 3663 11135 44 
H38 7940 2709 12083 48 
H39A 10679 3357 13026 70 
H39B 9012 2872 13610 70 
H40A 11509 5808 8737 51 
H40B 11848 4956 9835 51 
H40C 10633 6098 9784 51 
H41A 9457 2973 8630 51 
H41B 11223 3187 9023 51 
H41C 10604 3897 7919 51 
H42A 7476 10049 3425 132 
H42B 6680 11213 3842 132 
H42C 5793 9935 4023 132 
H43A 11268 10399 4515 151 
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H43B 12290 9583 3816 151 
H43C 12524 9397 5064 151 
H44A 12139 5613 6738 89 
H44B 13653 6469 6734 89 
H44C 12726 6394 5662 89 
H21A 7521 1224 6681 93 
H21B 6089 530 7326 93 
H21C 7318 1286 7910 93 
H21D 7603 1353 7685 90 
H21E 8072 2400 6744 90 
H21F 7307 1166 6492 90 
H20A 1484 1308 7839 77 
H20B 3132 637 8229 77 
H20C 1760 -110 7765 77 
H20D 1804 -165 7748 91 
H20E 696 932 7183 91 
H20F 1951 1173 8060 91 
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Chapter 4: Background Cryptocaryol A 
4.1 Introduction 
 Protein kinase C (PKC) has been of significant interest to drug developers since it was 
first identified as the receptor for tumor promoter phorbol ester.112 While PKC has been shown to 
play a role in numerous diseases, such as Parkinson’s disease,113 Alzheimer’s disease,114 ischemic 
heart disease,115 and cancer,116 no drugs have been approved that specifically target PKC. The 
challenges associated with selective modulation and regulation of PKC has led to the search for 
alternative downstream kinase targets such as mTOR and Akt. It is anticipated that regulation of 
these alternative targets will produce desirable results, such as tumor suppression without 
exhibiting cytotoxicity to non-cancer cells.117  
 Programmed cell death 4 (PDCD4), a downstream target of Akt, is a novel tumor 
suppressor protein.118 Downregulation of PDCD4 has been linked to diverse human cancers, 
including liver,119 colorectal,120 brain,121 and breast.122 Conversely, murine epidermal cells that 
possess elevated levels of PDCD4 are resistant to tumor promotion. Phosphorylation of PDCD4 
by PI3K/Akt leads to ubiquitination and proteasomal degradation.123 Knowledge of this 
degradation pathway coupled with the associated benefits of increased expression levels has 
made novel agents capable of stabilizing PDCD4 attractive targets. 
4.2 Isolation and Bioactivity 
In 2011, using a high-throughput cell-based reporter assay124 to screen extracts of a 
collection of the plant Cryptocarya sp. (Lauraceae, NSC number N098347), Gustafson and 
coworkers identified a new class of small-molecule PDCD4-stabilizers, the amphiphilic type I 
polyketides cryptocaryols A-H (purported structure 4.1a-h, Figure 4.1).125 These compounds 
were found in samples of a shrub, identified as Cryptocarya, which were collected in the East 
Sepik Province, Papua New Guinea in 1995. The sample material was extracted multiple times 
with CH2Cl2/MeOH (1:1) and 100% MeOH. The extract was fractionated using diol flash 
chromatography eluting sequentially with hexanes, EtOAc, and MeOH. PDCD4-stabilizing 
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activity was observed in the EtOAc extract, which was subjected to flash chromatography, size 
exclusion chromatography, and finally semipreparative reversed-phase HPLC separation to 
afford 4.1a (0.5 mg), 4.1b (1.1 mg), 4.1c (1.5 mg), 4.1d (0.9 mg), 4.1e (0.3 mg), 4.1f (1.0 mg), 
4.1g (2.0 mg), and 4.1h (1.8 mg). 
Figure 4.1 Purported structures of cryptocaryols A-H, 4.1a-h and revised structures of 
cryptocaryol A and B, 4.2a and 4.2b. 
 
Stabilization of PDCD4 was evaluated according to a previously developed procedure.124 
HEK-39 cells expressing a fusion protein comprised of a fragment of PDCD4 containing the 
regulatory region (amino acids 39-91) and luciferase were plated and allowed to attach 
overnight. TPA (final concentration 10 nM) was added followed by test samples or controls. 
After 8 h incubation, luciferase activity was measured. Cryptocaryols A-H 4.1a-h were found to 
exhibit EC50 values in the low µM range, and the EC50 of cryptocaryol A 4.1a was found to be 
4.9 µM. 
4.3 Structural Elucidation 
Gustafson and coworkers reported the relative structure of cryptocaryol A 4.1a. 
Observation of the [M + H]+ ion at m/z 529.4105 via HRESIMS was consistent with the 
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cryptocaryol A using 1H NMR, 13C NMR, HMBC, COSY, and ECD were used to elucidate the 
structure. The absolute configuration of the pyranone at C6 was assigned as R from its Cotton 
effect.126 The relative configuration of the all syn-tetraol moiety was assigned according to 
Kishi’s 13C NMR database.127 The database indicates the expected 13C NMR chemical shifts for 
the C3 in a 1,3,5-polyol are 66.3 ± 0.5 for an anti/anti orientation, 68.6 ± 0.5 for syn/anti or 
anti/syn, and 70.7 ± 0.5 for syn/syn arrangements. The measured 13C NMR shifts for C10, C12, 
and C14 were 69.9, 70.2, and 68.3, respectively. This revealed that C10 and C12 had syn/syn 
configurations relative to their neighboring hydroxyl groups, and C14 was either syn/anti or 
anti/syn relative to C16. As C12 could be assigned as syn/syn, C14 could be assigned to syn/anti, 
thus the relative stereochemistry of the polyol portion of the molecule was reported as 8S*, 10S*, 
12S*, 14S*, 16R*.  However, it was not possible to relate the absolute configuration of C6 with 
C8 or any other chiral carbons in 4.1a due to extensive overlap of NMR signals even in a variety 
of solvents.  
 Due to the convolution of the NMR spectra, the structures of cryptocaryol A and B, 4.1a 
and 4.1b, were initially incorrectly reported as (6R, 8S*, 10S*, 12S*, 14S*, 16R*). The erroneous 
assignment of these structures was later discovered and corrected by O’Doherty and coworkers 
during the course of their total synthesis of these natural products. They found that the correct 
structure for cryptocaryols A and B, 4.1a and 4.1b was (6R, 8R*, 10R*, 12R*, 14R*, 16R*).128 
4.4 Prior Total Syntheses 
The synthetic challenges involved with cryptocaryol A include the construction of the 
polyol fragment and the stereoselective installation of the rather sensitive pyrone moiety, along 
with the determination and validation of the absolute stereochemistry of the natural product. 
There have been four previous syntheses published from the laboratories of Mohapatra, 
O’Doherty, Dias, and Cossy.128-129 Each synthesis will be reviewed focusing primarily on how the 
above synthetic challenges were overcome. 
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4.4.1 Mohapatra’s Total Synthesis of Purported Cryptocaryol A (4.1a) 
Mohapatra and coworkers completed the first total synthesis of the purported structure of 
cryptocaryol A, 4.1a.129a The successful synthetic strategy relied on ring-closing metathesis 
(RCM) of acrylate 4.3 to install the pyrone moiety (Scheme 4.1). The polyol substructure was 
accessed in a linear manner through iterative epoxidation and ring-opening with vinylmagnesium 
bromide beginning from iodide 4.4, which was anticipated to be accessible via Bartlett-Smith 
iodocarbonate cyclization. The first stereocenter was to be installed via the Maruoka-modifed 
Keck allylation of cetyl alcohol 4.5.  
Scheme 4.1 Mohapatra’s retrosynthesis of purported cryptocaryol A 4.1a. 
 
The forward synthesis began with oxidation of cetyl alcohol to an aldehyde followed by 
asymmetric Keck allylation using Maruoka’s bis-titanium catalyst, which provided homoallylic 
alcohol 4.6 (Scheme 4.2).130 Benzylation of the hydroxyl group afforded benzyl ether 4.7. 
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Scheme 4.2 Synthesis of homoallylic alcohol 4.8. 
 
Next, homoallylic alcohol 4.8 was protected as carbonate ester 4.9 (Scheme 4.3). 
Exposure to N-iodosuccinimide effected Bartlett-Smith iodocyclization to afford cyclic 
carbonate 4.4. Upon treatment with K2CO3, iodocarbonate 4.4 underwent hydrolysis and 
intramolecular SN2 reaction to give epoxy alcohol 4.10. Protection of the hydroxyl group as PMB 
ether 4.11 followed by epoxide opening with vinylmagnesium bromide furnished homoallylic 
alcohol 4.12. 
Scheme 4.3 Synthesis of homoallylic alcohol 4.12. 
 
Homoallylic alcohol 4.12 was subjected to almost exactly the same sequence of steps 
shown in Scheme 4.3 to afford homoallylic alcohol 4.13, which again underwent another 
iteration of the five-step procedure to give homoallylic alcohol 4.14 (Scheme 4.4). Homoallylic 





Key: (a) PCC, CH2Cl2, rt; (b) TiCl4, Ti(OiPr)4, (S)-BINOL, Ag2O, allyltributylstannane, -20 °C; (c) NaH, BnBr, 





















Key: (a) Boc2O, Et3N, CH2Cl2, rt; (b) NIS, CH3CN, -40 to 0 °C; (c) K2CO3, MeOH, rt; (d) NaH, 












4.15, which was acylated with acryloyl chloride to give acrylate 4.3. Ring-closing metathesis 
proceeded smoothly with Grubbs I to furnish pyrone 4.16, which upon deprotection afforded the 
purported structure of cryptocaryol A 4.1a. This highly linear synthesis required 28 steps (LLS) 
from cetyl alcohol. 
Scheme 4.4 Completion of the total synthesis of purported cryptocaryol A 4.1a. 
 
4.4.2 O’Doherty’s Total Synthesis of (+)-Cryptocaryol A 
In 2013, O’Doherty and coworkers elucidated the correct structure of cryptocaryol A 4.2a 
and completed the first total synthesis.128 Ring-closing metathesis of acrylate 4.17 was 
anticipated to give the desired pyrone, which would be deprotected to furnish the natural product 
4.2a (Scheme 4.5). Acrylate 4.17 was anticipated to be accessible after Noyori reduction of 
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Key: (a) Boc2O, Et3N, CH2Cl2, rt; (b) NIS, CH3CN, -40 to 0 °C; (c) K2CO3, MeOH, rt; (d) NaH, 
MOMCl, THF, DMF, 0 °C; (e) vinylmagnesium bromide, CuI, THF, -20 °C; (f) acryloyl chloride, 






Scheme 4.5 O’Doherty’s retrosynthesis of (+)-cryptocaryol A 4.2a. 
 
The synthesis began with PMB protection of alkyne 4.20 followed by homologation of 
the terminal alkyne with methyl chloroformate, which provided ynoate 4.21 (Scheme 4.6). Upon 
treatment with PPh3 and phenol, ynoate 4.21 underwent isomerization to afford dienoate 4.22. 
Asymmetric Sharpless epoxidation of the alkene distal to the ester followed by protection of the 
1,2-diol gave carbonate 4.23. Regioselective reduction of 4.23 with catalytic PdPPh3, HCO2H, 























Scheme 4.6 Synthesis of enoate 4.19. 
 
Evans’ conditions for diastereoselective acetalization transformed 4.19 into benzylidene 
4.24 (Scheme 4.7).131 Ester-to-aldehyde reduction with DIBAL followed by Leighton allylation 
afforded homoallylic alcohol 4.25.132 Cross-metathesis of homoallylic alcohol 4.25 with ethyl 
acrylate using Grubbs II followed by another diastereoselective acetalization furnished 
benzylidene 4.26. Ester-to-aldehyde reduction was accomplished with DIBAL and nucleophilc 





















Key: (a) PMBCl, NaH, TFAB, 0 °C; (b) ClCO2Me, n-BuLi, THF, -78 to 0 °C; (c) PPh3, PhOH, benzene, 50 




Scheme 4.7 Synthesis of ynone 4.18. 
 
Asymmetric Noyori reduction of ynone 4.18 followed by diimide reduction of the alkyne 
gave secondary alcohol 4.27 (Scheme 4.8). Protection of the secondary alcohol as a TBS ether 
and deprotection of the PMB provided primary alcohol 4.28. Alcohol-to-aldehyde oxidation was 
followed by Leighton allylation and acylation of the resulting homoallylic alcohol afforded 
acrylate 4.17. Ring-closing metathesis was achieved using Grubbs I, and subsequent global 
deprotection furnished (+)-cryptocaryol A 4.2a. O’Doherty and coworkers completed the total 

























Key: (a) PhCHO, KOtBu, THF, 0 °C; (b) DIBALH, CH2Cl2, -78 °C; (c) (R,R)-Leighton, Sc(OTf)3, CH2Cl2, 
-10 °C, (d) ethyl acrylate, Grubbs II, CH2Cl2; (e) PhCHO, KOtBu, THF, 0 °C; (f) DIBALH, CH2Cl2, -78 





Scheme 4.8 Completion of the total synthesis of (+)-cryptocaryol A 4.2a. 
 
4.4.3 Dias’ Total Synthesis of (−)-Cryptocaryol A ent-4.2a 
In 2015, Dias and coworkers completed the total synthesis of (−)-cryptocaryol A ent-
4.2a,129b and they are the only group to not utilize ring-closing metathesis to install the pyrone 
substructure opting instead for a lactonization strategy (Scheme 4.9). The synthesis hinged on 
diastereoselective 1,5-anti aldol reaction between ketone 4.29 and hexadecanal to install the long 
aliphatic moiety. The ketone was to be synthesized from terminal alkene 4.30, which was 
anticipated to be accessible from ketone 4.31 via diastereoselective 1,5-anti aldol coupling. The 
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23 steps in LLS
h,i
Key: (a) (R,R)-Noyori, Et3N, HCO2H; (b) NBSH, Et3N, CH2Cl2; (c) TBSCl, imidazole, DMF; (d) DDQ, CH2Cl2, 
H2O, 0 °C; (e) DMP, CH2Cl2, 0 °C; (f) (S,S)-Leighton, Sc(OTf)3, CH2Cl2, -10 °C; (g) acrylic acid, DCC, DMAP, 

























Scheme 4.9 Dias’ retrosynthesis of (−)-cryptocaryol A ent-4.2a. 
 
The synthesis began from homoallylic alcohol 4.32, which was protected as PMB ether 
4.33 (Scheme 4.10). Wacker oxidation of the terminal alkene provided ketone 4.34, which 
underwent diastereoselective boron-mediated 1,5-anti aldol reaction with 3-butenal to afford β-
hydroxy ketone 4.35. Diastereoselective 1,3-syn reduction of 4.35 was achieved using LiBH4 in 
the presence of Et2BOMe to give diol 4.36. The diol was protected as acetonide 4.37 and 




























Scheme 4.10 Synthesis of ketone 4.31. 
 
Diastereoselective 1,5-anti aldol reaction between ketone 4.31 and 3-butenal provided 
homoallylic alcohol 3.38 (Scheme 4.11). 1,3-anti reduction was achieved using Me4NB(OAc)3 
and gave diol 4.39, which was protected as an acetonide to afford terminal alkene 4.30. 
Scheme 4.11 Synthesis of terminal alkene 4.30. 
 
Deprotection of the PMB ether of 4.30 gave secondary alcohol 4.40, which was oxidized 
to ketone 4.41 via Swern oxidation (Scheme 4.12). Oxidative cleavage of the terminal olefin 
provided aldehyde 4.42. Horner-Wadsworth-Emmons olefination of aldehyde 4.42 with ethyl-2-
(bis(o-tolyloxy)phosphoryl)acetate afforded enoate 4.29. Diastereoselective 1,5-anti aldol 
reaction between ketone 4.29 and 1-hexadecanal followed by 1,3-anti reduction gave diol 4.43. 































Key: (a) PMB trichloroacetimidate, CSA, CH2Cl2, rt; (b) PdCl2, CuCl, O2, DMF, H2O, rt; 
(c) (1) Cy2BCl, Et3N, Et2O, -30 °C (2) 3-butenal, -78 °C; (d) LiBH4, Et2BOMe, THF, 



















Key: (a) (1) Cy2BCl, Et3N, Et2O, -30 °C (2) 3-butenal, -78 °C; (b) Me4NHB(OAc)3, MeCN, AcOH, -30 to -20 °C; (c) 2,2-DMP, PPTS, rt.
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cryptocaryol A ent-4.2a. The synthesis accomplished by Dias and coworkers required 17 steps 
(LLS). 
Scheme 4.12 Completion of the synthesis of (−)-cryptocaryol A ent-4.2a. 
 
4.4.4 Cossy’s Total Synthesis of (+)-Cryptocaryol A 
In 2015, Cossy and coworkers published their total synthesis of cryptocaryol A 4.2a.129c 
The synthesis was envisaged from aldehyde 4.47 and heptadecan-2-one by using a 
diastereoselective boron-mediated aldol coupling (Scheme 4.13). It was anticipated that aldehyde 
4.47 could be accessed from bis-pyran 4.45 by reductive cleavage and ring-closing metathesis. 
Bis-pyran 4.45 was to be synthesized from pyran 4.46 via Prins cyclization. Pyran 4.46 would be 
obtained by a Prins cyclization between aldehyde 4.47 and homoallylic alcohol 4.48. 
  
Key: (a) DDQ, CH2Cl, buffer, 0 °C; (b) (COCl)2, DMSO, Et3N, CH2Cl2, -78 °C; (c) OsO4, NMO, t-BuOH, THF, 
H2O, rt; (d) NaIO4, THF, H2O; (e) ethyl 2-(bis(o-tolyloxy)phosphoryl)acetate, NaH, THF, -78 °C; (f) (1) Cy2BCl, 











































Scheme 4.13 Cossy’s retrosynthesis of (+)-cryptocaryol A 4.2a. 
 
The synthesis began with preparation of aldehyde 4.47 and homoallylic alcohol 4.48 
(Scheme 4.14). Monoprotection of 1,3-propanediol followed by oxidation using PCC provided 
aldehyde 4.47. Tosylation of (R)-glycidol followed by epoxide-opening with vinylmagnesium 
bromide in the presence of a catalytic amount of Li2CuCl4 produced the desired homoallylic 
alcohol 4.48. Prins cyclization between 4.47 and 4.48 was achieved using TFA to produce 4.51 
as a mixture of diastereomers (25:75 in favor of the undesired diastereomer). The mixture was 
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Scheme 4.14 Synthesis of pyran 4.46. 
 
Next, diastereoselective reduction of ketone 4.46 was performed with L-selectride to 
afford 4.51 again, but now as an 80:20 mixture of diastereomers in favor of the desired 
diastereomer (as depicted, Scheme 4.15). Protection of the secondary alcohol as the TBDPS 
ether and deprotection of the benzyl ether was followed by oxidation of the primary alcohol to 
generate aldehyde 4.52. Exposure of aldehyde 4.52 to 4.48 in the presence of TFA resulted in 
Prins cyclization, and oxidation of the resulting secondary alcohol with Dess-Martin periodinane 
afforded ketone 4.53. Reduction of ketone 4.53 with NaBH4 led to formation of secondary 
alcohol 4.54 with high diastereoselectivity (95:5, seperable). Double SN2 displacement of the 
tosylates was achieved with NaI under microwave irradiation to provide bis-iodide 4.55. 
Esterification with acryolyl chloride furnished bis-pyran 4.45.  
  







Key: (a) NaH, BnBr, n-Bu4NI, THF, rt, 7h; (b) PCC, NaOAc, 4 Å MS, CH2Cl2, rt, 3h.















Key: (a) TFA, CH2Cl2, rt, 3 h then NaHCO3, Et3N; (b) DMP, CH2Cl2, rt 2.5 h.
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Scheme 4.15 Synthesis of bis-pyran 4.45. 
 
Bernet-Vasella ring-opening of bis-pyran 4.45 gave diol 4.56 (Scheme 16). Protection of 
the hydroxyl groups as TBS ethers and ring-closing metathesis to install the pyrone was followed 
by oxidative cleavage of the terminal olefin to afford aldehyde 4.44. 1,3-syn-Aldol reaction 
between heptadecan-2-one and aldehyde 4.44 successfully installed the aliphatic moiety and 
subsequent diastereoselective reduction followed by global deprotection furnished the natural 





















































Key: (a) L-Selectride, THF, -78 °C, 1 h; (b) TBDPSCl, imidazole, CH2Cl2, rt, 14 h; (c) H2, Pd/C, MeOH, 
EtOAc, rt, 16 h; (d) TPAP, NMO, CH2Cl2, rt, 2 h; (e) 4.48, TFA, CH2Cl2, rt, 3 h then Et3N, NaHCO3 
(aq); (f) DMP, CH2Cl2, rt, 2 h; (g) NaBH4, MeOH, -40 °C, 1 h; (h) NaI, acetone, µw, 120 ºC, 2 h; (i) 






Scheme 4.16 Completion of the total synthesis of (+)-cryptocaryol A 4.2a. 
 
4.5 Conclusions 
Cryptocaryol A possesses impressive PDCD4 stabilization ability and interesting 
structure combining both a pyrone moiety and a long polyoxygenated substructure. These 
interesting structural and biological features inspired researchers to synthesize the natural 
product. While the initial total synthesis was later found to have been the incorrect structure, 
work by O’Doherty and coworkers revealed the absolute structure of the natural product. The 
prior syntheses illustrate the utility and limitations of methodologies used to construct 
polyketides. However, these routes typically required many synthetic concessions such as 
repeated protecting group manipulations and oxidation state adjustments. Additionally, all of the 
prior syntheses are quite linear and therefore generally lack synthetic efficiency.95, 97, 100, 133 
Our intention was to develop a more concise, convergent, and versatile synthetic route 
that combines the information learned from these previous syntheses with our newly developed 
metal-catalyzed transformations. In doing so, development of a synthetic route to (+)-
cryptocaryol A that requires fewer than half the number of steps as the shortest previous 













20 steps in LLS
Key: (a) Zn, THF/H2O = 5:1, 70 °C, 1 h; (b) TBSOTf, 2,6-lutidine, CH2Cl2, -78 °C, 1 h; (c) Grubbs I (10 
mol%), CH2Cl2, 45 °C, 2.5 h; (d) O3, CH2Cl2, -78 °C then PPh3; (e) (1) heptadecan-2-one, Cy2BCl, Et3N, 
pentane, 0 °C, 2 h (2) 4.44, pentane, -78 °C to 40 °C, 4 h (3) MeOH/pH7 buffer/H2O2,    -40 °C to rt, 16 h; (f) 




Chapter 5: Total Synthesis of (+)-Cryptocaryol A 
5.1 Initial Efforts Toward (+)-Cryptocaryol A 
In prior syntheses of cryptocaryol A 5.1, relatively lengthy syntheses were required in 
order to construct the natural product (Scheme 5.1). Due to the highly oxygenated nature of 5.1, 
oxidation state adjustments and differential protection of hydroxyl functional groups represented 
a significant fraction of the total number of synthetic transformations. While the majority of 
syntheses used catalytic, enantioselective methods in order to introduce chirality, many of the 
syntheses required the use of premetallated C-nucleophiles. While premetallated carbanions are 
often employed with great success, their synthesis typically requires multiple stages of pre-
activation and generates stoichiometric waste products. These waste products are often of higher 
molecular weight than the nucleophile that was incorporated into the chemical structure of the 
product. Finally, every prior synthesis of the natural product was based on a linear strategy for 
construction of the molecule.  
While these strategies ultimately led to the successful total synthesis of the natural 
product, the overall yield of each synthesis was quite poor due to the shear number of synthetic 
transformations performed. These issues of atom,98 step,99 and redox-economy100 are all 
concessions and illustrate the need for synthetic methodologies and strategies that can be used to 
synthesize complex molecules in a more direct manner. These concerns helped to guide and 
shape our synthetic strategy as it applied to the total synthesis of (+)-cryptocaryol A and it was 
anticipated that the use of the iridium-catalyzed two-directional allylation could dramatically 
reduce the number of steps require to synthesize the natural product. 
5.1.1 Retrosynthetic Analysis 
Recognizing the significant number of steps required in prior linear syntheses of 
cryptocaryol A 5.1, we sought to develop a more convergent approach. As a consequence of the 
polyol structure of the natural product, it was believed that a convergent approach would be 
possible and would not only reduce the steps required to construct the carbon framework of the 
 150 
molecule but also significantly simplify the protecting group strategy. We envisaged that (+)-
cryptocaryol A 5.1 could be constructed from aldehyde 5.2 and ketone 5.3 via a boron-mediated 
1,5-anti aldol reaction (Scheme 5.1). Aldehyde 5.2, containing the 1,3-anti diol moiety, was 
anticipated to be synthesized from chiral C2-symmetric diol 5.4, which could be prepared directly 
from 1,3-propanediol 5.5 (~$11 / mol) via asymmetric iridium-catalyzed two-directional 
allylation. The pyrone substructure was to be constructed via ring-closing metathesis. Ketone 
fragment 5.3 was proposed to come from cetyl alcohol 5.6, a commercially available and 
inexpensive (~$8 / mol) chemical feedstock. 
Scheme 5.1 Retrosynthetic analysis of (+)-cryptocaryol A.  
 
5.1.2 Initial Synthesis of Aldehyde 5.2 and Ketone 5.3 
Our synthesis began with the installation of the C5 and C7 stereocenters through 































5.4 (Scheme 5.2). Upon exposure of 5.5 to allyl acetate in the presence of [Ir(cod)Cl]2, (R)-Cl-
MeO-BIPHEP, 4-Cl-3-NO2-benzoic acid, and Cs2CO3 in 1,4-dioxane, C2-symmetric, chiral diol 
5.4 is obtained in 70% yield with very high levels of stereoselectivity (30:1 d.r., > 99% e.e.). As 
with the total synthesis of (−)-cyanolide A, (R)-BINAP was substituted for the (R)-Cl-MeO-
BIPHEP on large-scale reactions in order to reduce costs; however, the yield of the two-
directional allylation was reduced to 54%. Nevertheless, diol 5.4 was synthesized reproducibly 
on gram-scale directly from 1,3-propanediol 5.6. 
Scheme 5.2 Synthesis of diol 5.4.  
 
 
With chiral, C2-symmetric diol 5.4 in hand, desymmetrization was achieved via a borinic-
acid catalyzed monoacylation developed by Taylor and coworkers to provide acrylate 5.7 in 97% 
yield (Scheme 5.3, top).134 At this stage, it was anticipated that tandem ring-closing-metathesis-
cross-metathesis (RCM/CM) with acrolein would install the pyrone moiety as well as establish 
the aldehyde functionality necessary for aldol coupling in a later step. Significant screening of 
temperature, catalyst, solvent, and mode of addition was performed; however, the highest yield 
of the desired pyrone 5.8 was only 14%, which was not sufficient to carry forward in the 
synthesis. The reaction produced a complex mixture hypothesized to come from side reactions 
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moieties as well as the possibility of intramolecular ring-closing metathesis (Scheme 5.3, 
bottom).  
Scheme 5.3 Synthesis of pyrone 5.8 and potential side products.  
 
5.1.3 Revised Strategy and Attempted Synthesis of the Ketone Fragment 
Undeterred by our initial failure, we hypothesized that carbonyl addition that led to an 
undesired side product could be suppressed if acrolein was exchanged for methyl vinyl ketone. 
Importantly, this would require that the aldehyde and ketone partners for the key fragment union 
would need to be swapped and the substrate-directed aldol would be a 1,5-syn aldol, in which the 
β-alkoxy stereocenter of the ketone fragment would influence the stereochemistry of the newly 
formed stereocenter to give a 1,5-syn relationship between the two. While boron-mediated 1,5-
anti aldol reactions are well known in the literature, 1,5-syn aldol reactions are much less 
common and frequently suffer from poor diastereoselectivity unless chiral boron reagents are 
employed. It was anticipated that the requisite 1,5-syn aldol reaction could be overcome and thus 
we turned our attention to the synthesis of ketone 5.9 (Scheme 5.4, top). Unfortunately, treatment 
of acrylate 5.7 with methyl vinyl ketone in the presence of HG-II was unsuccessful and 
polymerization hindered identification of the side products. This was presumably due to side 
reactions involving conjugate addition of the C7 hydroxyl group onto the enoate moiety as well 













Key: (a) acryloyl chloride (150 mol%), i-Pr2NEt (200 mol%), 2-aminoethyl diphenylborinate 
(10 mol%), MeCN (0.2 M); (b) acrolein (2000 mol%), HG-II (10 mol%), toluene (0.05 M), rt 
to 120 °C.
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Scheme 5.4 Attempt to synthesis of pyrone 5.9 and potential side products.  
 
 
In order to test the plausibility of the tandem RCM/CM, removal of the acrylate moiety 
was desired as a means to eliminate the conjugate addition pathway. O-allylation of diol 5.4 with 
allyl bromide afforded allylic alcohol 5.10 (Scheme 5.5). Exposure of 5.10 to methyl vinyl 
ketone in the presence of HG-II went smoothly to produce pyran 5.11 in excellent yield. This 
made it clear that not only was the tandem reaction possible but that the problem with earlier 
attempts had been due to the presence of the C7 hydroxyl group and the acrylic ester. With pyran 
5.11 in hand, we sought to install the C9 hydroxyl group in a stereoselective manner. Under 
Evans’ conditions for oxa-conjugate and acetal formation, pyran 5.11 was transformed into 
ketone 5.12. It was anticipated that installation of the C1 carbonyl would be possible through 
allylic oxidation; however, two locations for allylic oxidation were possible. All attempts to 
selectively oxidize C1 were unsuccessfully and reactions typically produced mixtures of C1 and 
C4 oxidatized material. The low selectivity of the oxidation coupled with a yield that was 
typically quite low (<40% combined yield for both isomers) forced us to go back and redesign 
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Scheme 5.5 Synthesis of pyrone 5.12.  
 
5.1.4 Revised Strategy and Attempted Coupling 
 The difficulty associated with selective allylic oxidation of pyran 5.12 posed a significant 
challenge, as the development of conditions for tandem RCM/CM had met with great success 
without oxygenation at C1. It was hypothesized that the tandem reaction using acrylate 5.7 could 
be made possible through protection of the C7 hydroxyl group prior to metathesis. While we 
initially viewed this step as a concession, it was believed that careful choice of the protecting 
group could still allow for a single step global deprotection at the conclusion of the synthesis.   
 Protection of acrylate 5.7 was accomplished with TESOTf and 2,6-lutidine to give silyl 
ether 5.13 (Scheme 5.6). Gratifyingly, exposure of 5.13 to methyl vinyl ketone in the presence of 
the Hoveyda-Grubbs II catalyst in refluxing toluene afforded pyrone 5.14 in 71% yield. 
Acetalization and intermolecular oxa-conjugate cyclization of 5.14 with acetaldehyde under 
Taylor’s conditions delivered ketone 5.15.134 The versatility of this method is of significance as it 
promoted acetalization directly from the silyl ether without necessitating deprotection prior to the 











Key: (a) allyl bromide, KI (100 mol%), K2CO3 (110 mol%), 2-aminoethyl diphenylborinate 
(10 mol%), MeCN (0.2 M), 60 °C; (b) methyl vinyl ketone (500 mol%), G-II (5 mol%), 












Scheme 5.6 Synthesis of ketone 5.12.  
 
 With the ketone fragment in hand, our focus shifted towards the synthesis of the requisite 
aldehyde for aldol coupling. Commerically available cetyl alcohol 5.6 underwent asymmetric 
iridium-catalyzed allylation to afford chiral homoallylic alcohol 5.16 (Scheme 5.7). Protection of 
the secondary hydroxyl group was achieved with p-methoxybenzyl trichloroacetimidate with 
catalytic La(OTf)3 to provide alkene 5.17. Oxidative cleavage using OsO4 and NaIO4 furnished 
aldehyde 5.18 in an efficient three-step sequence from cetyl alcohol with an overall yield of 
47%. 
Scheme 5.7 Synthesis of aldehyde 5.18.  
 
 With ketone 5.15 and aldehyde 5.18 in hand, the stage was set for the key aldol coupling 










Key: (a) TESOTf (150 mol%), 2,6-lutidine (200 mol%), CH2Cl2 (0.05 M), -78°C; (b) methyl 
vinyl ketone (300 mol%), HG-II (10 mol%), toluene (0.01 M), rt to 120 °C; (c) acetaldehyde 
















Key: (a) allyl acetate (200 mol%), [Ir(cod)Cl]2 (2.5 mol%), (R)-binap (5 mol%), 
4-Cl-3-NO2-BzOH (10 mol%), Cs2CO3 (20 mol%), THF (0.2 M), 100 °C; (b) p-
methoxybenzyl trichloroacetimidate (150 mol%), La(OTf)3 (5 mol%), toluene 
(0.15 M); (c) OsO4 (2 mol%), NaIO4 (400 mol%), 2,6-lutidine (200 mol%), 1,4-
















respect to the original fragments proposed in the retrosynthesis, the current aldol would require 
construction of a 1,5-syn relationship between C9 and C13 in the aldol product. Highly 
diastereoselective methods for such boron-mediated aldol reactions are quite challenging135 and 
Mukaiyama 1,5-syn aldol reactions are also difficult.136 Various conditions for generation of the 
enolborinate of ketone 5.15 were tested. The boron sources screened included Bu2BOTf, Cy2BCl, 
and (−)-diisopinocampheylborane chloride. Amine bases assessed were Et3N, iPr2NEt, and 2,6-
lutidine. In all cases, the aldol reaction with aldehyde 5.18 produced a complex inseparable 
mixture that proved difficult to characterize. It was hypothesized that not only did the coupling 
suffer from poor diastereoselectivity but also retro aldol could be a competing side reaction. In 
order to circumvent the inherent challenges associated with overcoming the substrate’s proclivity 
to 1,5-anti addition, and having discovered that the tandem RCM/CM was successful upon 
protection of the C7 hydroxyl group, it was decided to attempt the original synthetic plan once 
more.  
Scheme 5.8 Attempted boron-mediated aldol coupling.  
 
5.2 Final Strategy for (+)-Cryptocaryol A 
The important lessons learned in the first approach to the total synthesis of (+)-
cryptocaryol A 5.1 were used to help guide the second attempt of the synthesis of aldehyde 5.2. 
As protection of the C7 hydroxyl group had proven to be essential in the successful tandem 
metathesis reactions, it was hypothesized that coupling of silyl ether 5.13 with acrolein would 
provide the desired α,β-unsaturated aldehyde. Gratifyingly, exposure of 5.13 to acrolein and a 
catalytic amount of Hoveyda-Grubbs II in refluxing toluene afforded enal 5.19 in 58% yield 













the solvent to F8-toluene, which had previously been shown to enhance efficiency in metathesis 
reactions.137  
Scheme 5.9 Synthesis of aldehyde 5.2.  
 
With aldehyde 5.2 in hand, our focus shifted to the synthesis of the ketone fragment 5.3 
(Scheme 5.10). Fortunately, access to the ketone was achieved through Wacker oxidation of 
homoallylic alcohol 5.16 using Sigman’s modified conditions.138  
Scheme 5.10 Sigman’s modified conditions for Wacker oxidation to provide ketone 5.3.  
 
Having successfully synthesized aldehyde 5.2 and ketone 5.3, we next attempted the 
crucial aldol coupling (Scheme 5.11). While the 1,5-syn aldol reaction had proven to be quite 
challenging, there existed many examples of high diastereoselectivity in boron-mediated 1,5-anti 
aldol couplings.139 Exposure of ketone 5.3 to Cy2BCl and Et3N in Et2O at -30 °C resulted in a 
white suspension, which was further cooled to -78 °C. Addition of a solution of aldehyde 5.2 in 
Et2O resulted in the formation of β-hydroxy ketone 5.20 as a single diastereomer in 64% yield. 
Hydroxy-directed reduction of the aldol product delivered diol 5.21 in 94% yield with good 
levels of 1,3-diastereoselectivity (15:1). Finally, global deprotection of the acetal and PMB ether 
using triflic acid and 1,3-dimethoxybenzene140 furnished (+)-cryptocaryol A 5.1. The total 
synthesis was accomplished in 8 steps (LLS) from 1,3-propanediol, fewer than half the number 












Key: (a) acrolein (180 mol%), HG-II (10 mol%), solvent (0.05 M), rt to 120 °C; (b) acetaldehyde (2000 mol%), 





















Scheme 5.11 Completion of the total synthesis of (+)-cryptocaryol A 5.1.  
 
5.3 Conclusions 
Application of C-C bond forming hydrogenation methods facilitated a remarkably 
concise synthesis of (+)-cryptocaryol A. Over the course of our synthetic efforts, many 
challenges had to be overcome. First, the inability to directly perform the tandem RCM/CM 
reaction on the desired acrylate forced us to reconsider our forward synthetic strategy. Secondly, 
once the fragments had been synthesized, the boron-mediated 1,5-syn aldol reaction was 
unsuccessful and necessitated redesign of our synthetic strategy. Finally, protection of the C7 
hydroxyl group was determined to be essential for the success of the RCM/CM reaction and 
changing the solvent from toluene to F8-toluene improved the yield significantly. According to 
the metric for synthetic efficiency developed by Baran,95 the current synthesis of (+)-
cryptocaryol A is ~64% ideal. The major synthetic concessions were the need to protect the C7 
and C15 hydroxyl groups, the latter of which required deprotection at the conclusions of the 
synthesis. Despite these concessions, the strategy employed in the total synthesis of (+)-
cryptocaryol A has produced the most concise synthesis of the natural product to date. 
In summary, with the exception of eribulin,141 all FDA approved polyketides are accessed 
through fermentation or semi-synthesis, as current synthetic methodology cannot address the 





























Key: (a) Cy2BCl (250 mol%), Et3N (270 mol%), Et2O (0.05 M), -30 °C to -78 °C; (b) Et2BOMe (200 mol%), 








has developed a suite of catalytic methods for the construction of polyketides which addition or 
exchange of hydrogen is accompanied by C-C bond formation.110 As illustrated by the present 
total synthesis of (+)-cryptocaryol A, application of this technology has availed the most concise 
route to any member of this family of polyketide natural products. 
5.4 Experimental Details 
5.4.1 General Information 
All reactions were run under an atmosphere of argon under anhydrous conditions unless 
otherwise indicated. Dichloroethane (DCE), triethylamine (Et3N), Hünig’s Base (iPr2EtN), 
acetonitrile (MeCN), and dichloromethane (CH2Cl2) were distilled over CaH2. Diethyl ether 
(Et2O), tetrahydrofuran (THF), and toluene (PhMe) were distilled over sodium. Pressure tubes 
(25x150 mm, PYREXPLUS, and 350 mL flask, purchased from Chem Glass) were dried in an 
oven overnight and cooled under a stream of nitrogen prior to use. Commercially available allyl 
acetate (Aldrich) was purified by distillation prior to use. Acrolein was purified by distillation 
prior to use. All other commercial reagents were used directly without further purification unless 
specified. All analytical thin-layer chromatography (TLC) was carried out using 0.2 mm 
commercial silica gel plates (DC-Fertigplatten Kieselgel 60 F254). Plates were visualized by 
treatment with UV, acidic p-anisaldehyde stain, ceric ammonium molybdate stain, or KMnO4 
stain with gentle heating.  
5.4.2 Spectrometry and Spectroscopy 
Infrared spectra were recorded on a Nicolet 380 FTIR. High-resolution mass spectra 
(HRMS) were obtained on a Karatos MS9 and are reported as m/z (relative intensity). Accurate 
masses are reported for the molecular ion ([M+H]+, [M-H]+, or [M+Na]+). Nuclear magnetic 
resonance spectra (1H NMR and 13C NMR) were recorded with a Varian Gemini (400 MHz or 
600 MHz) spectrometer for CDCl3 and (CD3)2O solutions and chemical shifts are reported as 
parts per million (ppm) relative to residual CHCl3 δH (7.26 ppm), CDCl3 δC (77.0 ppm), CD3OD 
δH (4.87 ppm), CD3OD δC (49.0 ppm) respectively, as internal standards. Coupling constants are 
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reported in hertz (Hz). Optical rotations were measured on an ATAGO AP-300 automatic 
polarimeter at a path length of 100 mm. 
5.4.3 Procedures and Spectra 
(4R,6R)-nona-1,8-diene-4,6-diol (5.4) 
To an oven-dried sealed tube under one atmosphere of argon gas charged with 
[Ir(cod)Cl]2 (0.672 g, 1.00 mmol, 5 mol%), (R)-BINAP (1.25 g, 2.00 mmol, 10 mol%), Cs2CO3 
(2.61 g, 8.00 mmol, 40 mol%) and 4-chloro-3-nitrobenzoic acid (0.806 g, 4.00 mmol, 20 mol%) 
was added THF (50 mL) followed by allyl acetate (20.0 g, 200 mmol, 1000 mol%). The reaction 
mixture was stirred at 90 ºC for 0.5 h before cooling to ambient temperature. 1,3-propanediol 5.5 
(1.52 g, 20.0 mmol, 100 mol%) in THF (50 mL, 0.2 M overall) was added and the reaction 
mixture was stirred at 100 ºC for 5 days. The reaction mixture was cooled to ambient 
temperature, filtered through Celite, and excess solvent was removed under reduced pressure. 
The crude material was dissolved in EtOAc (50 mL) and vigorously stirred. Et2O (100 mL) was 
added slowly followed by hexanes (100 mL). The precipitate was filtered through Celite and the 
solution was then concentrated onto silca gel. Purification of the product by column 
chromatography (SiO2, EtOAc:hexanes, 1:6 to 1:4 with 0.1% TEA) provided 5.4 (1.68 g, 54% 
yield, dr = 20:1, ee > 99%) as a pale yellow oil.  
TLC (SiO2): Rf = 0.25 (EtOAc:hexanes, 1:4). 
1H NMR: (400 MHz, CDCl3): δ 5.87-5.77 (m, 2H), 5.17-5.15 (m, 2H), 5.13-5.12 (m, 2H), 4.04-
3.97 (m, 2H), 2.39 (d, J = 3.5 Hz, 2H), 2.30-2.24 (m, 4H), 1.66-1.63 (m, 2H). 
13C NMR: (100 MHz, CDCl3): δ 134.8, 118.4, 68.2, 42.2, 41.6. 
FTIR (neat): ν 3333, 2936, 2359, 2342, 1214, 1434, 1325, 1133, 1047.cm-1.  
HRMS: (ESI) Calcd. for C9H16O2Na (M+Na)+: 179.1048, Found: 179.1042. 










(4R,6R)-6-hydroxynona-1,8-dien-4-yl acrylate (5.7) 
To a stirred solution of diol 5.4 (104.1 mg, 0.666 mmol, 100 mol%) in dry MeCN (3.30 
mL, 0.2 M) was added iPr2NEt (230 µL, 1.33 mmol, 200 mol%) followed by 2-aminoethyl 
diphenylborinate (14.9 mg, 0.07 mmol, 10 mol%). Acryloyl chloride (90.5 mg, 1.00 mmol, 150 
mol%) was added dropwise and the solution was stirred at ambient temperature for 3 h. The 
reaction mixture was poured into H2O and EtOAc and extracted with EtOAc (3 x 10 mL). The 
combined organic extracts were washed with brine, dried over anhydrous MgSO4, filtered 
through Celite, and concentrated by rotary evaporation. The crude material was purified via flash 
column chromatography (SiO2, EtOAc:hexanes 1:9) to afford 5.7 (136.4 mg, 97% yield) as a 
colorless oil.  
TLC (SiO2): Rf = 0.21 (1:9 EtOAc:hexanes) 
1H NMR: (400 MHz, CDCl3): δ = 6.43 (dd, J = 17.3, 1.4 Hz, 1H), 6.13 (dd, J = 17.3, 10.4 Hz, 
1H), 5.87 (dd, J = 10.4, 1.4 Hz, 1H), 5.84-5.71 (m, 2H), 5.27-5.21 (m, 1H), 5.13-5.06 (m, 4H), 
3.61-3.54 (m, 1H), 2.83 (d, J = 3.8 Hz, 1H), 2.41-2.37 (m, 2H), 2.25-2.21 (m, 2H), 1.74-1.60 (m, 
2H). 
13C NMR: (100 MHz, CDCl3): δ = 166.9, 134.7, 133.3, 131.4, 128.2, 118.0, 117.6, 70.9, 66.5, 
41.6, 41.6, 39.2. 
FTIR (neat): ν 3464, 3016, 2970, 1739, 1407, 1366, 1297, 1228, 1217, 1206, 1049 cm-1. 
HRMS: (ESI) Calcd. for C12H18O3Na (M+Na)+: 233.1154, Found: 233.1147 









To a solution of 5.7 (48.6 mg, 0.231 mmol, 100 mol%) in dry toluene (23.1 mL, 0.01 M) 
was added acrolein (0.046 mL, 0.693 mmol, 300 mol%). Hoveyda-Grubbs II (14.5 mg, 0.023 
mmol, 10 mol%) was added and the reaction was heated to reflux for 3 h. The crude reaction 
mixture was concentrated under vacuum and purified via flash column chromatography (SiO2, 
acetone:CHCl3 1:9 to 3:7) to afford 5.8 (6.8 mg, 14% yield) as a brown oil. 
TLC (SiO2): Rf = 0.35 (3:7 acetone:CHCl3) 
1H NMR: (400 MHz, CDCl3): δ = 9.54 (d, J = 7.8 Hz, 1H), 6.94-6.85 (m, 2H), 6.24-6.17 (m, 
1H), 6.04 (dt, J = 9.8, 1.9 Hz, 1H), 4.76 (dtd, J = 10.2, 7.9, 2.3 Hz, 1H), 4.31-4.28 (m, 1H), 2.61-
2.49 (m, 2H), 2.39-2.36 (m, 2H), 2.12-2.11 (m, 1H), 1.93 (ddd, J = 14.5, 10.0, 2.4 Hz, 1H), 1.74 
(ddd, J = 14.5, 10.2, 2.6 Hz, 1H). 
13C NMR: (100 MHz, CDCl3): δ = 193.8, 164.2, 153.5, 145.4, 135.6, 121.5, 74.6, 65.9, 42.0, 
41.1, 29.9 
FTIR (neat): ν 3423, 2923, 1683, 1393, 1254, 1138, 1045 cm-1. 
HRMS: (ESI) Calcd. for C11H14O4Na (M+Na)+: 233.07840, Found: 233.07900  








To a stirred solution of diol 5.4 (501.5 mg, 3.21 mmol, 100 mol%) in dry MeCN (16.0 
mL, 0.2 M) was added 2-aminoethyl diphenylborinate (72.3 mg, 0.321 mmol, 10 mol%) 
followed by KI (532.9 mg, 3.21 mmol, 100 mol%) and K2CO3 (487.9 mg, 3.53 mmol, 110 
mol%) and the solution was heated to 60 °C. Freshly distilled allyl bromide (0.83 mL, 9.63 
mmol, 300 mol%) was added dropwise and the solution was stirred at 60 °C for 24 h. The 
reaction mixture was poured into H2O (15 mL) and extracted with EtOAc (3 x 15 mL). The 
combined organic extracts were washed with brine, dried over anhydrous MgSO4, filtered 
through Celite, and concentrated by rotary evaporation. The crude material was purified via flash 
column chromatography (SiO2, EtOAc:hexanes 1:9) to afford 5.10 (407.5 mg, 65% yield) as a 
colorless oil.  
TLC (SiO2): Rf = 0.19 (1:9 EtOAc:hexanes) 
1H NMR: (400 MHz, CDCl3): δ = 5.97-5.73 (m, 3H), 5.27 (dq, J = 17.2, 1.6 Hz, 1H), 5.19-5.05 
(m, 5H), 4.11 (ddt, J = 12.6, 5.5, 1.4 Hz, 1H), 4.03-3.94 (m, 2H), 3.73-3.68 (m, 1H), 2.65 (d, J = 
3.7 Hz, 1H), 2.43-2.37 (m, 1H), 2.32-2.21 (m, 3H), 1.64 (t, J = 5.7 Hz, 2H). 
13C NMR: (100 MHz, CDCl3): δ = 135.05, 134.95, 134.55, 117.83, 117.58, 117.18, 76.44, 
70.45, 67.72, 42.38, 39.70, 38.27 










To a stirred solution of 5.10 (167.7 mg, 0.854 mmol, 100 mol%) in dry CH2Cl2 (62 mL) 
was added freshly distilled methyl vinyl ketone (0.37 mL, 4.27 mmol, 500 mol%) and the 
solution was heated to 50 °C. A solution of Grubbs II (36.3 mg, 0.043 mmol, 5 mol%) in dry 
CH2Cl2 (12 mL, 0.01M final concentration) was added via syringe pump addition over 5 h and 
the solution was left to stir at 50 °C overnight. The reaction was cooled to room temperature and 
concentrated by rotary evaporation. The crude material was purified via flash column 
chromatography (SiO2, EtOAc:hexanes 2:3 to 1:1) to afford 5.11 (178.4 mg, 99% yield) as a 
light brown oil. 
TLC (SiO2): Rf = 0.17 (1:1 EtOAc:hexanes) 
1H NMR: (400 MHz, CDCl3): δ = 6.86 (dt, J = 16.0, 7.2 Hz, 1H), 6.14 (dt, J = 16.0, 1.4 Hz, 1H), 
5.83-5.80 (m, 1H), 5.73-5.70 (m, 1H), 4.21-4.18 (m, 2H), 4.11-4.08 (m, 1H), 3.87-3.83 (m, 1H), 
2.95 (d, J = 4.7 Hz, 1H), 2.45-2.40 (m, 2H), 2.26 (s, 3H), 2.17-2.13 (m, 1H), 1.95-1.89 (m, 1H), 
1.74-1.70 (m, 2H). 
13C NMR: (100 MHz, CDCl3): δ = 198.7, 144.7, 133.5, 126.0, 124.2, 71.3, 67.8, 66.1, 41.5, 
40.6, 30.7, 27.0 









To a solution of 5.11 (129.0 mg, 0.613 mmol, 100 mol%) in dry CH2Cl2 (6.1 mL, 0.1 M) 
was added acetaldehyde (0.70 mL, 12.27 mmol, 2000 mol%). Bi(NO3)3⋅5H2O (29.7 mg, 0.061 
mmol, 10 mol%) was added and the solution was allowed to stir at room temperature for 24 h. 
The solution was then poured into sat. aq. NaHCO3 (10 mL) and extracted with CH2Cl2 (3 x 10 
mL). The combined organic extracts were dried over MgSO4, filtered through Celite, and 
concentrated via rotary evaporation. The crude material was purified via flash column 
chromatography (SiO2, EtOAc:hexanes 1:9 to 2:3) to afford 5.12 (83.8 mg, 54% yield) as a 
colorless oil.  
TLC (SiO2): Rf = 0.21 (1:1 EtOAc:hexanes) 
1H NMR: (400 MHz, CDCl3): δ = 5.82-5.77 (m, 1H), 5.71 (ddq, J = 10.3, 3.3, 1.7 Hz, 1H), 4.74 
(q, J = 5.1 Hz, 1H), 4.22-4.15 (m, 2H), 4.11 (dddd, J = 11.2, 7.4, 5.1, 2.4 Hz, 1H), 3.93-3.86 (m, 
1H), 3.77-3.71 (m, 1H), 2.75 (dd, J = 16.1, 7.4 Hz, 1H), 2.46 (dd, J = 16.1, 5.2 Hz, 1H), 2.18 (s, 
3H), 2.00-1.96 (m, 2H), 1.69-1.55 (m, 4H), 1.29 (d, J = 5.1 Hz, 3H). 
13C NMR: (100 MHz, CDCl3): δ = 206.8, 126.4, 124.4, 98.7, 72.8, 72.4, 69.8, 66.0, 49.7, 42.6, 
37.3, 31.6, 31.3, 21.2 









(4R,6R)-6-((triethylsilyl)oxy)nona-1,8-dien-4-yl acrylate (5.13) 
To a stirred solution of acrylate 5.7 (136.4 mg, 0.65 mmol, 100 mol%) in dry CH2Cl2 
(13.0 mL, 0.05 M) was added 2,6-lutidine (150 µL, 1.30 mmol, 200 mol%) and the reaction 
cooled to -78 °C. TESOTf (220 µL, 0.97 mmol, 150 mol%) was added dropwise and the solution 
was stirred at -78 °C for 1.5 h. The reaction was quenched with sat. aq. NH4Cl and warmed to 
ambient temperature. The reaction mixture was poured into H2O and extracted with CH2Cl2 (3 x 
15 mL). The combined organic extracts were washed with brine, dried over anhydrous MgSO4, 
filtered through Celite, and concentrated by rotary evaporation. The crude material was purified 
via flash column chromatography (SiO2, EtOAc:hexanes 1:32) to afford 5.13 (198.4 mg, 94% 
yield) as a colorless oil. 
TLC (SiO2): Rf = 0.42 (1:19 ethyl acetate:hexanes) 
1H NMR: (400 MHz, CDCl3): δ = 6.38 (dd, J = 17.3, 1.5 Hz, 1H), 6.10 (dd, J = 17.3, 10.4 Hz, 
1H), 5.84-5.70 (m 2H), 5.80 (dd, J = 10.4, 1.5 Hz, 1H), 5.09-5.03 (m, 5H), 3.84-3.78 (m, 1H), 
2.40-2.36 (m, 2H), 2.26-2.22 (m, 2H), 1.76 (ddd, J = 14.5, 9.5, 3.2 Hz, 1H), 1.62 (ddd, J = 14.5, 
9.0, 3.2 Hz, 1H), 0.94 (t, J = 7.9 Hz, 9H), 0.57 (q, J = 8.0 Hz, 6H). 
13C NMR: (100 MHz, CDCl3): δ = 165.8, 134.6, 133.5, 130.5, 129.0, 118.0, 117.5, 71.3, 68.7, 
42.9, 40.7, 39.3, 7.1, 5.2. 
FTIR (neat): ν 3016, 2970, 1739, 1405, 1366, 1229, 1217, 1205, 1092 cm-1. 
HRMS: (ESI) Calcd. for C18H32O3SiNa (M+Na)+: 347.2018, Found: 347.2015 








To a solution of 5.13 (503.9 mg, 1.55 mmol, 100 mol%) in dry toluene (155 mL, 0.01 M) 
was added freshly distilled methyl vinyl ketone (326.5 mg, 0.43 mL, 4.66 mmol, 300 mol%) 
followed by Hoveyda-Grubbs 2nd Generation catalyst (97.1 mg, 0.155 mmol, 10 mol%) and the 
solution stirred at rt for 1.5 h. The reaction mixture was then heated to 120 °C for 3 h. The 
solvent was then removed in vacuo and the crude material purified by flash column 
chromatography (SiO2, EtOAc:hexanes 1:4 to 1:2) to afford 5.14 (371.8 mg, 71% yield) as a tan 
oil. 
TLC (SiO2): Rf = 0.18 (1:2 ethyl acetate:hexanes) 
1H NMR: (400 MHz, CDCl3): δ  6.89 (ddd, J = 9.8, 4.8, 3.7 Hz, 1H), 6.78 (dt, J = 16.0, 7.4 Hz, 
1H), 6.11 (dt, J = 16.0, 1.4 Hz, 1H), 6.03 (dt, J = 9.8, 1.8 Hz, 1H), 4.63-4.56 (m, 1H), 4.30-4.24 
(m, 1H), 2.48-2.39 (m, 2H), 2.34-2.30 (m, 2H), 2.26 (s, 3H), 1.83 (ddd, J = 14.3, 10.3, 2.4 Hz, 
1H), 1.65-1.59 (m, 1H), 0.95 (t, J = 7.9 Hz, 9H), 0.63 (q, J = 8.0 Hz, 6H). 
13C NMR: (100 MHz, CDCl3): δ 198.4, 164.1, 145.4, 143.3, 134.1, 121.6, 74.4, 66.5, 42.5, 41.4, 
30.1, 27.0, 7.0, 5.0. 
FTIR (neat): ν 2955, 2913, 2877, 1720, 1674, 1628, 1423, 1381, 1362, 1250, 1179, 1150, 1086, 
1061, 1005 cm-1. 
HRMS: (ESI) Calcd. for C18H30O4SiNa (M+Na)+: 361.1811, Found: 361.1809 








To a solution of enone 5.14 (371.8 mg, 1.10 mmol, 100 mol%) in CH2Cl2 (11 mL, 0.1 M) 
at rt was added acetaldehyde (967.6 mg, 1.25 mL, 22.0 mmol, 2000 mol%) followed by 
Bi(NO3)3⋅5H2O (53.4 mg, 0.11 mmol, 10 mol%) and was stirred at rt for 5 days. The reaction 
mixture was poured into sat. NaHCO3 and extracted with CH2Cl2 (3 x 25 mL) then the organic 
extracts were combined and dried over anhydrous Na2SO4. The solution was decanted and the 
solvent removed in vacuo. The crude material was purified via flash column chromatography 
(SiO2, EtOAc:hexanes 1:1 to 2:1) to afford 5.15 (268.8 mg, 91% yield) as a tan oil. 
TLC (SiO2): Rf = 0.29 (7:3 ethyl acetate:hexanes) 
1H NMR: (400 MHz, CDCl3): δ 6.90-6.86 (m, 1H), 6.03 (ddd, J = 9.8, 2.5, 1.2 Hz, 1H), 4.76-
4.68 (m, 2H), 4.11 (dddd, J = 11.1, 7.4, 5.2, 2.3 Hz, 1H), 4.06-3.99 (m, 1H), 2.75 (dd, J = 16.1, 
7.2 Hz, 1H), 2.48 (dd, J = 16.1, 5.3 Hz, 1H), 2.37-2.31 (m, 2H), 2.20 (s, 3H), 1.88 (ddd, J = 14.6, 
9.6, 2.4 Hz, 1H), 1.75 (ddd, J = 14.6, 10.0, 2.9 Hz, 1H), 1.61-1.57 (m, 2H), 1.28 (d, J = 5.11 Hz, 
3H). 
13C NMR: (100 MHz, CDCl3): δ 206.5, 164.4, 145.3, 121.6, 98.7, 74.0, 72.3, 71.4, 49.5, 41.5, 
36.8, 31.2, 30.0, 21.1. 
FTIR (neat): ν 3016, 2943, 2364, 1714, 1653, 1379, 1251, 1215, 1191, 1093, 1040 cm-1. 
HRMS: (ESI) Calcd. for C14H20O5Na (M+Na)+: 291.1208, Found: 298.1205 









Cetyl alcohol 5.6 (4.849 g, 20.0 mmol, 100 mol%), [Ir(cod)Cl]2 (336.0 mg, 0.50 mmol, 
2.5 mol%), (R)-BINAP (622.7 mg, 1.00 mmol, 5 mol%), 4-chloro-3-nitrobenzoic acid (403.1 
mg, 2.00 mmol, 10 mol%), and Cs2CO3 (1.303 g, 4.00 mmol, 20 mol%) were added to a flame-
dried pressure tube equipped with a magnetic stir bar and purged with Ar for 5 minutes. Dry 
THF (100 mL, 0.2 M) was added followed by freshly distilled allyl acetate (4.4 mL, 40.0 mmol, 
200 mol%) and the vessel sealed. The reaction mixture was heated to 100 °C for 24 h. The 
reaction mixure was then cooled to room temperature and poured through a plug of Celite, which 
was washed with fresh THF. The solvent was then removed by rotary evaporation and the crude 
material purified via column chromatography (SiO2, Et2O:hexanes 1:19) to afford 5.16 (4.091 g, 
72% yield) as a waxy white solid. 
TLC (SiO2): Rf = 0.20 (1:19 ethyl acetate:hexanes) 
1H NMR: (400 MHz, CDCl3): δ 5.85-5.78 (m, 1H), 5.16-5.14 (m, 1H), 5.13-5.11 (m, 1H), 3.65-
3.63 (m, 1H), 2.30-2.27 (m, 1H), 2.17-2.12 (m, 1H), 1.56-1.54 (m, 1H), 1.47-1.43 (m, 3H), 1.34-
1.23 (m, 25H), 0.89-0.86 (m, 3H). 
13C NMR: (100 MHz, CDCl3): δ 135.1, 118.2, 70.8, 42.1, 37.0, 32.1, 29.8, 29.8, 29.5, 25.8, 22.9, 
14.3. 
FTIR (neat): ν 3319, 2915, 2849, 2360, 1636, 1470 cm-1. 
HRMS: (CI) Calcd. for C19H39O (M+H)+: 283.3001, Found: 283.3000 
MP: 47 - 48 °C 










To a solution of alcohol 5.16 (1.009 g, 3.57 mmol, 100 mol%) in dry toluene (24 mL, 
0.15 M) was added 4-methoxybenzyl-2,2,2-trichloroacetimidate (1.514 g, 5.36 mmol, 150 
mol%) followed by La(OTf)3 (0.1046 g, 0.179 mmol, 5 mol%). The solution was stirred at rt 
overnight. The reaction mixture was poured into H2O and hexanes, extracted with hexanes (5 x 
35 mL), dried over Na2SO4, filtered, and concentrated in vacuo onto silica gel. The crude 
material was purified via column chromatography (SiO2, Et2O:hexanes 1:19) to afford 5.17 
(1.333 g, 93% yield) as a colorless oil. 
TLC (SiO2): Rf = 0.36 (1:19 Et2O:hexanes) 
1H NMR: (400 MHz, CDCl3): δ  7.29-7.25 (m, 2H), 6.89-6.85 (m, 2H), 5.85 (ddt, J = 17.2, 10.1, 
7.1 Hz, 1H), 5.11-5.03 (m, 2H), 4.46 (q, J = 15.2 Hz, 2H), 3.80 (s, 3H), 3.41 (qd, J = 6.0, 5.5 Hz, 
1H), 2.34-2.28 (m, 2H), 1.54-1.46 (m, 2H), 1.34-1.21 (m, 26H), 0.88 (t, J = 6.9 Hz, 3H). 
13C NMR: (100 MHz, CDCl3): δ 159.0, 135.2, 131.0, 129.3, 116.7, 113.7, 78.2, 70.5, 55.3, 38.3, 
33.8, 31.9, 29.7, 29.7, 29.7, 29.7, 29.6, 29.4, 25.4, 22.7, 14.1. 
FTIR (neat): ν 2924, 2853, 1513, 1247, 1215, 1037 cm-1. 
HRMS: (ESI) Calcd. for C27H46O2Na (M+Na)+: 425.3396, Found: 425.3372 









To a solution of alkene 5.17 (1.333 g, 3.31 mmol, 100 mol%) in 1,4-dioxane (27.6 mL) 
and H2O (9.2 mL) was added 2,6-lutidine (0.77 mL, 6.62 mmol,  200 mol%) followed by OsO4 
in 1,4-dioxane (16.8 mg, 0.066 mg, 2 mol%). NaIO4 (2.832 g, 13.24 mmol, 400 mol%) and the 
solution stirred at rt overnight. The reaction mixture was poured into H2O and CH2Cl2, extracted 
with CH2Cl2 (5 x 35 mL), dried over NaSO4, filtered, and concentrated in vacuo. The crude 
material was purified via column chromatography (SiO2, ethyl acetate:hexanes 1:19 to 1:9) to 
afford 5.18 (896.1 mg, 67%) as a colorless oil.  
TLC (SiO2): Rf = 0.28 (1:4 Et2O:hexanes) 
1H NMR: (400 MHz, CDCl3): δ 9.78 (dd, J = 2.5, 2.0 Hz, 1H), 7.25-7.22 (m, 2H), 6.89-6.85 (m, 
2H), 4.47 (q, J = 9.8 Hz, 2H), 3.95-3.89 (m, 1H), 3.80 (s, 3H), 2.65 (ddd, J = 16.3, 7.3, 2.6 Hz, 
1H), 2.54 (ddd, J = 16.3, 4.7, 1.9 Hz, 1H), 1.67-1.62 (m, 1H), 1.52 (dd, J = 9.5, 4.4 Hz, 1H), 
1.35-1.26 (m, 26H), 0.88 (t, J = 6.9 Hz, 3H). 
13C NMR: (100 MHz, CDCl3): δ 202.1, 159.4, 130.5, 129.5, 114.0, 74.1, 71.0, 55.4, 48.5, 34.4, 
32.1, 29.85, 29.83, 29.82, 29.80, 29.77, 29.74, 29.72, 29.52, 25.3, 22.8, 14.3. 
FTIR (neat): ν 2922, 2852, 1724, 1613, 1513, 1465, 1302, 1173, 1063, 1036 cm-1. 
HRMS: (ESI) Calcd. for C26H44O3Na: 427.3188, Found: 427.3182 






A 100 mL round bottom flask was charged with Hoveyda-Grubbs II catalyst (62.7 mg, 
0.10 mmol, 10 mol%), stir bar, and fitted with a reflux condenser. The flask was purged with 
argon, sealed with a septum and octafluorotoluene (10 mL) was injected and degassed by 
bubbling argon. A solution of the 5.13 (325.5 mg, 1.0 mmol, 100 mol%), freshly distilled 
acrolein (100 mg, 1.8 mmol, 180 mol%) in octafluorotoluene (10 mL, 0.05 M overall) was 
injected and degassed with bubbling argon for another 5 minutes. The solution was stirred at 
room temperature for 10 minutes and gradually heated to 120 °C over 30 minutes. Stirring at 120 
°C was continued for 2 h and the mixture was cooled to room temperature. The mixture was 
concentrated in vacuo to a dark oil. Purification by flash column chromatography (SiO2, 
EtOAc:hexanes 1:4 to 3:7) gave 5.19 as an orange oil (269.1 mg, 82% yield). 
TLC (SiO2): 0.29 (3:7 EtOAc:hexanes). 
1H NMR: (400 MHz, CDCl3): δ = 9.52 (d, J=7.9, 1H), 6.94 – 6.79 (m, 2H), 6.16 (ddt, J=15.7, 
7.9, 1.3, 1H), 6.03 (dt, J=9.8, 1.8, 1H), 4.66 – 4.52 (m, 1H), 4.37 – 4.25 (m, 1H), 2.60 (ddd, 
J=14.4, 6.7, 1.4, 1H), 2.56 – 2.46 (m, 1H), 2.35 – 2.27 (m, 2H), 1.82 (ddd, J=14.3, 10.3, 2.4, 
1H), 1.63 (ddd, J=14.3, 10.1, 2.2, 1H), 0.95 (t, J=7.9, 9H), 0.63 (q, J=7.8, 6H). 
13C NMR: (100 MHz, CDCl3): δ = 193.8, 164.1, 153.5, 145.3, 135.6, 121.5, 74.3, 66.3, 42.4, 
41.5, 30.0, 7.0, 5.0. 
FTIR (neat): 2954, 2876, 1720, 1689, 1381, 1246 cm-1 
HRMS: (ESI) Calcd. for C17H28O4SiNa (M+Na)+: 347.16490, Found: 347.16530. 











A 10 mL screw cap tube was charged with Bi(NO3)3 5H2O (14.9 mg, 0.031 mmol, 10 
mol%) and a solution of 5.19 (100 mg, 0.308 mmol, 100 mol%) and acetaldehyde (271.3 mg, 
6.16 mmol, 2000 mol%) in dichloromethane (3.1 mL, 0.1 M) was added. A stir bar was added 
and the mixture was stirred for three days at room temperature. The cloudy mixture was filtered 
through Celite, washing with chloroform (10 mL). The filtrate was washed with saturated 
NaHCO3 (3 x 5 mL), water (5 x 5 mL), brine (1 x 5 mL) and dried over anhydrous Na2SO4. The 
organic extract was filtered and concentrated to a yellow oil, which was dissolved in acetonitrile 
(5 mL) and washed with pentane (4 x 5 mL) to remove residual triethylsilanol. The acetonitrile 
layer was concentrated to a viscous yellow oil, providing the aldehyde (71.5 mg, 91% yield) in 
good purity. The aldehyde could be further purified by flash chromatography (florisil, 
EtOAc:CHCl3, 1:19 to 2:3) to provide the aldehyde 5.2 as a clear viscous oil (45.4 mg, 58% 
yield). 
TLC (SiO2): 0.26 (1:4 EtOAc:CHCl3). 
1H NMR: (400 MHz, CDCl3): δ = 9.81 – 9.74 (m, 1H), 6.87 (ddd, J=9.7, 5.6, 2.9, 1H), 6.01 
(ddd, J=9.7, 2.4, 1.2, 1H), 4.75 (q, J=5.1, 1H), 4.72 – 4.63 (m, 1H), 4.18 (dddd, J=11.2, 7.5, 4.9, 
2.5, 1H), 4.07 – 3.97 (m, 1H), 2.66 (ddd, J=16.7, 7.5, 2.4, 1H), 2.51 (ddd, J=16.7, 4.9, 1.6, 1H), 
2.41 – 2.23 (m, 2H), 1.86 (ddd, J=14.6, 9.8, 2.4, 1H), 1.74 (ddd, J=14.6, 10.1, 2.7, 1H), 1.57 (dt, 
J=12.9, 2.5, 1H), 1.29-1.38 (m, 1H), 1.27 (d, J=5.1, 3H). 
13C NMR: (100 MHz, CDCl3): δ 200.5, 164.4, 145.3, 121.5, 98.8, 73.9, 71.3, 71.2, 49.4, 41.5, 
36.7, 30.0, 21.1. 
FTIR (neat): 2918, 1716, 1380, 1342, 1248, 1133, 1096 cm-1 
HRMS: (ESI) Calcd. for C13H18O5Na (M+Na)+ : 277.1046, Found: 277.1044. 










The following procedure was performed in the dark. To a sealed tube was added 
Pd(Quinox)Cl2 (7.1 mg, 0.0159 mmol, 5 mol%) and AgSbF6 (16.2 mg, 0.0472 mmol, 12.5 
mol%) followed by CH2Cl2 (2.8 mL). The solution was stirred at rt for 10 minutes before 
tBuOOH (70% w/w, 0.64 mL, 4.54 mmol, 1200 mol%) was added and the reaction cooled to 0 
°C. After 10 minutes, PMB ether 5.17 (152.2 mg, 0.378 mmol, 100 mol%) in CH2Cl2 (1.0 mL, 
0.1 M overall) was added dropwise. The reaction was warmed to rt and let stir for 16 h. The 
reaction mixture was diluted with hexanes and washed with sat. aq. Na2S2O3 (2 x 10 mL). The 
aqueous portion was then extracted with hexanes (2 x 15 mL) and the combined organic extracts 
were dried over Na2SO4, filtered, and concentrated under vacuum. The crude reaction mixture 
was purified via column chromatography (SiO2, Et2O:CHCl3 1:99) to afford ketone 5.3 (112.3 
mg, 71% yield) as a colorless oil. 
TLC (SiO2): Rf = 0.45 (1:4 EtOAc:hexanes) 
1H NMR (400 MHz, CDCl3) δ = 7.23 (d, J=8.7, 2H), 6.86 (d, J=8.7, 2H), 4.46 (d, J=10.9, 1H), 
4.41 (d, J=10.9, 1H), 3.94 – 3.84 (m, 1H), 3.79 (s, 3H), 2.73 (dd, J=15.7, 7.6, 1H), 2.49 (dd, 
J=15.8, 4.8, 1H), 2.15 (s, 3H), 1.25 (s, 28H), 0.88 (t, J=6.9, 3H). 
13C NMR (100 MHz, CDCl3) δ = 207.9, 159.1, 130.6, 129.4, 113.7, 75.4, 71.2, 55.3, 55.2, 48.6, 
34.3, 31.9, 31.2, 31.2, 29.7, 29.6, 29.4, 25.2, 22.7, 14.1. 
FTIR (neat): 2922, 2852, 1717, 1613, 1513, 1465, 1356, 1249 cm-1 
HRMS: (ESI) Calcd. for C27H46O2Na (M+Na)+: 425.3396, Found: 425.3372 









A 50 mL round bottom flask was charged with ketone 5.3 (205.7 mg, 0.491 mmol, 125 
mol%), stir bar and diethyl ether (9.0 mL, 0.05 M). The solution was degassed with bubbling 
argon and cooled to -30 °C. Dicyclohexylchloroborane (208.9, 0.983 mmol, 250 mol%) was 
injected neat and the mixture stirred vigorously for 15 minutes. Triethylamine (107.9 mg, 1.06 
mmol, 270 mol%) was injected and the cloudy mixture stirred for 30 minutes. The mixture was 
cooled to -78 °C and aldehyde 5.2 (100 mg, 0.393 mmol, 100 mol%) in a solution of diethyl 
ether (800 μL) was added drop wise with stirring. The mixture was allowed to stir for 1.5 h, then 
warmed to 0 °C. A solution of methanol, pH 7 buffer and 30% hydrogen peroxide (1:1:1, 6 mL) 
was added. The biphasic mixture was allowed to stir overnight, washed with saturated NaHCO3 
(3 x 10 mL), brine (1 x 10 mL) and dried over anhydrous Na2SO4. The organic extract was 
filtered and concentrated in vacuo to a clear oil and purified by flash column chromatography 
(SiO2, acetone:hexanes 1:9 to 1:4) to provide 5.20 as a clear, colorless oil (168.5 mg, 64% yield). 
TLC (SiO2): Rf = 0.31 (1:2 acetone:hexanes) 
1H NMR: (400 MHz, CDCl3): δ = 7.24 – 7.18 (m, 2H), 6.92 – 6.81 (m, 3H), 6.03 (ddd, J=9.7, 
2.4, 1.1, 1H), 4.78 – 4.66 (m, 2H), 4.46 (d, J=10.9, 1H), 4.39 (d, J=10.9, 1H), 4.27 (dq, J=12.0, 
3.9, 1H), 4.00 (ddd, J=13.5, 3.9, 1.6, 1H), 3.95 – 3.84 (m, 2H), 3.79 (s, 3H), 3.44 (s, 1H), 2.75 
(dd, J=15.8, 7.9, 1H), 2.63 (dd, J=16.9, 7.8, 1H), 2.52 (ddd, J=18.4, 16.4, 4.5, 2H), 2.42 – 2.25 
(m, 2H), 1.87 (ddd, J=14.6, 9.7, 2.3, 1H), 1.80 – 1.65 (m, 2H), 1.60 – 1.42 (m, 3H), 1.36 – 1.18 
(m, 31H), 0.87 (t, J=6.9, 3H). 
13C NMR: (100 MHz, CDCl3): δ 209.8, 164.5, 159.3, 145.3, 130.7, 129.5, 121.6, 113.9, 98.5, 
75.6, 75.5, 74.0, 71.5, 71.4, 66.5, 55.4, 50.9, 48.8, 41.5, 37.0, 34.4, 32.1, 30.0, 29.9, 29.8, 29.8, 
29.5, 25.3, 22.8, 21.2, 14.3. 
FTIR (neat): 3529, 3432, 2923, 2853, 1810, 1713, 1613, 1587, 1514, 1487, 1465, 1380, 1342, 
1248, 1171, 1138, 1094, 1058, 1035 cm-1. 
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HRMS: (ESI) Calcd. for C40H64O8Na (M+Na)+: 695.4499, Found: 695.4495. 









A solution of ketone 5.20 (67.2 mg, 0.100 mmol, 100 mol%) in THF:MeOH (4:1, 0.1 M, 
1 mL) was cooled to –78 °C under argon. To this solution was added diethylmethoxy borane 
(200 μL, 1.0 M in THF, 0.2 mmol, 200 mol%) and the mixture was allowed to stir for 0.5 h 
before adding NaBH4 (220 μL, 0.5 M in diglyme, 0.110 mmol, 110 mol%). After stirring for 3 h 
at -78 °C, the mixture was warmed to 0 °C, diluted with Et2O (10 mL), and stirred vigorously 
with a mixture of methanol, pH 7 buffer, and 30% hydrogen peroxide (1.5 mL, 1:1:1), then the 
solution was warmed to room temperature. After 1 h at room temperature, the organic phase was 
washed with saturated NaHCO3 (3 x 5 mL), brine (1 x 5 mL), dried over anhydrous Na2SO4, 
filtered, and concentrated in vacuo to provide diol 5.21 as a yellow oil (63.2 mg, 94% yield). 
TLC (SiO2): Rf = 0.24 (3:7 acetone:hexanes) 
1H NMR: (400 MHz, CDCl3): δ  = 7.29 – 7.23 (m, 2H), 6.94 – 6.80 (m, 3H), 6.03 (ddd, J=9.7, 
2.4, 1.1, 1H), 4.76 (q, J=5.2, 1H), 4.74 – 4.66 (m, 1H), 4.51 (d, J=11.0, 1H), 4.46 (d, J=11.0, 
1H), 4.19 – 3.96 (m, 3H), 3.90 (ddd, J=21.3, 8.6, 6.4, 3H), 3.80 (s, 3H), 3.74 – 3.63 (m, 1H), 
2.43 – 2.25 (m, 2H), 1.88 (ddd, J=14.6, 9.7, 2.4, 1H), 1.80 – 1.71 (m, 2H), 1.71 – 1.37 (m, 8H), 
1.36 – 1.20 (m, 30H), 0.88 (t, J=6.9, 3H). 
13C NMR: (100 MHz, CDCl3): δ 164.4, 159.4, 145.3, 130.8, 129.7, 121.6, 114.0, 98.5, 76.6, 
76.0, 74.0, 71.6, 71.2, 69.2, 55.4, 44.0, 43.2, 41.6, 41.3, 37.2, 34.0, 32.1, 30.1, 30.0, 29.9, 29.8, 
29.8, 29.8, 29.5, 25.5, 22.8, 21.2, 14.3. 
FTIR (neat): 3488, 2924, 2853, 1716, 1248 cm-1. 
HRMS: (ESI) Calcd. for C40H66O8Na (M+Na)+: 697.4650, Found:.697.4650 
[α]22D: +19.87 ° (c = 0.52, CHCl3).  
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Synthesis of 5.21 starting from crude 5.2:  
Due to the instability of 5.2 during storage and the instability of the aldol product 5.20 
during chromatography, procedures were developed to carry out the aldol and reduction with 
crude reaction products. A 10 mL screw cap vial was charged with stir bar and solution of ketone 
5.3 (41.9 mg, 0.1 mmol, 100 mol%) in diethyl ether (1 mL). The vial was sealed and the solution 
sparged with argon, then cooled to -30 °C. Chlorodicyclohexylborane (31.9 mg, 1.5 mmol, 150 
mol%) was injected neat, resulting in a yellow solution. After 5 min, triethylamine (20.3 mg, 
0.200 mmol, 200 mol%) was injected and a cloudy mixture formed immediately. The mixture 
was allowed to stir for 30 minutes, then cooled to -78 °C. Crude aldehyde 5.2 (31.8mg, 0.125 
mmol, 125 mol%) in diethyl ether (1 mL) was added dropwise. After 4 hours, the mixture was 
warmed 0 °C and a solution of methanol, pH 7 buffer and 30% hydrogen peroxide (1:1:1, 6 mL) 
was added. The biphasic mixture was allowed to stir overnight at room temperature, extracted 
with diethyl ether (3 x 5 mL), washed with saturated NaHCO3 (3 x 10 mL), brine (1 x 10 mL) 
and dried over anhydrous Na2SO4. The organic extract was filtered and concentrated in vacuo to 
a clear oil. The oil was dissolved in acetonitrile (5 mL), washed with pentane (4 x 5 mL) to 
remove methyl ketone 5.3, then concentrated in vacuo to a clear oil, providing crude aldol (64.8 
mg) in good purity. The methyl ketone 5.3 could be recovered from the pentane extract (6.2 mg, 
15%). 
A 10 mL screw cap vial was charged with crude aldol 5.20 (64.8 mg, 0.0964 mmol) and 
dissolved in THF/MeOH (4:1, 1 mL). The solution was cooled to -78 °C and 
diethylmethoxyborane (1.0 M in THF, 0.2 mL, 200 mol%) was added dropwise. The cloudy 
solution was stirred for 30 minutes then NaBH4 (0.5 M in diglyme, 0.22 mL, 110 mol%) was 
added dropwise. The mixture was allowed to stir for 3 h, then warmed to 0 °C, diluted with 
diethyl ether (10 mL), and stirred vigorously with a mixture of methanol, pH 7 buffer, and 30% 
hydrogen peroxide (1.5 mL, 1:1:1) allowing the solution to warm to room temperature. After 1 h 
at room temperature, the organic phase was washed with saturated NaHCO3 (3 x 5 mL), brine (1 
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x 5 mL), dried over anhydrous Na2SO4, filtered and concentrated to a yellow oil. Purification by 
flash column chromatography (SiO2, 1:4 to 3:7 acetone:hexanes) provided 5.21 as a colorless oil 








(+)-Cryptocaryol A (5.1) 
A 10 mL screw cap vial was charged with 5.21 (32.4 mg, 0.0480 mmol, 100 mol%), 1,3-
dimethoxybenzene (59.7 mg, 0.200 mmol, 900 mol%), stir bar, and dichloromethane (2.4 mL, 
0.02 M). Triflic acid (21.6 mg, 0.144 mmol, 300 mol%) was added and a dark red solution 
developed immediately. The solution was stirred for 30 min at room temperature then quenched 
with saturated NaHCO3 (5 mL) with vigorous stirring. The cloudy mixture was extracted with 
chloroform (5 x 5 mL), dried over anhydrous Na2SO4, and concentrated in vacuo to a white semi-
solid. The semi-solid was absorbed onto silica gel and purified by flash column chromatography 
(SiO2, MeOH:CHCl3 1:99 to 1:19) providing (+)-cryptocaryol A 5.1 as a white solid (19.1 mg, 
75% yield). 
TLC (SiO2): 0.32 (1:9 MeOH:CHCl3) 
1H NMR: (400 MHz, CD3OD): δ = 7.05 (ddd, J=9.7, 5.9, 2.6, 1H), 5.98 (ddd, J=9.7, 2.6, 1.1, 
1H), 4.82 – 4.61 (m, 1H), 4.22 – 3.92 (m, 4H), 3.90 – 3.69 (m, 1H), 2.46 (dddd, J=18.6, 5.8, 4.4, 
1.1 Hz, 1H), 2.37 (ddt, J=18.7, 11.4, 2.6, 1H), 1.95 (ddd, J=14.5, 9.8, 2.6, 1H), 1.74 – 1.54 (m, 
7H), 1.52 (dd, J=6.7, 5.5 Hz, 2H), 1.48 – 1.40 (m, 3H), 1.38 – 1.21 (m, 27H), 0.90 (t, J=6.9, 3H). 
13C NMR: (126 MHz, CD3OD) δ = 166.9, 148.5, 121.4, 76.6, 70.1, 69.9, 69.1, 68.2, 66.6, 46.0, 
45.9, 45.7, 45.2, 43.9, 39.2, 33.1, 30.9, 30.8-30.8 (9C), 30.5, 26.8, 23.7, 14.4. 
FTIR (neat): 3365, 2916, 2849, 1718, 1470, 1389, 1268, 1139 cm-1. 
HRMS: (ESI) Calcd. for C30H56O7 (M+Na)+: 551.3918, Found: 551.3920. 



















Chapter 6: Ruthenium-Catalyzed Oxidative Spirolactonization 
6.1 Background of Ruthenium-Catalyzed Reductive Couplings 
The Krische research group had developed a suite of ruthenium-catalyzed hydrogenative 
methods for C-C bond formation. Specifically, methods had been established for crotylation,53b, 
54-55, 142 vinylation,143 and propargylation144 of aldehydes by reductive coupling of aldehydes and 
π-unsaturates, or by redox neutral coupling of primary alcohols and π-unsaturates. However, 
despite a growing understanding of the reactivity and selectivity in these transformations, 
coupling of π-unsaturates with ketones or secondary alcohols had not been achieved. There has 
been one exception, the cyclic keto-amide of isatin, which has been shown to undergo 
ruthenium- and iridium-catalyzed coupling via transfer hydrogenation.145  
Recognizing this limitation, a literature survey was performed to identify ruthenium 
catalysts that act on secondary alcohols. A promising complex, Ru3(CO)12, was found to exhibit 
two characteristics crucial for transfer hydrogenative reductive coupling.146 First, Ru3(CO)12 was 
shown to participate in the amination of α-hydroxy amides via transfer hydrogenation (Scheme 
6.1).147 This transformation occurs via a reductive amination pathway in which ruthenium-
catalyzed dehydrogenation generates a keto-amide and ruthenium hydride. The newly formed 
carbonyl next undergoes condensation with a primary amine to produce an imine, which is 
hydrogenated by the ruthenium hydride to afford an α-amino amide as well as ruthenium(0). 
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Scheme 6.1 Ruthenium-catalyzed transfer hydrogenation of an α-hydroxy amide.  
 
 Second, Ru3(CO)12 was shown to catalyze a [2+2+1] oxidative coupling reaction between 
1,2-dicarbonyl compounds, ethylene, and carbon monoxide to construct products of 
spirolactonization. (Scheme 6.2).148 These characteristics indicate that a Ru0 complex is capable 
of hydrogenation and oxidative coupling. It was anticipated that similar conditions could 
facilitate transfer hydrogenative coupling of π-unsaturates and α-hydroxy carbonyl compounds. 
Scheme 6.2 Oxidative coupling of an α-keto ester with ethylene and CO using catalytic 
Ru3(CO)12. 
 
 Inspired by these reports, application of similar reaction conditions was attempted in 
order to couple ethyl mandelate and isoprene. Fortunatly, after extensive optimization of the 
reaction conditions, it was found that coupling could be achieved (Scheme 6.3).149 This oxidative 
coupling was unique in that, unlike other reductive couplings of dienes and carbonyl compounds, 
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Scheme 6.3 Oxidative coupling of ethyl mandelate and isoprene via transfer 
hydrogenation. 
 
 Modification of the reaction conditions led to successful couplings of isoprene to  N-
benzyl-3-hydroxyoxindole (Scheme 6.4, top), as well as to 1,2-diols. In the case of the 1,2-diols, 
dehydrogenation affords a 1,2-diketone. Upon coupling of the isoprene to one of the ketones, 
intramolecular addition to the adjacent ketone took place delivering the product of formal [4+2] 
cycloaddition (Scheme 6.4, bottom).150  
Scheme 6.4 Oxidative coupling of isoprene to 3-hydroxyoxindole and 1,2-
cyclohexane diol via transfer hydrogenation. 
 
 Encouraged by the successful ruthenium-catalyzed oxidative coupling with ketones, 
further applications of this reaction class were explored. The unique regioselectivity observed in 
the ruthenium-catalyzed oxidative couplings was of particular interest and further investigation 
revealed that α-olefins, a feedstock chemical, could be directly coupled with N-benzyl-3-
hydroxyoxindole to afford products of carbonyl addition. Importantly, it was found that addition 
of 1-adamantanecarboxylic acid as an additive promoted efficient couplings of N-benzyl-3-











































Scheme 6.5 Oxidative coupling of propene to 3-hydroxyoxindole via transfer 
hydrogenation. 
 
6.2 Oxidative Coupling and Spirolactonization Using Acrylates 
6.2.1 Introduction 
In the course of evaluating suitable π-unsaturates that would couple under conditions of 
Ru0 catalysis, methyl acrylate and other acrylic esters were investigated. Interestingly, it was 
found that oxidative coupling of in situ generated carbonyl compounds with acrylic esters 
furnished spirocyclic γ-butryolactones. These structurally intriguing functional groups are 
ubiquitous in natural products that exhibit a wide range of biological activity, including 
spironolactone and abyssomycin C (Figure 6.1). 
Figure 6.1 Pharmaceutically active natural products containing spirolactones. 
 
Spirocycles found in nature all contain a sterically congested quaternary center. Due to 
their interesting structure and prevalence in biologically active natural products, many methods 
have been developed for the construction of spirocyclic γ-butyrolactones. Examples of which 
include oxidative dearomatizations using iodine or cerium ammonium nitrate,152 Michael 
additions using α,β-unsaturated esters,153 cationic rearrangements of epoxides and bromonium 






































acids,156 Reformatsky type reactions,157 and Pauson-Khand and other types of carbonyl insertion 
reactions. 148, 158 However, it was expected that a method to construct spirolactones via transfer 
hydrogenative C-C bond formation would complement these methods and would represent a new 
functional group interconversion using methyl acrylate, an inexpensive feedstock chemical. 
Additionally, few examples exist for asymmetric spirolactonization and thus a metal-catalyzed 
methodology could potentially address this shortcoming.159  
6.2.2 Reaction Development, Optimization, and Scope 
To probe the reactivity of α,β-unsaturated esters with diols to access spirolactones, trans-
1,2-hexanediol 6.1a and methyl acrylate 6.2a were exposed to Ru3(CO)12 and various ligands 
(Table 6.1). Contrary to previous reported work that illustrated PCy3 to be an effective ligand, no 
product was obtained when it was used in the reaction (entry 1). Bidentate nitrogen-based 
ligands BIPY or Phen were similarly ineffective (entries 2-3). Conversely, the bidentate electron-
rich phosphine ligand DPPP produced the desired spirolactone in 76% yield (entry 4). Increased 
loadings of methyl acrylate did enhance conversion (entries 5-7), however, efforts were focused 
on improving the reaction efficiency. Variation of the reaction temperature did not lead to 
improved conversion (entries 8-9). In previous work, it was found that carboxylic acid additives 
often have a significant effect on reaction yield.151 This increase in yield was hypothesized to be 
a result of accelerated hydrogenolysis of the oxo-metallacycle formed upon oxidative 
coupling.160 In the reaction of 1,2-trans-cyclohexanediol with methyl acrylate, addition of 
catalytic amounts of benzoic acid or 1-adamantanecarboxylic acid proved to be highly effective, 
with 1-adamantanecarboxylic acid performing best for a number of substrates (entries 10-11). 
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Table 6.1 Optimization of the spirolactonization reaction with 6.1a. 
 
Having identified conditions for efficient conversion of diol 6.1a to spirolactone 6.3a, the 
scope of the reaction was assessed. A variety of cylic, acyclic, and polycyclic diols were found to 
undergo spirolactonization in high yield to afford spirolactones 6.3a-l (Figure 6.2). In the case of 
nonsymmetric diols, regioselectivity was variable. Acyclic diols 6.1g-h exhibited incomplete 
regioselectivity illustrated by the 4:1 r.r. for spirolactone 6.3g and 1:1 r.r. for 6.3h. However, 
cyclic nonsymmetric 1,2-diols exhibited complete regioselectivity. Importantly, both cis- and 
trans-1,2-diols were suitable substrates under the reaction conditions.  
  




































































Figure 6.2 Spirolactones 6.3a-l synthesized from coupling of diols 6.1a-l with methyl 
acrylate 6.2a. 
 
 It was hypothesized that oxidative coupling occurs from the 1,2-diketone oxidation state. 
To evaluate this hypothesis, the reaction was performed from the 1,2-diol, α-hydroxy ketone, 
and 1,2-diketone oxidation levels (Scheme 6.6). It was anticipated that the 1,2-diol would 
participate via an oxidative pathway, the α-hydroxy ketone via a redox neutral pathway, and the 
1,2-diketone via a reductive pathway. Indeed, all three pathways led to formation of 6.3f, 
however, while diol 6.1f and α-hydroxy ketone 6.4f both afforded 6.3f in excellent yield, 

































6.3b, 85% yieldb,c6.3a, 96% yielda 6.3c, 64% yieldd 6.3d, 79% yieldb
6.3e, 93% yieldd 6.3f, 90% yieldd 6.3g, 71% yielda
4:1 rr



































atrans-1,2-diol was employed, bcis-1,2-diol was employed, c400 mol% of 6.2a was employed, dA 
mixture of cis- and trans-1,2-diol was employed
6.1a R1,R2=(CH2)4 6.1b R1,R2=(CH2)3 6.1c R1,R2=(CH2)5 6.1d R1,R2=(CH2)6
6.1e R1,R2=Me 6.1f R1,R2=Ph 6.1g R1=Ph, R2=Me 6.1h R1=tBu, R2=Me
6.1i Indanyl 6.1j H4Naphthyl 6.1k Acenaphthyl 6.1l Me2Chromanyl
6.3a-l
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reduction in yield could be due to competitive reduction of acrylate 6.2a instead of oxidative 
coupling upon generation of a ruthenium hydride formed from the Ru0 catalyst and reductant.  
Scheme 6.6 Oxidative coupling of isoprene to 3-hydroxyoxindole and 1,2-
cyclohexane diol via transfer hydrogenation. 
 
 Regrettably, substituted α,β-unsaturated esters did not couple under these conditions. It 
was observed that substitution at the α or β position resulted in no product formation. However, 
2-hydroxymethyl substituted methyl acrylate 6.2b did engage in oxidative coupling, after which 
elimination of the hydroxyl group afforded α-methylene-γ-butyrolactone 6.6b (Scheme 6.7). The 
ineffective coupling of substituted acrylates could be a result of poor coordination between the 
acrylate and the ruthenium due to the steric environment at the metal center. Alternatively, 2-
hydroxymethyl substituted acrylate 6.2b may chelate ruthenium and act as a directing group for 
olefin coordination and subsequent oxidative coupling. 
Scheme 6.7 Generation of α-methylene-γ-butyrolactone 6.6b via coupling of 6.1a 

































iPrOH (300 mol%) 90% yield (from 6.1f)
92% yield (from 6.4f)





















 Prior work had illustrated that other α-hydroxyl carbonyl compounds, such as mandelic 
esters and 3-hydroxyoxindoles, could engage in oxidative coupling with dienes in the presence of 
Ru3(CO)12. Application of the reaction conditions for oxidative spirolactonization to mandelic 
ester 6.7a and 6.7b resulted in the successful formation of 6.8a and 6.8b (Scheme 6.8).  
Scheme 6.8 Spirolactonization of mandelic esters 6.7a and 6.7b to afford 6.8a and 
6.8b. 
 
 Unlike with 1,2-diols, 3-hydroxyoindole 6.9 was found to couple with various substituted 
acrylic esters (6.2c-I, Figure 6.3). It is hypothesized that the observed variation in reactivity 
between 6.9 and various 1,2-diols or α-hydroxy esters may be a result of strain energy in the 5-
membered ring of the isatin that is formed upon dehydrogenation of 3-hydroxyoxindole. This 
increased energy may compensate for the inefficient ligation of substituted acrylic esters. 
Application of the established conditions for oxidative spirolactonization to 3-hydroxyoxindole 
6.9 with methyl crotonate 6.2c afforded the corresponding spirolactone quantitatively, but as a 
1:1 mixture of diastereomers. Further reaction optimization was performed, which revealed that 
use of TERPY as a ligand and addition of KOtBu (10 mol%) resulted in formation of 6.10c as a 
single diastereomer in high yield. Expansion of the scope of this reaction with various substituted 
acrylates was successful and led to the generation of spirooxindole products 6.10a, c-i (Figure 
6.3). Use of β-substituted acrylic esters 6.2c-d, g-i led to the formation of 6.10c-d, g-i as a single 
diastereomer, while use of α-substituted methyl methacrylate 6.2e resulted in formation of 












6.7a Ar = Ph













may be due to epimerization of one of the chiral centers under the reaction conditions. β,β-
disubstituted ester 6.2f engaged in oxidative spirolactonization to furnish spirooxindole 6.10f, 
which contained two adjacent quaternary centers, albeit in diminished yield. 
Figure 6.3 Oxidative spirolactonization of 3-hydroxyoxindole 6.9 with substituted 
acrylic esters 6.2a, c-i to generate spirooxindole products 6.10a, c-i.  
 
6.2.3 Mechanistic Considerations and Discussion 
A plausible mechanism for the oxidative coupling of dione 6.5a, formed upon 
dehydrogenation of 6.1a, and methyl acrylate 6.2a is shown in Figure 6.4. It is hypothesized that 





















































































6.2a R1=R2=R3=H 6.2c R1=R2=H, R3=H 6.2d R1=R2=H, R3=Ph 6.2e R1=Me, R2=R3=H
6.2f R1=H, R2=R3=Me 6.2g R1=R2=H, R3=Cy 6.2h R1=R2=H, R3=2-piperonyl 6.2i R1=R2=H, R3=2-thienyl
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between the C-bound enolate I and the O-bound enolate II via isomerization. Protonolysis of the 
oxaruthenacycle generates ruthenium alkoxide III and it is hypothesized that this step is 
accelerated through use of the carboxylic acid additive, which results in a significant 
improvement in yield. Alkoxide III then undergoes lactonization, which upon release of the 
product 6.3a regenerates RuII species IV. Ligand exchange of methoxide with the alkoxide of 
diol 6.1a or α-hydroxy ketone 6.4a expels methanol. The resulting ruthenium alkoxide 
undergoes β-hydride elimination to give 6.4a or 6.5a, and reductive elimination to regenerate the 
acid, HA, as well as the Ru0 complex to close the catalytic cycle.  
Figure 6.4 Proposed mechanism for oxidative spirolactonization of dione 6.5a with 
methyl acrylate 6.2a.  
 
 A monomeric ruthenium species is proposed for this mechanism, as previous work has 
suggested that the trimeric Ru3(CO)12 can be broken into monomeric form in the presence of 
phosphine ligands.161 This hypothesis was confirmed through isolation of ruthenium complex 
6.11, which was obtained upon exposure of Ru3(CO)12 to DPPP and 1-adamantane carboxylic 











































Figure 6.5 ORTEP representation of the structure of Ru(CO)(DPPP)[(H15C10O2-)2] 6.11.  
 
 The isolated ruthenium complex proved to be catalytically competent, which suggests 
that protonation by the diol followed by β-hydride elimination and reductive elimination can 
reform the requisite Ru0 for oxidative coupling (Scheme 6.9).  
Scheme 6.9 Regeneration of Ru0 catalyst from 6.11.  
 
One can imagine other modes of coupling, including Lewis acid catalyzed Michael 






































hydroxy ketone that forms upon β-hydride elimination of the 1,2-diol. Control experiments were 
performed in order to investigate the plausibility of this type of reactivity mode. Exposure of α-
hydroxy ketone 6.4j to methyl acrylate in the presence of a variety of Lewis acids, including 
Ru3(CO)12, RuCl3, B(OMe)3, MgCl2, InCl3, and ZnI2, led to only small quanitites (<16% yield) of 
the corresponding spirolactone product (Scheme 6.10). This indicates that while spirolactone 
products are capable of being synthesized through Michael addition, the reported catalytic 
system is significantly more effective.  
Scheme 6.10 Control experiment to test plausibility of Lewis acid catalyzed Michael 
addition. 
 
Another control reaction was performed to evaluate the plausibility of an anionic addition 
pathway. α-hydroxy ketone 6.4j was methylated to afford 6.4j-OMe, which was subjected to the 
established reaction conditions (Scheme 6.11). Methylation of the hydroxyl group allowed for 
enolization and Michael addition but eliminated the possibility of an oxidative coupling pathway. 
The results of the reaction were that no product had formed and only the starting material was 
recovered, which could indicate that the diketone is necessary for C-C bond formation.  
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methyl acrylate (300 mol%)
m-xylene (1.0 M)
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 Further investigation of the incongruent regioselectivities of products 6.3i, 6.3j, and 6.3l 
compared to that of 6.3g was warranted. Specifically, 1,2-diol 6.1g underwent spirolactonization 
to provide spirolactone 6.3g as a 4:1 mixture of regioisomers in favor of the product coupled at 
the benzylic postion, whereas 1,2-diol 6.1i gave 6.3i as a single diastereomer favoring coupling 
at the carbonyl distal to the aromatic ring when subjected to the reaction conditions. This 
regioselectivity is consistent with other reports of oxidative couplings to 1-phenyl-2,3-dione162 as 
well as with reports of nucleophilic addition to, or hydrogenation of, 1,2-indanone.163 Studies by 
Hoffman suggest that, in the conversion of bis-olefin complexes to metallocyclopentanes, 
regioselectivity is dictated by the interactions of frontier molecular orbitals, indicating that 
coupling should be preferred at the position which bears the largest LUMO coefficient.164 
To understand the character of the frontier molecular orbitals involved in the 
spirolactonization reaction, density functional theory calculations were performed. 1,2-
indanedione 6.5i (synthesized from 6.1i), 1-phenylpropan-1,2-dione 6.5g (synthesized from 
6.1g), two para-substituted 1-phenylpropan-1,2-dione derivatives, 1-(4-methoxyphenyl)propane-
1,2-dione 6.5m and methyl 4-(2-oxopropanoyl)benzoate 6.5n with varying electronic character 
in the aromatic ring were evaluated to deduce the role of the electronics in each system as it 
applied to regioselectivity. The experimentally observed regioselectivities when 1,2-diols 6.1g, i, 
m, n are subjected to the reaction conditions as well as the calculated LUMO coefficients are 
presented in Table 6.2.  
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Table 6.2 LUMO coefficients and experimentally observed regioselectivities for 
diketones 6.5i, g, m, and n. 
 
 The carbonyl at the benzylic position (A) bore a larger LUMO coefficient than the 
carbonyl distal to the aromatic ring (B) for each diketone examined. While this is consistent with 
the observed regioselectivities for acyclic diketones 6.5g, m-n, it did not explain the 
regioselectivity observed for 1,2-indanedione 6.5i. However, it was found that as the difference 
between the LUMO coefficients at each carbonyl increased, so did the regioselectivity in favor 
of coupling at the benzylic carbonyl. The smallest difference in LUMO coefficients was found to 
be for 1,2-indanedione 6.5i (0.013), which coupled at carbonyl B with complete regioselectivity. 
However, in the acyclic systems the smallest difference in LUMO coefficients was calculated for 
6.5m (0.019), but the spirolactone product was generated as a 1.3:1 mixture of regioisomers. 
Increasing the electron-deficient character of the aromatic ring, such as in the case of diketone 
6.5n, led to a larger gap in LUMO coefficients (0.038) and corresponded to a product that was a 
10:1 mixture of regioisomers. While this trend is consistent with the observed regioselectivity, 
one must also consider other factors that could rationalize such a drastic change in 
regioselectivity. One such factor to be considered is that the DFT calculations were performed on 
the ground state diketones, which coordinate to ruthenium prior to oxidative coupling. DFT 
calculations of the ruthenium-bound diketones could reveal useful information about the 















6.5i -0.12189 -0.10896 0.013 1:>20
6.5m, R=OMe -0.13750 -0.11802 0.019 1.3:1
6.5g, R=H -0.13943 -0.11213 0.027 4:1




Another consideration is that of the steric environment around either of the carbonyls. In 
the case of 1,2-indanedione 6.5i, the majority of the atoms are sp2 hybridized, resulting in a 
mostly planar molecular structure. As a result of this geometry, ketone A (Figure 6.6) would be 
coplanar with both an aryl hydrogen as well as ketone B, whereas ketone B is flanked by 
carbonyl A as well as a non-eclipsed methylene. This environment may favor coupling at ketone 
B further removed from the aromatic ring. In the acyclic system, for example 6.5g, C-C bond 
rotation can minimize steric interactions permitting oxidative coupling to be achieved at the site 
bearing the larger LUMO coefficient.  
Figure 6.6 Comparison of conformational flexibility of diketones 6.5i and 6.5g. 
 
 The reaction of α-hydroxy esters 6.7a-b and 3-hydroxyoxindole 6.9 likely 
proceed through a similar mechanism to that shown in Figure 6.4. The stereochemical model 
shown in Figure 6.7 may explain the high levels of diastereoselectivity attained upon 
spirolactonization. One can envision that in the favored transition state, the metallacycle orients 
the ester substituent away from the ruthenium, and the ester and methyl substituents are 
positioned on opposite sides of the ring to avoid eclipsing interactions.  
Figure 6.7 Stereochemical model for the diastereoselectivity observed in the oxidative 
coupling involved in spirooxindole formation. 
 
This model accurately describes the stereochemistry observed in spirooxindole formation, 













also warranted. If the oxidative coupling were a concerted event, it would be anticipated that the 
favored transition state in Figure 6.7 would lead to formation of a single diastereomer. However, 
if protonolysis of the metallacycle occurs and generates the C-bound enolate, β-hydride 
elimination followed by another hydrometallation could scramble the stereocenter and lead to 
erosion of diastereoselectivity. Alternatively, upon protonolysis of the metallacycle, retro-
Michael addition could expel 3-hydroxyoxindole 6.9 and could potentially scramble the olefin 
geometry of the crotonic ester 6.2c. In other ruthenium catalyzed reactions, acceleration of ligand 
exchange is proposed when alkoxide additives are employed.165 In the spirolactonization 
reaction, it is proposed that high levels of diastereoselectivity are the result of increased turnover 
and the prevention of other modes of reactivity that could erode the selectivity (Scheme 6.12).  




In summary, this work illustrates the conversion of 1,2-diols 6.1a-l, α-hydroxy esters 
6.7a-b, and 3-hydroxyoxindole 6.9 to spirolactone products 6.3a-l, 6.6b, 6.8a-b, and 6.10a, c-i 
via coupling with acrylic esters 6.2a-i. Direct transformation of inexpensive chemical feedstocks 
into complex molecules is of great importance in industrial synthesis. In that spirit, this reaction 
employs readily available, highly tractable diols and furnishes structurally complex and highly 
functionalized products. One limitation of this methodology is that use of substituted acrylic 
esters was not tolerated except when coupling to 3-hydroxyoxindole, which afforded 
spirooxindole products with complete levels of diastereoselectivity. Additionally, attempts at 



























unsuccessful. Furthermore, application of this methodology to simple, unactivated ketones is an 
unmet challenge. Expansion of the substrate scope and conditions for asymmetric induction will 
make this a more valuable and useful method.  
6.4 Experimental Details 
6.4.1 General Information 
All reactions were run under an atmosphere of argon in sealed tubes (13x100 mm2), dried 
overnight in an oven and cooled under a stream of argon prior to use. Anhydrous solvents were 
distilled using solvent stills and solvent was transferred by oven-dried syringe. Catalyst 
Ru3(CO)12, all ligands and acid additives were used without purification. Diols 6.1c, 6.1g, 6.1h 
and 6.1i were prepared from the corresponding alkene using the protocol described by Hayashi et 
al.166 Diol 6.1j was prepared according to the method described by Rodrigues et al.167 Diols 6.1k 
and 6.1m were prepared according to the method described by Dakdouki et al.168 Diol 6.1l was 
prepared from the corresponding chromene169 by osmium catalyzed dihydroxylation. 
Hydroxyester 6.7b was prepared by reduction of the corresponding oxoester170 by the method 
described by Hui et al.171 3-Hydroxyoxindole 6.9 was prepared by the method described by 
Autrey and Tahk.172 Alkynes were prepared by Sonagashira coupling, in a method analogous to 
that described by Krische et al.143b Thin-layer chromatography (TLC) was carried out using 0.25 
mm commercial silica gel plates (Silicycle Siliaplate F-254). Visualization was accomplished 
with UV light followed by staining. Purification of product was carried out by flash column 
chromatography using Silicycle silica gel (40-63 um), according to the method described by 
Still.173  
6.4.2 Spectrometry and Spectroscopy 
Infrared spectra were recorded on a Thermo Nicolet 380 spectrometer. Low- and high-
resolution mass spectra (LRMS or HRMS) were obtained on a Karatos MS9 and are reported as 
m/z (relative intensity). Accurate masses are reported for the molecular ion or a suitable 
fragment ion. Melting points were obtained on a Stuart SMP3 apparatus and are uncorrected. 1H 
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NMR spectra were recorded on a Varian Gemini (400 MHz) spectrometer at ambient 
temperature. Chemical shifts are reported in delta (d) units, parts per million (ppm), relative to 
the center of the singlet at 7.26 ppm for deuteriochloroform, or other reference solvents as 
indicated. Data are reported as chemical shift, multiplicity (s=singlet, d=doublet, t=triplet, 
q=quartet, m=multiplet), integration and coupling constant(s) in Hz. 13C NMR spectra were 
recorded on a Varian Gemini (100 MHz) spectrometer and were routinely run with broadband 
decoupling. Chemical shifts are reported in ppm, with the residual solvent resonance employed 
as the internal standard (CDCl3 at 77.0 ppm). Regiochemical assignments were made by HMBC 
or NOESY NMR experiments. 
6.4.3 Computational Analysis 
All structures were optimized and characterized to determine each atom’s contribution to 
the LUMO orbital. Density functional theory (DFT) calculations were carried out with QChem 
4.0 using B3LYP hybrid functional and G-311G(d,p) basis set.  
6.4.4 General Procedures for Spirolactonization  
General Procedure A: To a re-sealable pressure tube (13 x 100 mm) equipped with 
magnetic stir bar, diol (or hydroxy ester) (0.3 mmol, 100 mol%), Ru3(CO)12 (3.8 mg, 0.006 
mmol, 2 mol%), 1,3-bis(diphenylphosphino)propane (7.4 mg, 0.018 mmol, 6 mol%), and 1-
adamantanecarboxylic acid (5.4 mg, 0.03 mmol, 10 mol%). The tube was sealed with a rubber 
septum and purged with argon. Methyl acrylate (2a) (81 μL, 0.90 mmol, 300 mol%) and m-
xylene (0.22 mL, 1.0 M overall) were added. The rubber septum was quickly replaced with a 
screw cap. The mixture was heated at 140 °C (oil bath temperature) for 20 h, at which point the 
reaction mixture was allowed to cool to ambient temperature. The reaction mixture was 
concentrated and subjected to flash column chromatography to furnish the corresponding product 
of spirolactonization.  
General Procedure B: To a re-sealable pressure tube (13 x 100 mm) equipped with 
magnetic stir bar, 1-benzyl-3-hydroxyoxindole  (6.9) (72 mg, 0.30 mmol, 100 mol%), Ru3(CO)12 
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(3.8 mg, 0.006 mmol, 2 mol%), 2,2’;6,2”-terpyridine (4.2 mg, 0.018 mmol, 6 mol%) and KOtBu 
(3.3 mg, 0.03 mmol, 10 mol%) was added. The tube was sealed with a rubber septum and purged 
with argon. Acrylic ester (0.90 mmol, 300 mol%) and m-xylene (1.0 M overall) were added. The 
rubber septum was quickly replaced with a screw cap. The mixture was heated at 140 °C (oil 
bath temperature) for 20 h, at which point the reaction mixture was allowed to cool to ambient 
temperature. The reaction mixture was concentrated and subjected to flash column 
chromatography to furnish the corresponding product of spirolactonization.  
6.4.5 Characterization of 6.3a-l, 6.6b, 6.8a-b, 6.10a, c-i 
1-oxaspiro[4.5]decane-2,6-dione (6.3a) 
In accordance with general procedure A using trans-6.1a, upon stirring at 140 °C for 20 
h, the reaction mixture was concentrated and subjected to flash column chromatography (SiO2: 
50% EtOAc/hexanes) to furnish 6.3a (48 mg, 0.29 mmol, 96% yield) as a clear, yellow oil. The 
spectroscopic properties of this compound were consistent with the data available in the 
literature.156b 
TLC (SiO2): Rf = 0.23 (hexanes:EtOAc = 1:1).  
1H NMR: (400 MHz, CDCl3): δ 2.77-2.67 (m, 2H) 2.53 (dd, J = 9.5, 2.1 Hz, 1H), 2.52-2.50 (m, 
1H), 2.47-2.41 (m, 1H), 2.20 (dddd, J = 13.2, 6.6, 3.5, 1.8 Hz, 1H), 2.04-1.67 ppm (m, 6H).  
13C NMR: (100 MHz, CDCl3): δ 206.0, 175.5, 88.3, 39.2, 38.8, 28.7, 28.2, 26.8, 21.5 ppm. 
HRMS (ESI): Calculated for C9H12O3 [M+Na]+: 191.06790, Found: 191.06790. 
FTIR (neat): 3538, 2943, 2868, 1776, 1718, 1451, 1421, 1339, 1316, 1253, 1201, 1171, 1145, 




1H NMR of 6.3a 
 





In modification of general procedure A using cis-6.1b, upon addition of  Ru3(CO)12 (3.8 
mg, 0.006 mmol, 2 mol%), 1,3-bis(diphenylphosphino)propane (7.4 mg, 0.018 mmol, 6 mol%), 
and 1-adamantanecarboxylic acid (5.4 mg, 0.03 mmol, 10 mol%), the reaction tube was sealed 
with a rubber septum and purged with argon.  Methyl acrylate (2a) (109 μL, 1.20 mmol, 400 
mol%) and m-xylene (0.19 mL, 1.0 M overall) were added upon stirring at 140 °C for 20 h, the 
reaction mixture was concentrated and subjected to flash column chromatography (SiO2: 30% 
EtOAc/hexanes) to furnish 6.3b (39 mg, 0.25 mmol, 85% yield) as a colorless solid. The 
spectroscopic properties of this compound were consistent with the data available in the 
literature.156a  
TLC (SiO2): Rf = 0.17 (hexanes: EtOAc = 3:1). 
1H NMR: (400 MHz, CDCl3): δ 2.81 (dt, J = 9.7, 9.6 Hz, 1H), 2.57 (ddd, J = 17.8, 9.8, 4.0 Hz, 
1H), 2.48-2.31 (m, 4H), 2.19-2.01 (m, 3H), 1.98-1.88 ppm (m, 1H). 
13C NMR: (100 MHz, CDCl3): δ 213.6, 175.8, 86.6, 35.2, 35.0, 28.7, 28.1, 17.8 ppm. 
MP: 103 – 104 °C. 
HRMS (ESI): Calculated for C8H10O3 [M+Na]+:177.05220, Found: 177.05180. 
FTIR (neat): 1981, 1772, 1745, 1454, 1398, 1246, 1222, 1156, 1037 cm-1. 
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In accordance with general procedure A using a mixture of cis- and trans-6.1c, upon 
stirring at 140 °C for 20 h, the reaction mixture was concentrated and subjected to flash column 
chromatography (SiO2: 40% EtOAc/hexanes) to furnish 6.3c (35 mg, 0.19 mmol, 64% yield) as a 
colorless solid. The spectroscopic properties of this compound were consistent with the data 
available in the literature.154a 
TLC (SiO2): Rf = 0.3 (hexanes:EtOAc = 1:1). 
1H NMR: (400 MHz, CDCl3): δ 2.68 (m, 1H), 2.63 – 2.49 (m, 3H), 2.42 (ddd, J = 13.0, 8.8, 4.1 
Hz, 1H), 2.13 (ddd, J = 15.0, 7.1, 1.8 Hz, 1H), 1.99 (m, 1H), 1.94 – 1.56 (m, 6H), 1.41 ppm (m, 
1H). 
13C NMR: (100 MHz, CDCl3): δ 209.2, 176.0, 90.7, 40.1, 37.1, 31.3, 29.0, 27.9, 25.2, 24.7 ppm. 
MP: 64 - 65 °C. 
HRMS (ESI): Calculated for C10H14O3 [M+Na]+: 205.08350, Found: 205.08390. 
FTIR (neat): 2930, 2860, 1773, 1713, 1455, 1227, 1150, 943, 694 cm-1. 
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In accordance with general procedure A using cis-6.1d, upon stirring at 140 °C for 20 h, 
the reaction mixture was concentrated and subjected to flash column chromatography (SiO2: 
40% EtOAc/hexanes) to furnish 6.3d (46 mg, 0.24 mmol, 79% yield) as a clear yellow oil.  
TLC (SiO2): Rf = 0.27 (hexanes:EtOAc = 3:2). 
1H NMR: (400 MHz, CDCl3): δ 2.60 (ddd, J = 12.2, 7.1, 4.0 Hz, 1H), 2.54-2.37 (m, 4H), 2.27 
(ddd, J = 14.9, 11.7, 4.0 Hz, 1H), 2.10-1.92 (m, 3H), 1.90-1.62 (m, 3H), 1.60-1.34 ppm (m, 4H). 
13C NMR: (100 MHz, CDCl3): δ 212.6, 176.0, 90.3, 38.1, 36.4, 31.0, 28.1, 27.7, 26.3, 24.4, 22.8 
ppm. 
HRMS (ESI): Calculated for C11H16O3 [M+Na]+: 219.09920, Found 219.09890. 
FTIR (neat): 2923, 2854, 1708, 1438, 1408, 1205, 1170, 1032 cm-1. 
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In accordance with general procedure A using a mixture of cis- and trans-6.1e, upon 
stirring at 140 °C for 20 h, the reaction mixture was concentrated and subjected to flash column 
chromatography (SiO2: 40% EtOAc/hexanes) to furnish 6.3e (40 mg, 0.28 mmol, 93% yield) as a 
colorless solid. The spectroscopic properties of this compound were consistent with the data 
available in the literature.148b 
TLC (SiO2): Rf = 0.3 (hexanes:EtOAc = 2:1). 
1H NMR: (400 MHz, CDCl3): δ 2.63-2.46 (m, 3H), 2.27 (s, 3H), 2.08-2.02 (m, 1H), 1.51 ppm (s, 
3H).  
13C NMR: (100 MHz, CDCl3): δ 207.1, 174.6, 88.2, 39.8, 27.3, 24.3, 22.4 ppm. 
HRMS (ESI): Calculated for C7H10O3 [M+Na]+:165.05220, Found: 165.05200. 
FTIR: (neat): 1774, 1718, 1361, 1234, 1209, 1166, 1139, 1092, 10003, 947, 903, 667 cm-1. 
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5-benzoyl-5-phenyldihydrofuran-2(3H)-one (6.3f)  
In accordance with general procedure A using a mixture of cis- and trans-6.1f, upon 
stirring at 140 °C for 20 h, the reaction mixture was concentrated and subjected to flash column 
chromatography (SiO2: 40% EtOAc/hexanes) to furnish 6.3f (72 mg, 0.27 mmol, 90% yield) as a 
colorless oil. The spectroscopic properties of this compound were consistent with the data 
available in the literature.148b  
TLC (SiO2): Rf = 0.14 (hexanes:EtOAc = 9:1). 
1H NMR: (400 MHz, CDCl3): δ 7.96-7.94 (m, 2H), 7.49-7.44 (m, 3H), 7.42-7.37 (m, 2H), 7.36-
7.30 (m, 3H), 3.43 (ddd, J = 13.0, 8.3, 7.1 Hz, 1H), 2.60-2.55 (m, 2H), 2.34 ppm (dt, J = 13.0, 
8.3 Hz, 1H). 
13C NMR: (100 MHz, CDCl3): δ 195.2, 175.6, 139.3, 133.5, 133.4, 13.7, 129.3, 128.5, 128.3, 
123.7, 92.1, 34.3, 28.0 ppm. 
HRMS (ESI): Calculated for C17H14O3 [M+Na]+: 289.08350, Found: 289.08430. 
FTIR (neat): 3062, 1784, 1580, 1597, 1448, 1268, 1159, 1086, 1056, 899, 758, 701, 687 cm-1. 
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In accordance with general procedure A using trans-6.1g, upon stirring at 140 °C for 20 
h, the reaction mixture was concentrated to afford the crude spirolactones (rr = 4:1, as 
determined by 1H NMR spectroscopy). The crude reaction mixture was subjected to flash 
column chromatography (SiO2: 30% EtOAc/hexanes) to furnish 6.3g (36 mg, 0.18 mmol, 74% 
yield) as a colorless oil. The spectroscopic properties of this compound were consistent with the 
data available in the literature.148b  
TLC (SiO2): Rf = 0.57 (hexanes:EtOAc = 1:1). 
1H NMR: (400 MHz, CDCl3): δ 7.46 – 7.33 (m, 5H), 3.12 (ddd, J = 12.9, 8.7, 7.0 Hz, 1H), 2.64 
– 2.45 (m, 2H), 2.35 (m, 1H), 2.19 ppm (s, 3H). 
13C NMR: (100 MHz, CDCl3): δ 204.7, 175.2, 137.7, 129.0, 128.8, 124.4, 92.1, 31.6, 28.2, 25.1 
ppm. 
HRMS (ESI): Calculated for C12H12O3 [M+Na]+: 227.06790, Found: 227.06790. 
FTIR (neat): 3062, 2922, 2852, 1783, 1719, 1682, 1449, 1235, 1153, 1091, 700 cm-1. 
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In accordance with general procedure A using trans-6.1h, upon stirring at 140 °C for 20 
h, the reaction mixture was concentrated to afford the crude spirolactones (rr = 1.3:1, as 
determined by 1H NMR spectroscopy). The crude reaction mixture was subjected to flash 
column chromatography (SiO2: 20% EtOAc/hexanes) to furnish 6.3h (42 mg, 0.25 mmol, 75% 
yield) as a colorless oil.  
TLC (SiO2): Rf = 0.50 (hexanes:EtOAc = 2:1). 
1H NMR: (400 MHz, CDCl3): δ 2.59-2.10 (m, 7.4H), 2.26 (s, 3H, major), 1.54 (s, 2.3H, minor), 
1.24 (s, 7.4H, minor), 0.99 ppm (s, 9H, major). 
13C NMR: (100 MHz, CDCl3): δ 214.9, 211.1, 175.9, 175.9, 96.8, 90.8, 44.9, 37.1, 33.4, 29.6, 
28.8, 27.8, 26.9, 26.3, 26.3, 24.8 ppm.  
HRMS (ESI): Calculated for C10H16O3 [M+Na]+: 207.09920, Found: 207.09910. 




1H NMR of 6.3h 
 






In accordance with general procedure A using trans-6.1i, upon stirring at 140 °C for 20 h, 
the reaction mixture was concentrated to afford the crude spirolactones (rr = >20:1, as 
determined by 1H NMR spectroscopy). The crude reaction mixture was subjected to flash 
column chromatography (SiO2: 50% EtOAc/hexanes) to furnish 6.3i (54 mg, 0.27 mmol, 89% 
yield) as a colorless solid.  
TLC (SiO2): Rf = 0.35 (hexanes:EtOAc = 1:1). 
1H NMR: (400 MHz, CDCl3): δ 7.80 (d, J = 7.7 Hz, 1H), 7.68 (td, J = 7.6, 1.2 Hz, 1H), 7.46 (m, 
2H), 3.61 (d, J = 17.4 Hz, 1H), 3.33 (d, J = 17.4 Hz, 1H), 3.02 (dt, J = 17.7, 9.6 Hz, 1H), 2.67 
(ddd, J = 17.7, 9.5, 4.0 Hz, 1H), 2.51 (ddd, J = 13.6, 9.7, 4.0 Hz, 1H), 2.27 ppm (dt, J = 13.1, 9.6 
Hz, 1H). 
13C NMR: (100 MHz, CDCl3): δ 201.5, 176.2, 150.1, 136.5, 133.1, 128.5, 126.6, 125.2, 86.4, 
39.7, 31.2, 28.6 ppm. 
MP: 68 - 70 °C. 
HRMS (ESI): Calculated for C12H10O3 [M+Na]+:225.05220, Found: 225.05190. 
FTIR (neat): 2942, 1776, 1713, 1603, 1462, 1227, 1167, 1061, 940, 759 cm-1. 
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In accordance with general procedure A using a mixture of cis- and trans-6.1j, upon 
stirring at 140 °C for 20 h, the reaction mixture was concentrated to afford the crude 
spirolactones (rr = >20:1, as determined by 1H NMR spectroscopy). The crude reaction mixture 
was subjected to flash column chromatography (SiO2: 30% EtOAc/hexanes) to furnish 6.3j (57 
mg, 0.26 mmol, 88% yield) as a colorless solid. The spectroscopic properties of this compound 
were consistent with the data available in the literature.156b  
TLC (SiO2): Rf = 0.38 (hexanes:EtOAc = 1:1). 
1H NMR: (400 MHz, CDCl3): δ 8.07 (dd, J = 7.9, 1.3 Hz, 1H), 7.54 (td, J = 7.5, 1.4 Hz, 1H), 
7.37 (dd, J = 7.8, 7.4 Hz, 1H), 7.28 (d, J = 7.8 Hz, 1H), 3.20 (dt, J = 17.2, 5.3 Hz, 1H), 3.09 
(ddd, J = 17.2, 9.9, 4.7 Hz, 1H), 2.80 (ddd, J = 17.9, 10.8, 9.8 Hz, 1H), 2.59 (m, 3H), 2.31 (ddd, 
J = 13.5, 5.5, 5.0 Hz, 1H), 2.15 ppm (ddd, J = 13.0, 10.8, 9.7 Hz, 1H). 
13C NMR: (100 MHz, CDCl3): δ193.5, 176.1, 143.0, 134.4, 130.0, 128.7, 128.5, 127.3, 85.0, 
34.5, 29.6, 27.9, 25.7 ppm. 
MP: 94 - 95 °C. 
HRMS (ESI). Calculated for C13H12O3 [M+Na]+:239.06790, Found: 239.08610. 
FTIR (neat): 2951, 2937, 1772, 1687, 1602, 1454, 1217, 1067, 949, 743 cm-1. 
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In accordance with general procedure A using a mixture of cis- and trans-6.1k, upon 
stirring at 140 °C for 20 h, the reaction mixture was concentrated and subjected to flash column 
chromatography (SiO2: 20% EtOAc/hexanes) to furnish 6.3k (42 mg, 0.18 mmol, 59% yield) as 
a tan solid.  
TLC (SiO2): Rf = 0.28 (hexanes:EtOAc = 3:1). 
1H NMR: (400 MHz, CDCl3): δ 8.19 (dd, J = 8.3, 0.6 Hz, 1H), 8.03 (dd, J = 7.1, 0.7 Hz, 1H), 
7.98 (dd, J = 8.3, 0.7 Hz, 1H), 7.80 (dd, J = 8.3, 7.1 Hz, 1H), 7.74 (dd, J = 8.3, 7.1 Hz, 1H), 7.66 
(dd, J = 7.1, 0.7 Hz, 1H), 3.25 (ddd, J = 17.7, 9.7, 10.4 Hz, 1H), 2.87 (ddd, J = 17.7, 9.0, 3.9 Hz, 
1H), 2.68-2.55 ppm (m, 2H). 
13C NMR: (100 MHz, CDCl3): δ 200.2, 176.3, 142.1, 136.1, 132.4, 130.6, 129.6, 128.9, 128.8, 
126.6, 123.0, 120.8, 86.0, 31.3, 28.6 ppm. 
MP: 131 - 132 °C. 
HRMS (ESI): Calculated for C15H10O3 [M+Na]+:261.05220, Found: 261.05230. 
FTIR (neat): 1778, 1719, 1493, 1452, 1203, 1179, 1160, 1135, 1029, 919, 876, 782 cm-1. 
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In accordance with general procedure A using cis-6.1l, upon stirring at 140 °C for 20 h, 
the reaction mixture was concentrated to afford the crude spirolactones (rr = >20:1, as 
determined by 1H NMR spectroscopy). The crude reaction mixture was subjected to flash 
column chromatography (SiO2: 20% EtOAc/hexanes) to furnish 6.3l (55 mg, 0.22 mmol, 74% 
yield) as a colorless solid.  
TLC (SiO2): Rf = 0.54 (hexanes:EtOAc = 1:1) 
1H NMR: (400 MHz, CDCl3): δ 7.88 (dd, J = 7.9, 1.6 Hz, 1H), 7.53 (td, J = 8.5, 1.8 Hz, 1H), 
7.05 (dt, J = 7.9, 0.9 Hz, 1H), 6.94 (dd, J = 8.4, 0.5 Hz, 1H), 2.74 (dt, J = 18.1, 10.0 Hz, 1H), 
2.61 (ddd, J = 18.0, 9.4, 4.2 Hz, 1H), 2.36 (m, 2H), 1.49 (s, 3H), 1.46 ppm (s, 3H). 
13C NMR: (100 MHz, CDCl3): δ 189.6, 175.4, 158.6, 137.0, 127.6, 121.7, 118.4, 118.2, 86.5, 
81.8, 28.0, 24.6, 21.3, 21.2 ppm. 
MP: 145 - 147 °C. 
HRMS (ESI): Calculated for C14H14O4 [M+Na]+: 269.07840, Found: 269.07820. 




1H NMR of 6.3l 
 





In modification of general procedure A, upon addition trans-6.1a (0.3 mmol, 100 mol%), 
Ru3(CO)12 (3.8 mg, 0.006 mmol, 2 mol%), 1,3-bis(diphenylphosphino)propane (7.4 mg, 0.018 
mmol, 6 mol%), and 1-adamantanecarboxylic acid (5.4 mg, 0.03 mmol, 10 mol%)., the tube was 
sealed with a rubber septum and purged with argon. Acrylate 6.2b (104 mg, 0.90 mmol, 300 
mol%) and m-xylenes (0.22 mL, 1.0 M overall) The reaction mixture was concentrated and 
subjected to flash column chromatography (SiO2: 30% EtOAc/hexanes) to furnish 6.6b (32 mg, 
0.18 mmol, 59% yield) as a clear, colorless oil.  
TLC (SiO2): Rf = 0.23 (hexanes:EtOAc = 2:1). 
1H NMR: (400 MHz, CDCl3): δ 6.24 (t, J = 2.9 Hz, 1H), 5.67 (t, J = 2.5 Hz, 1H), 3.53 (dt, J = 
17.3, 2.6 Hz, 1H), 2.83 (ddd, J = 13.9, 10.9, 6.0 Hz, 1H), 2.51 (d, J = 17.3, 2.9Hz, 1H), 2.45 (m, 
1H), 2.22 (m, 1H), 2.09 – 2.00 (m, 2H), 1.92 – 1.67 ppm (m, 3H). 
13C NMR: (100 MHz, CDCl3): δ 205.1, 168.5, 133.4, 123.5, 85.3, 39.9, 38.8, 33.6, 27.1, 21.3 
ppm. 
HRMS (ESI): Calculated for C10H12O3 [M+Na]+: 203.06790, Found: 203.06750. 
FTIR (neat): 2941, 2868, 1767, 1724, 1665, 1452, 1265, 1083, 957 cm-1. 
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In accordance with general procedure A using α-hydroxy ester 6.7a, upon stirring at 140 
°C for 20 h, the reaction mixture was concentrated and subjected to flash column 
chromatography (SiO2: 30% EtOAc/hexanes) to furnish 6.8a (64 mg, 0.29 mmol, 97% yield) as a 
colorless solid. The spectroscopic properties of this compound were consistent with the data 
available in the literature.148a 
TLC (SiO2): Rf = 0.31 (hexanes:EtOAc = 3:1). 
1H NMR: (400 MHz, CDCl3): δ 7.52-7.50 (m, 2H), 7.42-7.34 (m, 3H), 3.75 (s, 3H), 3.10 (ddd, J 
= 10.5, 8.6, 3.1 Hz), 2.72-2.51 ppm (m, 3H). 
13C NMR: (100 MHz, CDCl3): δ 174.9, 170.8, 138.0, 128.8, 128.7, 125.0, 53.4, 33.4, 28.1 ppm. 
MP: 48 °C. 
HRMS (ESI): Calculated for C12H12O4 [M+Na]+: 243.06280, Found: 243.06260. 




1H NMR of 6.8a 
 




Methyl 2-(1-methyl-1H-indol-2-yl)-5-oxotetrahydrofuran-2-carboxylate (6.8b) 
In accordance with general procedure A using α-hydroxy ester 6.7b, upon stirring at 140 
°C for 20 h, the reaction mixture was concentrated and subjected to flash column 
chromatography (SiO2: 30% EtOAc/hexanes) to furnish 6.8b (48 mg, 0.18 mmol, 58% yield) as 
a yellow solid.  
TLC (SiO2): Rf = 0.29 (hexanes:EtOAc = 2:1). 
1H NMR: (400 MHz, CDCl3): δ 7.63 (dt, J = 8.0, 0.9 Hz, 1H), 7.36 – 7.27 (m, 2H), 7.14 (ddd, J 
= 8.0, 6.7, 1.2 Hz, 1H), 6.66 (d, J = 0.5 Hz, 1H), 3.79 (s, 3H), 3.75 (s, 3H), 3.06 (ddd, J = 12.1, 
9.5, 8.2 Hz, 1H), 2.89 – 2.79 (m, 1H), 2.78 – 2.65 ppm (m, 2H). 
13C NMR: (100 MHz, CDCl3): δ 174.9, 170.6, 138.8, 134.4, 126.3, 123.1, 121.2, 120.1, 109.5, 
102.2, 82.5, 53.6, 31.5, 31.1, 27.8 ppm. 
MP: 109 - 110 °C. 
HRMS (ESI): Calculated for C15H15NO4 [M+Na]+: 296.08930, Found: 296.08980. 
FTIR (neat): 2958, 2920, 1771, 1745, 1614, 1460, 1262, 1199, 1170, 1047, 800 cm-1. 
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In accordance with general procedure B using acrylic ester 6.2a, upon stirring at 140 °C 
for 20 h, the reaction mixture was concentrated and subjected to flash column chromatography 
(SiO2: 25% EtOAc/hexanes) to furnish 6.10a (88 mg, 0.30 mmol, 99% yield) as a colorless solid.  
TLC (SiO2): Rf = 0.44 (hexanes:EtOAc = 5:2). 
1H NMR: (400 MHz, CDCl3): δ 7.76-7.37 (m, 7H), 7.10 (td, J = 7.7, 0.9 Hz, 1H), 6.75 (d, J = 
7.7 Hz, 1H), 4.88 (s, 2H), 3.26 (ddd, J = 17.6, 10.8, 9.7 Hz, 1H), 2.80 (ddd, J = 17.6, 9.6, 3.0 Hz, 
1H), 2.64 (ddd, J = 13.4, 9.7, 3.0 Hz, 1H), 2.50 ppm (ddd, J = 13.4, 10.8, 9.6 Hz, 1H). 
13C NMR: (100 MHz, CDCl3): δ 176.0, 174.4, 143.0, 134.9, 131.1, 128.9, 127.9, 127.2, 126.3, 
124.3, 123.6, 109.9, 82.3, 43.9, 31.4, 28.3 ppm. 
MP: 118 – 119 °C. 
HRMS (ESI): Calculated for C18H15NO3 [M+Na]+: 316.09440, Found: 316.09430. 
FTIR (neat): 1782, 1720, 1615, 1468, 1367, 1175, 1054, 983, 753, 723, 697, 680 cm-1. 
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In accordance with general procedure B using acrylic ester 6.2c, upon stirring at 140 °C 
for 20 h, the reaction mixture was concentrated to afford the crude spirolactone (dr = >20:1, as 
determined by 1H NMR spectroscopy). The crude reaction mixture was subjected to flash 
column chromatography (SiO2: 25% EtOAc/hexanes) to furnish 6.10c (85 mg, 0.28 mmol, 92% 
yield) as a colorless solid.  
TLC (SiO2): Rf = 0.50 (hexanes:EtOAc = 5:2). 
1H NMR: (400 MHz, CDCl3): δ 7.35-7.26 (m, 7H), 7.07 (td, J = 7.7, 1.0 Hz, 1H), 6.77 (d, J = 
7.8 Hz, 1H), 4.90 (dd, J = 62.3, 15.7 Hz, 2H), 3.28 (dd, J = 17.4, 8.4, 1H), 3.08-2.99  (m, 1H), 
2.53 (dd, J = 17.4, 7.5 Hz, 1H), 1.04 ppm (d, J = 7.0 Hz, 1H). 
13C NMR: (100 MHz, CDCl3): δ 175.4, 174.2, 143.0, 135.0, 130.9, 129.0, 127.9, 127.2, 137.2, 
124.0, 123.0, 110.1, 85.8, 44.1, 37.3, 35.9, 16.2 ppm. 
MP: 146 – 147 °C. 
HRMS (ESI): Calculated for C19H17NO3 [M+H]+: 308.12810, Found: 308.12830. 




1H NMR of 6.10c 
 





In accordance with general procedure B using acrylic ester 6.2d, upon stirring at 140 °C 
for 20 h, the reaction mixture was concentrated to afford the crude spirolactone (dr = >20:1, as 
determined by 1H NMR spectroscopy). The crude reaction mixture was subjected to flash 
column chromatography (SiO2: 25% EtOAc/hexanes) to furnish 6.10d (91 mg, 0.25 mmol, 82% 
yield) as a colorless solid. The spectroscopic properties of this compound were consistent with 
the data available in the literature.172 
TLC (SiO2): Rf = 0.62 (hexanes:EtOAc = 5:2). 
1H NMR: (400 MHz, CDCl3): δ 7.35-7.19 (m, 7H), 7.10 (td, J = 7.8, 1.2 Hz, 1H), 7.02-6.99 (m, 
2H), 6.73 (td, J = 7.6, 1.0 Hz, 1H), 6.62 (d, J = 7.8, 1H), 6.42 (dq, J = 7.6, 0.6 Hz, 1H), 4.98 (d, J 
= 15.8 Hz, 1H), 4.81 (d, J = 15.8 Hz, 1H), 4.08 (dd, J = 8.6, 5.8 Hz, 1H), 3.67 (dd, J = 17.4, 8.6 
Hz, 1H) 3.15 ppm (3d, J = 17.4, 5.8 Hz, 1H). 
13C NMR: (100 MHz, CDCl3): δ 175.7, 174.2, 142.9, 136.3, 134.8, 130.7, 128.9, 128.7, 128.2, 
128.0, 127.9, 127.2, 126.0, 123.4, 122.7, 109.6, 86.0, 48.3, 44.0, 34.0 ppm. 
MP: 176 – 177 °C. 
HRMS (ESI): Calculated for C24H10NO3 [M+Na]+: 392.12570, Found: 392.12580. 
FTIR (neat): 1793, 1723, 1614, 1468, 1365, 1182, 1153, 1029, 1001, 752, 699 cm-1. 
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In accordance with general procedure B using acrylic ester 6.2e, upon stirring at 140 °C 
for 20 h, the reaction mixture was concentrated to afford the crude spirolactone (dr = 2:1, as 
determined by 1H NMR spectroscopy). The crude reaction mixture was subjected to flash 
column chromatography (SiO2: 25% EtOAc/hexanes) to furnish 6.10e (92 mg, 0.30 mmol, 99% 
yield) as a colorless solid.  
TLC (SiO2): Rf (minor)= 0.62, Rf (major)= 0.47 (hexanes:EtOAc = 5:2). 
Spectral Data for Major Isomer: 
1H NMR (400 MHz, CDCl3): δ 7.35-7.23 (m, 7H), 7.06 (t, J = 7.6 Hz, 1H), 6.74 (d, J = 7.9 Hz, 
1H), 4.94 (d, J = 15.6 Hz, 1H), 4.87 (d, J = 15.6 Hz, 1H), 3.20-3.10 (m, 1H), 2.62 (dd, J = 13.1, 
9.5 Hz, 1H), 2.46 (dd, J = 13.1, 9.5 Hz, 1H), 1.54 ppm (d, J = 7.2 Hz, 3H). 
13C NMR (100 MHz, CDCl3): δ 178.5, 173.8, 142.6, 134.9, 130.9, 128.9, 127.9, 127.8, 127.2, 
123.7, 123.5, 110.0, 80.6, 44.1, 38.4, 34.7, 16.5 ppm. 
MP: 122 – 123 °C. 
HRMS (ESI): Calculated for C19H17NO3 [M+Na]+: 330.11010, Found: 330.11050. 
FTIR (neat): 1783, 1727, 1615, 1489, 1469, 1369, 1178, 1024, 984, 752, 697 cm-1. 
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1H NMR of 6.10e 
 






In accordance with general procedure B using acrylic ester 6.2f, upon stirring at 140 °C 
for 20 h, the reaction mixture was concentrated and subjected to flash column chromatography 
(SiO2: 25% EtOAc/hexanes) to furnish 6.10f (50 mg, 0.16 mmol, 52% yield) as a colorless solid.  
TLC (SiO2): Rf = 0.59 (hexanes:EtOAc = 5:2). 
1H NMR (400 MHz, CDCl3): δ 7.30-7.27 (m, 7H), 7.07 (td, J = 7.6, 0.8 Hz, 1H), 6.76 (d, J = 7.6 
Hz, 1H), 5.08 (d, J = 15.6  Hz, 1H), 4.66 (d, J = 15.6 Hz, 1H), 3.46 (d, J = 16.6 Hz, 1H), 2.41 (d, 
J = 16.6 Hz, 1H), 1.32 (s, 3H), 1.10 ppm (2, 3H).  
13C NMR (100 MHz, CDCl3): δ 175.7, 174.9, 144.1, 135.1, 130.9, 128.9, 127.9, 127.3, 127.1, 
122.7, 122.2, 109.8, 88.4, 44.0, 43.4, 41.7, 26.0, 21.7 ppm. 
MP: 142 – 143 °C. 
HRMS (ESI): Calculated for C20H19NO3 [M+Na]+: 344.12570, Found: 344.12580. 
FTIR (neat): 1793, 1723, 1614, 1467, 1368, 1224, 1185, 1017, 755 cm-1. 
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1'-benzyl-3- cyclohexyl-3H-spiro[furan-2,3'-indoline]-2',5(4H)-dione (6.10g) 
 In accordance with general procedure B using acrylic ester 6.2g, upon stirring at 140 °C 
for 20 h, the reaction mixture was concentrated to afford the crude spirolactone (dr = >20:1, as 
determined by 1H NMR spectroscopy). The crude reaction mixture was subjected to flash 
column chromatography (SiO2: 25% EtOAc/hexanes) to furnish 6.10g (86 mg, 0.23 mmol, 77% 
yield) as a tan solid.  
TLC (SiO2): Rf = 0.34 (hexanes:EtOAc = 7:3). 
1H NMR: (400 MHz, CDCl3): δ 7.34-7.23 (m, 7H), 7.07 (td, J = 7.6, 0.9 Hz, 1H), 6.82 (d, J = 
7.8 Hz, 1H), 4.98 (d, J = 15.4 Hz, 1H), 4.83  (d, J = 15.5 Hz, 1H), 3.00-2.86 (m, 2H), 2.74-2.60 
(m, 1H), 1.73-1.62 (m, 2H), 1.53-1.46 (m, 1H), 1.36-1.21 (m, 2H), 1.17-0.98 (m, 3H), 0.93-0.84 
(m, 1H), 0.77-0.67 ppm (m, 2H). 
13C NMR: (100 MHz, CDCl3): δ 174.8, 173.2, 143.3, 134.9, 131.1, 128.9, 128.1, 127.8, 125.2, 
124.7, 123.3, 110.3, 85.2, 47.9, 44.5, 38.8, 33.8, 31.8, 30.5, 25.8, 25.6, 25.2 ppm. 
MP: 161 – 163 °C. 
HRMS (ESI): Calculated for C24H25NO3 [M+Na]+: 398.17270, Found: 398.17290. 
FTIR (neat): 2934, 1788, 1731, 1614, 1487, 1350, 1206, 1184, 1159, 976, 770, 753, 708 cm-1. 
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1H NMR of 6.10g 
 






 In accordance with general procedure B using acrylic ester 6.2h, upon stirring at 140 °C 
for 20 h, the reaction mixture was concentrated to afford the crude spirolactone (dr = >20:1, as 
determined by 1H NMR spectroscopy). The crude reaction mixture was subjected to flash 
column chromatography (SiO2: 25% EtOAc/hexanes) to furnish 6.10h (112 mg, 0.27 mmol, 90% 
yield) as a pale pink solid.  
TLC (SiO2): Rf = 0.28 (hexanes:EtOAc = 7:3). 
1H NMR: (400 MHz, CDCl3): δ 7.34-7.22 (m, 5H), 7.14 (td, J = 7.8, 1.2 Hz, 1H), 6.82 (td, J = 
7.6, 0.9 Hz, 1H), 6.66-6.61 (m, 3H), 6.50-6.48 (m, 2H), 5.92 (d, J = 1.4 Hz, 1H), 5.91 (d, J = 1.4 
Hz, 1H), 4.99 (d, J = 15.8 Hz, 1H), 4.80 (d, J = 15.8, 1H), 4.03 (dd, J = 8.6, 6.4 Hz, 1H), 3.60 
(dd, J = 17.5, 8.6 Hz, 1H), 3.08 ppm (dd, J = 17.5, 6.4 Hz, 1H). 
13C NMR: (100 MHz, CDCl3): δ 175.5, 174.0, 147.9, 147.4, 142.9, 134.8, 130.8, 129.8, 128.9, 
127.9, 127.1, 125.9, 123.5, 122.9, 121.3, 109.7, 108.3, 101.3, 86.1,  48.1, 44.0, 34.3, 14.2 ppm. 
MP: 177 – 178 °C. 
HRMS (ESI): Calculated for C25H19NO5 [M+Na]+: 436.11550, Found: 436.11510. 
FTIR (neat): 1791, 1730, 1489, 1468, 1368, 1234, 1184, 1155, 1035, 1000, 760, cm-1 
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 In accordance with general procedure B using acrylic ester 6.2i, upon stirring at 140 °C 
for 20 h, the reaction mixture was concentrated to afford the crude spirolactone (dr = >20:1, as 
determined by 1H NMR spectroscopy). The crude reaction mixture was subjected to flash 
column chromatography (SiO2: 25% EtOAc/hexanes) to furnish 6.10i (98 mg, 0.26 mmol, 87% 
yield) as a white solid.  
TLC (SiO2): Rf = 0.49 (hexanes:EtOAc = 2:1). 
1H NMR: (400 MHz, CDCl3): δ 7.33-7.26 (m, 3H), 7.22-7.19 (m, 2H), 7.16 (dd, J = 7.8, 1.2 Hz, 
2H), 7.13 (dd, J = 5.1, 1.2 Hz, 1H), 6.89 (dd, J = 5.1, 3.6 Hz 1H), 6.85 (dd, J = 7.6, 0.9 Hz, 1H), 
6.79 (ddd, J = 3.6, 1.1, 0.6 Hz, 1H), 6.72 (ddd, J = 7.6, 1.2, 0.6 Hz, 1H), 6.66 (d, J = 7.8 Hz, 1H), 
4.96 (d, J = 15.8 Hz, 1H), 4.85 (d, J = 15.8 Hz, 1H), 4.38 (m, 1H), 3.65 (dd, J = 17.5, 8.7 Hz, 
1H), 3.15 ppm (dd, J = 17.5, 7.2 Hz, 1H).   
13C NMR: (100 MHz, C6D6): δ 173.5, 173.3, 143.0, 138.7, 135.1, 130.5, 128.6, 126.9, 126.6, 
126.2, 125.4, 124.7, 123.8, 122.5, 109.5, 85.2, 44.1, 43.4, 35.4 ppm. 
MP: 158 – 159 °C. 
HRMS (ESI): Calculated for C22H17NO3S [M+Na]+:398.08210, Found: 398.08200. 
FTIR (neat): 1790, 1722, 1614, 1467, 1379, 1368, 1194, 1183, 1155, 999, 768, 757, 732, 709, 
694, 676 cm-1. 
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6.4.6 Crystal Data and Structure Refinement for 6.11 
Empirical formula  C52 H60 Cl4 O5 P2 Ru 
Formula weight  1069.81 
Temperature  153(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 11.3017(3) Å α= 71.0490(10)°. 
 b = 14.8706(4) Å β= 86.7940(10)°. 
 c = 15.7363(4) Å γ = 81.2220(10)°. 
Volume 2471.99(11) Å3 
Z 2 
Density (calculated) 1.437 Mg/m3 
Absorption coefficient 0.645 mm-1 
F(000) 1108 
Crystal size 0.30 x 0.20 x 0.08 mm 
Theta range for data collection 1.46 to 27.50°. 
Index ranges -14<=h<=14, -19<=k<=19, -20<=l<=20 
Reflections collected 57107 
Independent reflections 11369 [R(int) = 0.0478] 
Completeness to theta = 27.50° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.00 and 0.855 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 11369 / 0 / 577 
Goodness-of-fit on F2 1.206 
Final R indices [I>2sigma(I)] R1 = 0.0419, wR2 = 0.0977 
R indices (all data) R1 = 0.0529, wR2 = 0.1036 
Largest diff. peak and hole 2.563 and -1.677 e.Å-3 
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Table 6.3 Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters 
(Å2x103) for 6.11.  U(eq) is defined as one third of  the trace of the orthogonalized 
Uij tensor. 
____________________________________________________________________________ 
 x y z U(eq) 
____________________________________________________________________________ 
C(1) 6057(3) 8955(2) 2956(2) 25(1) 
C(2) 5030(3) 9625(2) 2787(2) 35(1) 
C(3) 4799(3) 10278(2) 3262(3) 43(1) 
C(4) 5581(4) 10260(2) 3902(2) 45(1) 
C(5) 6596(4) 9595(3) 4081(3) 51(1) 
C(6) 6844(3) 8935(2) 3607(2) 41(1) 
C(7) 7551(2) 7226(2) 2889(2) 24(1) 
C(8) 7186(3) 6477(2) 3600(2) 27(1) 
C(9) 8022(3) 5702(2) 4046(2) 34(1) 
C(10) 9208(3) 5670(2) 3780(2) 37(1) 
C(11) 9576(3) 6403(2) 3083(2) 36(1) 
C(12) 8759(3) 7192(2) 2640(2) 30(1) 
C(13) 7172(2) 8926(2) 1318(2) 24(1) 
C(14) 7647(2) 8488(2) 583(2) 27(1) 
C(15) 6684(2) 8292(2) 55(2) 24(1) 
C(16) 7020(2) 6250(2) 836(2) 19(1) 
C(17) 7548(2) 6056(2) 80(2) 25(1) 
C(18) 8431(2) 5271(2) 175(2) 29(1) 
C(19) 8805(2) 4680(2) 1026(2) 29(1) 
C(20) 8299(2) 4874(2) 1775(2) 26(1) 
C(21) 7401(2) 5654(2) 1685(2) 22(1) 
C(22) 4884(2) 7246(2) -157(2) 20(1) 
C(23) 4527(2) 6376(2) -109(2) 24(1) 
C(24) 3727(3) 6328(2) -722(2) 32(1) 
C(25) 3268(3) 7152(2) -1392(2) 35(1) 
C(26) 3616(3) 8023(2) -1455(2) 34(1) 
C(27) 4416(3) 8069(2) -839(2) 29(1) 
C(28) 4162(2) 5878(2) 2422(2) 20(1) 
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C(29) 3726(2) 4909(2) 2720(2) 21(1) 
C(30) 4796(3) 4106(2) 2894(3) 38(1) 
C(31) 4341(3) 3118(2) 3208(3) 49(1) 
C(32) 3567(3) 3056(2) 2475(3) 41(1) 
C(33) 2485(3) 3830(2) 2318(2) 29(1) 
C(34) 2923(3) 4821(2) 1998(2) 31(1) 
C(35) 1767(3) 3743(2) 3169(2) 39(1) 
C(36) 2542(4) 3804(3) 3900(2) 47(1) 
C(37) 3624(4) 3031(3) 4062(3) 63(1) 
C(38) 2989(3) 4799(2) 3585(2) 39(1) 
C(39) 2985(3) 8161(2) 3106(2) 32(1) 
C(40) 2335(2) 8028(2) 4011(2) 25(1) 
C(41) 2205(4) 8953(3) 4260(3) 54(1) 
C(42) 1462(4) 8838(3) 5135(3) 62(1) 
C(43) 2119(4) 8017(5) 5881(3) 87(2) 
C(44) 2236(4) 7106(4) 5652(3) 82(2) 
C(45) 2970(3) 7213(3) 4776(2) 58(1) 
C(46) 1083(3) 7822(3) 3908(3) 55(1) 
C(47) 364(3) 7704(3) 4791(3) 59(1) 
C(48) 1006(4) 6894(3) 5515(4) 85(2) 
C(49) 246(3) 8611(3) 5009(3) 58(1) 
C(50) 4255(2) 8706(2) 1188(2) 23(1) 
C(51) 1597(3) 7832(3) 619(4) 82(2) 
O(1) 5128(2) 5994(1) 2722(1) 21(1) 
O(2) 3571(2) 6602(1) 1858(1) 23(1) 
O(3) 3932(2) 7568(1) 3112(1) 24(1) 
O(4) 2574(2) 8809(2) 2436(2) 69(1) 
O(5) 3896(2) 9425(1) 668(1) 34(1) 
P(1) 6400(1) 8163(1) 2270(1) 20(1) 
P(2) 5880(1) 7302(1) 693(1) 17(1) 
Ru(1) 4859(1) 7516(1) 1934(1) 17(1) 
Cl(1) 896(1) 8981(1) 379(2) 114(1) 
Cl(2) 643(1) 7042(1) 500(1) 88(1) 
C(52) 641(3) 10702(3) 1848(3) 51(1) 
Cl(3) -719(1) 10414(1) 2407(1) 77(1) 
Cl(4) 1166(1) 11612(1) 2139(1) 92(1) 
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Table 6.4 Bond lengths [Å] and angles [°] for 6.11. 
____________________________________________________________________________  
C(1)-C(6)  1.383(4) 
C(1)-C(2)  1.386(4) 
C(1)-P(1)  1.828(3) 
C(2)-C(3)  1.393(4) 
C(2)-H(2)  0.95 
C(3)-C(4)  1.368(5) 
C(3)-H(3)  0.95 
C(4)-C(5)  1.372(5) 
C(4)-H(4)  0.95 
C(5)-C(6)  1.403(4) 
C(5)-H(5)  0.95 
C(6)-H(6)  0.95 
C(7)-C(8)  1.394(4) 
C(7)-C(12)  1.397(4) 
C(7)-P(1)  1.814(3) 
C(8)-C(9)  1.389(4) 
C(8)-H(8)  0.95 
C(9)-C(10)  1.381(5) 
C(9)-H(9)  0.95 
C(10)-C(11)  1.369(5) 
C(10)-H(10)  0.95 
C(11)-C(12)  1.387(4) 
C(11)-H(11)  0.95 
C(12)-H(12)  0.95 
C(13)-C(14)  1.538(4) 
C(13)-P(1)  1.828(3) 
C(13)-H(13A)  0.99 
C(13)-H(13B)  0.99 
C(14)-C(15)  1.522(4) 
C(14)-H(14A)  0.99 
C(14)-H(14B)  0.99 
C(15)-P(2)  1.829(3) 
C(15)-H(15A)  0.99 
C(15)-H(15B)  0.99 
C(16)-C(21)  1.391(4) 
C(16)-C(17)  1.396(4) 
C(16)-P(2)  1.829(2) 
C(17)-C(18)  1.389(4) 
C(17)-H(17)  0.95 
C(18)-C(19)  1.389(4) 
C(18)-H(18)  0.95 
C(19)-C(20)  1.376(4) 
C(19)-H(19)  0.95 
C(20)-C(21)  1.395(4) 
C(20)-H(20)  0.95 
C(21)-H(21)  0.95 
C(22)-C(23)  1.392(4) 
C(22)-C(27)  1.393(4) 
C(22)-P(2)  1.826(3) 
C(23)-C(24)  1.383(4) 
C(23)-H(23)  0.95 
C(24)-C(25)  1.383(4) 
C(24)-H(24)  0.95 
C(25)-C(26)  1.381(4) 
C(25)-H(25)  0.95 
C(26)-C(27)  1.387(4) 
C(26)-H(26)  0.95 
C(27)-H(27)  0.95 
C(28)-O(1)  1.270(3) 
C(28)-O(2)  1.272(3) 
C(28)-C(29)  1.514(3) 
C(28)-Ru(1)  2.538(2) 
C(29)-C(38)  1.530(4) 
C(29)-C(30)  1.532(4) 
C(29)-C(34)  1.543(4) 
C(30)-C(31)  1.548(4) 
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C(30)-H(30A)  0.99 
C(30)-H(30B)  0.99 
C(31)-C(37)  1.510(6) 
C(31)-C(32)  1.520(5) 
C(31)-H(31)  1.00 
C(32)-C(33)  1.516(4) 
C(32)-H(32A)  0.99 
C(32)-H(32B)  0.99 
C(33)-C(35)  1.506(4) 
C(33)-C(34)  1.545(4) 
C(33)-H(33)  1.00 
C(34)-H(34A)  0.99 
C(34)-H(34B)  0.99 
C(35)-C(36)  1.516(5) 
C(35)-H(35A)  0.99 
C(35)-H(35B)  0.99 
C(36)-C(37)  1.515(6) 
C(36)-C(38)  1.554(4) 
C(36)-H(36)  1.00 
C(37)-H(37A)  0.99 
C(37)-H(37B)  0.99 
C(38)-H(38A)  0.99 
C(38)-H(38B)  0.99 
C(39)-O(4)  1.231(4) 
C(39)-O(3)  1.277(3) 
C(39)-C(40)  1.534(4) 
C(40)-C(46)  1.521(4) 
C(40)-C(45)  1.522(4) 
C(40)-C(41)  1.532(4) 
C(41)-C(42)  1.546(5) 
C(41)-H(41A)  0.99 
C(41)-H(41B)  0.99 
C(42)-C(49)  1.503(6) 
C(42)-C(43)  1.520(7) 
 
C(42)-H(42)  1.00 
C(43)-C(44)  1.497(8) 
C(43)-H(43A)  0.99 
C(43)-H(43B)  0.99 
C(44)-C(48)  1.513(8) 
C(44)-C(45)  1.544(5) 
C(44)-H(44)  1.00 
C(45)-H(45A)  0.99 
C(45)-H(45B)  0.99 
C(46)-C(47)  1.543(6) 
C(46)-H(46A)  0.99 
C(46)-H(46B)  0.99 
C(47)-C(49)  1.482(6) 
C(47)-C(48)  1.487(6) 
C(47)-H(47)  1.00 
C(48)-H(48A)  0.99 
C(48)-H(48B)  0.99 
C(49)-H(49A)  0.99 
C(49)-H(49B)  0.99 
C(50)-O(5)  1.146(3) 
C(50)-Ru(1)  1.829(3) 
C(51)-Cl(1)  1.700(5) 
C(51)-Cl(2)  1.769(5) 
C(51)-H(51A)  0.99 
C(51)-H(51B)  0.99 
O(1)-Ru(1)  2.1816(17) 
O(2)-Ru(1)  2.1708(18) 
O(3)-Ru(1)  2.0964(18) 
P(1)-Ru(1)  2.2776(7) 
P(2)-Ru(1)  2.2985(7) 
C(52)-Cl(4)  1.752(4) 
C(52)-Cl(3)  1.768(4) 
C(52)-H(52A)  0.99 





















































































































































































































































































Table 6.5 Anisotropic displacement parameters  (Å2x 103) for 6.11.  The anisotropic 
displacement factor exponent takes the form:  -2π2[ h2 a*2U11 + ...  + 2 h k a* b* 
U12 ] 
____________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
____________________________________________________________________________  
C(1) 34(2)  20(1) 25(1)  -10(1) 6(1)  -8(1) 
C(2) 36(2)  28(1) 43(2)  -17(1) 5(1)  -3(1) 
C(3) 51(2)  27(2) 55(2)  -20(2) 18(2)  -6(1) 
C(4) 76(3)  30(2) 39(2)  -21(1) 19(2)  -16(2) 
C(5) 80(3)  42(2) 40(2)  -24(2) -6(2)  -12(2) 
C(6) 55(2)  33(2) 38(2)  -19(1) -10(2)  0(1) 
C(7) 28(1)  20(1) 25(1)  -11(1) -4(1)  -2(1) 
C(8) 35(2)  27(1) 23(1)  -12(1) -3(1)  -2(1) 
C(9) 54(2)  26(1) 22(1)  -8(1) -5(1)  -2(1) 
C(10) 41(2)  34(2) 38(2)  -18(1) -14(1)  9(1) 
C(11) 28(2)  40(2) 41(2)  -18(1) -9(1)  2(1) 
C(12) 30(2)  28(1) 32(2)  -9(1) -6(1)  -3(1) 
C(13) 25(1)  21(1) 28(1)  -8(1) 2(1)  -8(1) 
C(14) 24(1)  28(1) 29(2)  -10(1) 7(1)  -10(1) 
C(15) 28(1)  20(1) 23(1)  -6(1) 6(1)  -8(1) 
C(16) 16(1)  18(1) 25(1)  -8(1) 3(1)  -4(1) 
C(17) 22(1)  27(1) 23(1)  -7(1) 4(1)  -2(1) 
C(18) 22(1)  33(1) 35(2)  -16(1) 8(1)  -2(1) 
C(19) 18(1)  27(1) 41(2)  -12(1) 2(1)  1(1) 
C(20) 22(1)  25(1) 30(2)  -7(1) -3(1)  0(1) 
C(21) 22(1)  22(1) 24(1)  -10(1) 1(1)  -3(1) 
C(22) 17(1)  24(1) 20(1)  -8(1) 2(1)  -1(1) 
C(23) 21(1)  25(1) 25(1)  -6(1) 0(1)  -4(1) 
C(24) 25(1)  39(2) 37(2)  -15(1) 0(1)  -11(1) 
C(25) 24(1)  52(2) 32(2)  -15(1) -5(1)  -6(1) 
C(26) 28(2)  38(2) 30(2)  -3(1) -9(1)  2(1) 
C(27) 28(1)  25(1) 32(2)  -7(1) -2(1)  0(1) 




C(29) 20(1)  20(1) 22(1)  -4(1) 4(1)  -4(1) 
C(30) 27(2)  25(1) 60(2)  -10(1) -4(1)  -3(1) 
C(31) 40(2)  25(2) 76(3)  -9(2) -19(2)  1(1) 
C(32) 38(2)  32(2) 57(2)  -20(2) 10(2)  -8(1) 
C(33) 29(1)  34(2) 30(2)  -16(1) 2(1)  -9(1) 
C(34) 33(2)  30(1) 28(2)  -7(1) 0(1)  -10(1) 
C(35) 35(2)  44(2) 43(2)  -19(2) 15(1)  -18(1) 
C(36) 64(2)  60(2) 28(2)  -18(2) 18(2)  -36(2) 
C(37) 91(3)  49(2) 40(2)  15(2) -26(2)  -38(2) 
C(38) 48(2)  48(2) 32(2)  -21(1) 17(1)  -25(2) 
C(39) 24(1)  40(2) 28(2)  -11(1) 2(1)  4(1) 
C(40) 20(1)  25(1) 28(1)  -8(1) 4(1)  0(1) 
C(41) 72(3)  42(2) 54(2)  -22(2) 26(2)  -22(2) 
C(42) 88(3)  51(2) 59(3)  -37(2) 33(2)  -22(2) 
C(43) 54(3)  170(6) 42(3)  -44(3) 6(2)  -9(3) 
C(44) 58(3)  92(3) 42(2)  25(2) 22(2)  43(2) 
C(45) 38(2)  69(3) 39(2)  6(2) 14(2)  23(2) 
C(46) 30(2)  80(3) 72(3)  -46(2) 10(2)  -16(2) 
C(47) 28(2)  68(3) 85(3)  -28(2) 19(2)  -17(2) 
C(48) 76(3)  36(2) 117(4)  0(2) 62(3)  0(2) 
C(49) 49(2)  53(2) 49(2)  -4(2) 17(2)  24(2) 
C(50) 22(1)  22(1) 26(1)  -10(1) 4(1)  -3(1) 
C(51) 30(2)  74(3) 99(4)  24(3) 9(2)  7(2) 
O(1) 18(1)  20(1) 23(1)  -6(1) 1(1)  -3(1) 
O(2) 21(1)  20(1) 26(1)  -5(1) -1(1)  -3(1) 
O(3) 24(1)  23(1) 23(1)  -9(1) 4(1)  0(1) 
O(4) 49(2)  94(2) 30(1)  2(1) 6(1)  41(2) 
O(5) 40(1)  21(1) 33(1)  -2(1) -1(1)  4(1) 
P(1) 22(1)  17(1) 22(1)  -8(1) 1(1)  -2(1) 
P(2) 18(1)  16(1) 18(1)  -5(1) 2(1)  -2(1) 
Ru(1) 17(1)  15(1) 19(1)  -5(1) 2(1)  -1(1) 
Cl(1) 68(1)  102(1) 201(2)  -83(1) -55(1)  3(1) 
Cl(2) 65(1)  54(1) 127(1)  -21(1) 31(1)  15(1) 
C(52) 42(2)  59(2) 48(2)  -14(2) -4(2)  -1(2) 
Cl(3) 36(1)  83(1) 98(1)  -13(1) 1(1)  0(1) 




Table 6.7 Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3) 
for 6.11. 
____________________________________________________________________________  
 x  y  z  U(eq) 
____________________________________________________________________________  
  
H(2) 4481 9640 2345 42 
H(3) 4095 10737 3141 52 
H(4) 5420 10708 4222 54 
H(5) 7135 9582 4529 61 
H(6) 7548 8476 3732 49 
H(8) 6368 6496 3779 33 
H(9) 7777 5193 4534 41 
H(10) 9775 5136 4084 44 
H(11) 10393 6370 2901 43 
H(12) 9021 7708 2169 36 
H(13A) 6614 9520 1036 29 
H(13B) 7855 9116 1554 29 
H(14A) 8144 8930 157 32 
H(14B) 8174 7877 866 32 
H(15A) 7060 8147 -477 29 
H(15B) 6098 8883 -163 29 
H(17) 7302 6463 -504 30 
H(18) 8780 5138 -343 35 
H(19) 9408 4143 1090 34 
H(20) 8564 4474 2356 31 
H(21) 7049 5778 2205 27 
H(23) 4837 5807 351 29 
H(24) 3494 5728 -682 39 
H(25) 2713 7120 -1809 42 
H(26) 3308 8589 -1920 41 
H(27) 4649 8670 -882 35 
H(30A) 5314 4151 3361 46 
H(30B) 5277 4175 2337 46 




H(32A) 4039 3140 1912 49 
H(32B) 3301 2416 2656 49 
H(33) 1968 3776 1846 35 
H(34A) 3380 4899 1429 37 
H(34B) 2226 5335 1883 37 
H(35A) 1450 3122 3371 47 
H(35B) 1080 4265 3053 47 
H(36) 2065 3726 4468 57 
H(37A) 4135 3091 4526 76 
H(37B) 3357 2391 4288 76 
H(38A) 2296 5316 3476 47 
H(38B) 3488 4853 4059 47 
H(41A) 1804 9495 3766 65 
H(41B) 3007 9100 4345 65 
H(42) 1377 9446 5291 74 
H(43A) 2923 8164 5959 105 
H(43B) 1671 7940 6454 105 
H(44) 2649 6565 6152 99 
H(45A) 3779 7350 4855 70 
H(45B) 3058 6606 4631 70 
H(46A) 1139 7227 3746 66 
H(46B) 663 8356 3418 66 
H(47) -450 7556 4715 71 
H(48A) 1085 6298 5353 102 
H(48B) 540 6793 6082 102 
H(49A) -234 8548 5566 69 
H(49B) -176 9142 4516 69 
H(51A) 1895 7605 1244 99 
H(51B) 2297 7818 214 99 
H(52A) 1250 10121 2006 61 
H(52B) 517 10915 1190 61 
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List of Abbreviations and Acronyms 
acac   Acetoacetyl 
BINOL  1,1’-Bi-2-naphthol 
BIPHEP  2,2’-Bis(diphenylphosphino)-1,1’-bihepnyl 
BIPY   2,2’-Bipyridine 
cod   1,5-Cycooctadiene 
COSY   Correlation Spectroscopy 
cot   Cyclooctatetraene 
Cy   Cyclohexyl 
DBU   1,8-Diazabicycloundec-7-ene 
DCE   Dichloroethane 
DCM   Dichloromethane 
DCyPF  1,1’-Bis(dicyclohexylphosphino)ferrocene 
DFT   Density functional theory 
DiPPF   1,1’-Bis(di-i-propylphosphino)ferrocene 
DMB   Dimethoxybenzyl 
DM-SEGPHOS (S)-(−)-5,5’-Bis(diphenyphosphino)-4,4’-bi-1,3-benzodioxole 
DMSO   Dimethylsulfoxide 
DPPB   1,4-Bis(diphenylphosphino)butane 
DPPF   1,1’-Bis(diphenylphosphino)ferrocene 
DPPP   1,3-Bis(diphenylphosphino)propane 
G2   Grubbs’ 2nd Generation Catalyst 
HG2   Hoveyda-Grubbs’ 2nd Generation Catalyst 
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HMBC  Heteronuclear Multiple Bond Correlation 
Ipc   Isopinocampheol 
LUMO  Lowest Unoccupied Molecular Orbital 
MeCN   Acetonitrile 
Mes   Mesityl 
MOM   Methoxymethyl 
NHC   N-Heterocyclic Carbene 
NOESY  Nuclear Overhauser Enhancement Spectroscopy 
ORTEP  Oak Ridge Thermal Ellipsoid Plot  
Phen   Phenanthroline 
Pin   Pinacol 
DMB   Dimethoxybenzyl 
PMB   para-Methoxy Benzyl 
PMHS   Polymethylhydrosiloxane 
BINAP  2,2’-Bis(diphenylphosphino)-1,1’-binaphthyl 
pTsOH  para-Toluenesulfonic Acid 
SEGPHOS  5,5’-Bis(diphenylphosphino)-4,4’-bi-1,3-benzodioxole 
TADDOL  α, α, α, α-tetraaryl-1,3-dioxalane-4,5-dimethanol 
TBAF   Tetrabutylammonium fluoride 
TBAI   Tetrabutylammonium iodide 
TBS   Tert-Butyldimethylsilyl 
TERPY  2,2’:6’,2”-Terpyridine 
TFA   Trifluoroacetic acid 
THF   Tetrahydrofuran 
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